Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Oncology›Condition·Updated Jul 11, 2026·v1

Prostate Cancer

Prostate cancer is a common malignancy with a wide spectrum of behavior. Early detection through PSA and MRI reduces mortality. Management is risk-stratified: active surveillance for low-risk, definitive local therapy for intermediate/high-risk, and systemic therapy intensification for metastatic disease. Genomic testing guides PARP inhibitor use. Survival has improved dramatically with combination therapies.

High Evidence834 references·9,329 words·38 min read·v1
prostate canceroncologyPSAGleason scoreandrogen deprivation therapyADTmetastatic prostate cancercastration-resistantPARP inhibitorsPSMA PETactive surveillancedocetaxelenzalutamideabirateronedarolutamideapalutamideolaparibnirapariblu-177 PSMA-617radium-223neuroendocrine prostate cancerbiochemical recurrencesalvage radiotherapygenomic testingHRR mutationsMSI-HdMMRpembrolizumabbone protectionzoledronic aciddenosumab

Quick Reference

RxDrug of choiceAndrogen deprivation therapy (ADT) with a GnRH agonist (e.g., leuprolide 22.5 mg IM q3mo) or antagonist (relugolix 120 mg PO daily) is the backbone. For mHSPC, add docetaxel 75 mg/m² IV q3wk x6 cycles plus an ARPI (e.g., darolutamide 600 mg BID, enzalutamide 160 mg daily, or abiraterone 1000 mg daily with prednisone 5 mg BID).
AltAlternativesApalutamide 240 mg daily, abiraterone 1000 mg daily with prednisone 5 mg BID, darolutamide 600 mg BID, enzalutamide 160 mg daily; for mCRPC with HRR mutations: olaparib 300 mg BID, niraparib 300 mg daily; for PSMA-positive mCRPC: 177Lu-PSMA-617 7.4 GBq q6wk x6 cycles; for bone metastases: radium-223 55 kBq/kg IV q4wk x6 cycles.
⊘Avoid5α-reductase inhibitors (finasteride, dutasteride) for prevention due to increased detection of high-grade disease; non-dihydropyridine CCBs (diltiazem, verapamil) in heart failure; immunotherapy without MSI-H/dMMR (no benefit).
DxTest of choiceSerum PSA for screening; multiparametric MRI (mpMRI) with PI-RADS v2.1 for risk stratification and biopsy guidance; combined systematic and MRI-targeted biopsy for histologic diagnosis; PSMA PET/CT for staging and biochemical recurrence detection.
ScKey scoreGleason grade group (GG1-5) and NCCN risk stratification (low, favorable intermediate, unfavorable intermediate, high, very high) for localized disease; CHAARTED criteria (high-volume vs low-volume) for metastatic disease; PSA doubling time ≤10 months for nmCRPC.
→When to referRefer to urology for abnormal DRE/elevated PSA and biopsy; to radiation oncology for definitive RT or salvage RT; to medical oncology for systemic therapy in metastatic or high-risk disease; to palliative care for advanced symptom management; to genetic counseling for men with germline mutations (BRCA2, HOXB13, Lynch syndrome).
Prostate cancer is highly treatable; early detection via PSA and MRI reduces mortality; management is risk-stratified from active surveillance for low-risk disease to triplet therapy (ADT + docetaxel + ARPI) for high-volume mHSPC; genomic testing for HRR mutations and MSI-H/dMMR guides PARP inhibitor and immunotherapy use, respectively.
Prostate cancer is the second most common cancer in men worldwide and a leading cause of cancer death, but early detection and risk-stratified management have dramatically improved outcomes. The backbone of treatment is androgen deprivation therapy (ADT), with intensification using docetaxel and androgen receptor pathway inhibitors (ARPIs) for metastatic disease. Genomic testing for BRCA1/2 and other HRR mutations identifies patients who benefit from PARP inhibitors. The key to optimal management is accurate risk stratification using PSA, Gleason grade group, TNM staging, and MRI/PSMA PET imaging, guiding decisions from active surveillance for low-risk disease to triplet therapy for high-volume metastatic disease. This page provides a comprehensive overview of the evaluation and management of prostate cancer across the disease spectrum.

Overview and Recommendations

Background

  • •Prostate cancer is the second most common cancer in men worldwide, with over 1.3 million new cases and 416,000 deaths annually, and the lifetime risk of diagnosis is approximately 1 in 8. Age is the strongest risk factor, with median age at diagnosis of 66 years; incidence rises sharply after age 50.
  • •The vast majority (>95%) are acinar adenocarcinomas, but histologic variants such as ductal, neuroendocrine, and small-cell carcinoma carry distinct biology and prognosis. Neuroendocrine prostate cancer (NEPC) is particularly aggressive, often AR-negative, and can arise de novo or as treatment-emergent transformation in 17% of CRPC patients.
  • •Risk factors include family history (RR 2.3), African American race (1.7-fold incidence), and germline mutations in BRCA2 (3-5 fold risk), HOXB13, and Lynch syndrome genes. Approximately 11.8% of men with metastatic prostate cancer carry a deleterious germline mutation in DNA repair genes.
  • •The molecular landscape is defined by recurrent TMPRSS2-ERG fusions (~50% of localized cases), SPOP mutations (~10-15%), and PTEN loss, with the AR pathway remaining central. Androgen receptor signaling drives progression to castration-resistant disease through AR amplification, mutations, and splice variants like AR-V7.
  • •Screening with PSA reduces prostate cancer mortality by 13% over 23 years (NNT 456), but overdiagnosis is a concern; MRI-based screening pathways halve detection of insignificant cancer. Shared decision-making beginning at age 45 (age 40 for high-risk) is recommended.
  • •The paradigm has shifted from single-agent ADT to biomarker-guided intensification: triplet therapy (ADT + docetaxel + ARPI) for fit patients with high-volume metastatic disease, and PARP inhibitors for HRR-mutated CRPC, improving survival substantially.

Evaluation

  • •Suspect prostate cancer in any man over 50 with lower urinary tract symptoms (hesitancy, weak stream, frequency, nocturia) or in younger men with a strong family history or African American ancestry. Many cases are asymptomatic, detected by elevated PSA on screening.
  • •Ask about the duration and severity of urinary symptoms, presence of hematuria or hematospermia (suggesting locally advanced disease), new-onset erectile dysfunction, and axial bone pain (suggesting metastases). Constitutional symptoms like unintentional weight loss or fatigue indicate high-volume disease.
  • •Examine with digital rectal examination (DRE): a palpable nodule, asymmetry, induration, or loss of seminal vesicle angle suggests extraprostatic extension. Palpable supraclavicular or inguinal lymphadenopathy indicates regional spread.
  • •Order serum PSA as the initial test. PSA >4.0 ng/mL is typical threshold for further workup, but age-specific and risk-stratified thresholds exist. Confirm with a repeat PSA if elevated.
  • •For patients with abnormal DRE or elevated PSA, proceed with multiparametric MRI (mpMRI) of the prostate using PI-RADS v2.1. A PI-RADS score of 4 or 5 independently predicts clinically significant cancer and guides biopsy targeting.
  • •Perform prostate biopsy via transrectal ultrasound (TRUS) or transperineal approach. Combined systematic (10-12 cores) and MRI-targeted biopsy from all visible lesions minimizes undergrading; MRI-targeted alone misses 8.8% of grade group ≥3 cancers.
  • •Histologic evaluation reports Gleason grade group (GG1-5) and notes cribriform architecture and intraductal carcinoma (IDC-P), which independently predict aggressive behavior. GG1 (Gleason ≤6) is considered low-risk; GG4-5 are high-risk.
  • •Stage the disease using the 8th edition AJCC TNM classification. Clinical T staging relies on DRE and MRI; pathological T staging after prostatectomy is the strongest predictor of recurrence. PSMA PET/CT is superior to conventional imaging for detecting nodal and distant metastases.
  • •For patients with metastatic disease, classify as high-volume (visceral metastases or ≥4 bone lesions with ≥1 outside axial skeleton) or low-volume, as this guides therapy intensification (docetaxel benefit primarily in high-volume).
  • •Assess for spinal cord compression in any patient with back pain and neurologic symptoms: emergency MRI and dexamethasone 10 mg IV bolus.
  • •Order germline and somatic genomic testing for all men with metastatic disease to identify HRR gene alterations (BRCA1/2, ATM) for PARP inhibitor eligibility, and MSI-H/dMMR for immunotherapy.
  • •Consider liquid biopsy (ctDNA, CTC) for monitoring disease evolution and detecting resistance mechanisms, particularly in CRPC.

Management

  • •For low-risk localized disease (cT1-cT2a, GG1, PSA <10 ng/mL), recommend active surveillance: PSA every 6 months, DRE annually, and repeat MRI/biopsy every 1-3 years. Avoid immediate treatment.
  • •For favorable intermediate-risk (one intermediate factor, <50% positive cores), options include active surveillance, radical prostatectomy (RP) with pelvic lymph node dissection, or definitive radiotherapy (RT) with or without short-term ADT (4-6 months). Use stereotactic body RT (SBRT) 36.25 Gy in 5 fractions if appropriate.
  • •For unfavorable intermediate-risk (two factors, GG3, or ≥50% positive cores), recommend RP or RT with ADT (4-6 months). Whole-pelvic RT improves biochemical failure-free survival (POP-RT: HR 0.23).
  • •For high-risk localized disease (cT3a, GG4/5, PSA >20 ng/mL), use multimodal therapy: RP with extended lymph node dissection, or RT with long-term ADT (18-36 months). Consider a focal boost to the intraprostatic lesion (FLAME: up to 95 Gy) to improve biochemical control.
  • •For very high-risk (cT3b-T4, primary pattern 5, >4 cores GG4/5), consider RT with ADT plus abiraterone/prednisone (STAMPEDE arm G) or RP with adjuvant RT.
  • •For biochemical recurrence after RP (PSA ≥0.2 ng/mL), observe until PSA reaches 0.2 ng/mL, then offer salvage RT to the prostate bed. If PSA doubling time ≤9 months, add enzalutamide 160 mg daily plus leuprolide 22.5 mg IM q3mo (EMBARK trial: HR 0.42 for MFS).
  • •For metastatic hormone-sensitive prostate cancer (mHSPC), initiate ADT (leuprolide 22.5 mg IM q3mo or relugolix 120 mg PO daily) plus an ARPI (darolutamide 600 mg BID, enzalutamide 160 mg daily, or abiraterone 1000 mg daily with prednisone 5 mg BID). For fit patients with high-volume disease, add docetaxel 75 mg/m² IV q3wk for 6 cycles (triplet therapy). This improves OS by 32% (ARASENS).
  • •For low-volume mHSPC, doublet therapy (ADT + ARPI) is sufficient; consider prostate RT (≤3 bone metastases, M1a only) to improve OS (HR 0.62).
  • •For nonmetastatic CRPC (nmCRPC) with PSA doubling time ≤10 months, continue ADT and add apalutamide 240 mg daily, darolutamide 600 mg BID, or enzalutamide 160 mg daily. These improve MFS by 22-24 months.
  • •For mCRPC, continue ADT. First-line options: if no prior ARPI, use abiraterone/prednisone or enzalutamide. If prior ARPI, consider docetaxel 75 mg/m² q3wk, or 177Lu-PSMA-617 (7.4 GBq q6wk x6 cycles) for PSMA-positive disease (VISION: OS 15.3 vs 11.3 months).
  • •For mCRPC with HRR mutations (BRCA1/2, ATM), use olaparib 300 mg BID (PROfound: HR 0.34 for rPFS) or niraparib 300 mg daily with abiraterone (MAGNITUDE: HR 0.53 for BRCA1/2). Test for MSI-H/dMMR; if positive, pembrolizumab 200 mg IV q3wk.
  • •For mCRPC with bone metastases, consider radium-223 55 kBq/kg IV q4wk x6 cycles (no visceral disease). Add bone-protective agent: zoledronic acid 4 mg IV q6mo or denosumab 120 mg SC monthly.
  • •For neuroendocrine prostate cancer, treat with platinum-based chemotherapy: carboplatin AUC 5 IV q3wk + docetaxel 75 mg/m², or etoposide 100 mg/m² IV days 1-3 + cisplatin 25 mg/m² IV days 1-3 q3wk.
  • •Avoid: 5α-reductase inhibitors for prevention (increase high-grade detection), non-dihydropyridine CCBs (worsen HF), and immunotherapy without MSI-H/dMMR (no benefit).
  • •Monitor: PSA every 3 months during therapy, imaging (CT, bone scan, PSMA PET) as indicated for progression. Assess for ADT side effects: hot flashes, fatigue, osteoporosis, cardiovascular risk. Use GnRH antagonist (relugolix) if prior cardiovascular disease.
  • •Refer to medical oncology for systemic therapy, radiation oncology for RT, urology for biopsy and surgery, and palliative care for advanced disease symptom management.
  • •Discharge criteria: not applicable; prostate cancer is chronic. For advanced disease, transition to hospice when no further disease-modifying therapy is appropriate.

Board Review — High Yield

  • •Gleason grade group, GG1 (Gleason ≤6) is low-risk; GG5 (Gleason 9-10) is high-risk; cribriform architecture and intraductal carcinoma independently predict aggressive behavior.
  • •NCCN risk groups, Low (cT1-T2a, GG1, PSA <10), favorable intermediate (one factor, <50% cores), unfavorable intermediate (≥2 factors, GG3, or ≥50% cores), high (cT3a, GG4/5, PSA >20), very high (cT3b-T4, primary pattern 5, >4 cores GG4/5).
  • •PSA screening, Reduces mortality by 13% over 23 years (NNT 456); MRI triage halves overdiagnosis; shared decision-making starting at age 45 (age 40 for high-risk).
  • •Triplet therapy for mHSPC, ADT + docetaxel 75 mg/m² q3wk x6 cycles + ARPI (darolutamide 600 mg BID, enzalutamide 160 mg daily, or abiraterone 1000 mg daily with prednisone 5 mg BID) reduces risk of death by 32% (ARASENS).
  • •PARP inhibitors in mCRPC, Olaparib 300 mg BID (PROfound: HR 0.34 for rPFS in BRCA1/2/ATM) and niraparib 300 mg daily with abiraterone (MAGNITUDE: HR 0.53 for BRCA1/2) are options for HRR-mutated tumors.
  • •PSMA PET/CT, Superior to conventional imaging for staging and biochemical recurrence; detection rate >80% for PSA ≥1.0 ng/mL; changes management in 52% of patients.
  • •Active surveillance, Preferred for low-risk disease; 15-year cause-specific survival 94.3%; requires PSA q6mo, DRE annually, repeat MRI/biopsy q1-3yr.
  • •Neuroendocrine prostate cancer, Aggressive, AR-negative, often treatment-emergent; treat with platinum-based chemotherapy (carboplatin AUC 5 + docetaxel 75 mg/m², or etoposide 100 mg/m² + cisplatin 25 mg/m² days 1-3 q3wk).
  • •Biochemical recurrence, PSA ≥0.2 ng/mL after RP; salvage RT at this threshold; consider adding enzalutamide + leuprolide if PSA doubling time ≤9 months (EMBARK: HR 0.42 for MFS).
  • •Bone protection, For patients on ADT with metastatic disease, use zoledronic acid 4 mg IV q6mo or denosumab 120 mg SC monthly to reduce skeletal-related events.

Deep Dive — Evidence Details

References

  1. [1]

    Benke IN, Leitzmann MF, Behrens G et al.. “Physical activity in relation to risk of prostate cancer: a systematic review and meta-analysis.” Annals of oncology : official journal of the European Society for Medical Oncology (2018). PMID: 29788165 ↗

    L2SR_OBSCited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation, Staging
  2. [2]

    Discacciati A, Orsini N, Wolk A. “Body mass index and incidence of localized and advanced prostate cancer--a dose-response meta-analysis of prospective studies.” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 22228452 ↗

    L2SR_OBSCited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation
  3. [3]

    Jones C, Dutey-Magni P, Murphy LR et al.. “Fracture-related hospitalisations in newly diagnosed high-risk localised or metastatic hormone-sensitive prostate cancer: secondary analysis of the STAMPEDE phase III trials of docetaxel and zoledronic acid using healthcare systems data.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 40680994 ↗

    L2RCTCited in: Definition and Epidemiology, Clinical Presentation, Special Populations
  4. [4]

    Saad F, Vjaters E, Shore N et al.. “Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 39279580 ↗

    L1RCTCited in: Definition and Epidemiology, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  5. [5]

    Kerkmeijer LGW, Groen VH, Pos FJ et al.. “Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 33471548 ↗

    L1RCTCited in: Definition and Epidemiology, Imaging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  6. [6]

    Lee WR, Dignam JJ, Amin MB et al.. “Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38759121 ↗

    L1RCTCited in: Definition and Epidemiology
  7. [7]

    Armstrong AJ, Liu VYT, Selvaraju RR et al.. “Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40239134 ↗

    L2RCTCited in: Definition and Epidemiology, Molecular Diagnostics and Biomarkers
  8. [8]

    Santoni M, Guerra F, Conti A et al.. “Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies.” Cancer treatment reviews (2017). PMID: 28818671 ↗

    L1SR_OBSCited in: Definition and Epidemiology, Prognosis and Prognostic Factors
  9. [9]

    Darcey E, Boyle T. “Tobacco smoking and survival after a prostate cancer diagnosis: A systematic review and meta-analysis.” Cancer treatment reviews (2018). PMID: 30055462 ↗

    L2SR_OBSCited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation, Prognosis and Prognostic Factors
  10. [10]

    Yazgan SC, Yekedüz E, Akkuş E et al.. “Venous thromboembolic event risk with PARP inhibitors in solid tumors: a systematic review and meta-analysis.” ESMO open (2025). PMID: 41027069 ↗

    L1SR_OBSCited in: Definition and Epidemiology, Risk Factors and Prevention, Management Overview
  11. [11]

    Discacciati A, Orsini N, Wolk A. “Coffee consumption and risk of nonaggressive, aggressive and fatal prostate cancer--a dose-response meta-analysis.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 24276028 ↗

    L2SR_OBSCited in: Definition and Epidemiology, Imaging, Staging
  12. [12]

    McDonald ML, Parsons JK. “The Case for Tailored Prostate Cancer Screening: An NCCN Perspective.” Journal of the National Comprehensive Cancer Network : JNCCN (2015). PMID: 26656524 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation, Molecular Diagnostics and Biomarkers
  13. [13]

    Wilt TJ, Dahm P. “PSA Screening for Prostate Cancer: Why Saying No is a High-Value Health Care Choice.” Journal of the National Comprehensive Cancer Network : JNCCN (2015). PMID: 26656523 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention, Molecular Diagnostics and Biomarkers
  14. [14]

    Dearnaley D, Syndikus I, Mossop H et al.. “Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.” The Lancet. Oncology (2016). PMID: 27339115 ↗

    L1RCTCited in: Definition and Epidemiology, Risk Factors and Prevention, Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  15. [15]

    Sweeney CJ, Martin AJ, Stockler MR et al.. “Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.” The Lancet. Oncology (2023). PMID: 36990608 ↗

    L1RCTCited in: Definition and Epidemiology, Management Overview, History and Evolution of Treatment, Special Populations
  16. [16]

    Nilsson P, Gunnlaugsson A, Beckman L et al.. “Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trial.” The Lancet. Oncology (2026). PMID: 41655576 ↗

    L1RCTCited in: Definition and Epidemiology, Molecular Diagnostics and Biomarkers, Staging
  17. [17]

    Buteau JP, Moon D, Fahey MT et al.. “Effect of [68Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial.” The Lancet. Oncology (2026). PMID: 42269655 ↗

    L1RCTCited in: Definition and Epidemiology, Imaging
  18. [18]

    Sartor O, de Bono J, Chi KN et al.. “Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.” The New England journal of medicine (2021). PMID: 34161051 ↗

    L1RCTCited in: Definition and Epidemiology, Imaging, Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Special Populations
  19. [19]

    Fizazi K, Shore N, Tammela TL et al.. “Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.” The New England journal of medicine (2019). PMID: 30763142 ↗

    L1RCTCited in: Definition and Epidemiology, Clinical Presentation, Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  20. [20]

    Manson JE, Cook NR, Lee IM et al.. “Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease.” The New England journal of medicine (2018). PMID: 30415629 ↗

    L1RCTCited in: Definition and Epidemiology, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  21. [21]

    Roobol MJ, de Vos II, Månsson M et al.. “European Study of Prostate Cancer Screening - 23-Year Follow-up.” The New England journal of medicine (2025). PMID: 41160819 ↗

    L1RCTCited in: Definition and Epidemiology, Risk Factors and Prevention, Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors, Special Populations
  22. [22]

    Hamdy FC, Donovan JL, Lane JA et al.. “Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.” The New England journal of medicine (2023). PMID: 36912538 ↗

    L1RCTCited in: Definition and Epidemiology, Clinical Presentation, Molecular Diagnostics and Biomarkers, Management Overview, Special Populations
  23. [23]

    Davis ID, Martin AJ, Stockler MR et al.. “Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.” The New England journal of medicine (2019). PMID: 31157964 ↗

    L1RCTCited in: Definition and Epidemiology, Clinical Presentation, Management Overview, Prognosis and Prognostic Factors
  24. [24]

    Shore ND, Saad F, Cookson MS et al.. “Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.” The New England journal of medicine (2020). PMID: 32469183 ↗

    L1RCTCited in: Definition and Epidemiology
  25. [25]

    Schröder FH, Hugosson J, Roobol MJ et al.. “Screening and prostate-cancer mortality in a randomized European study.” The New England journal of medicine (2009). PMID: 19297566 ↗

    L1RCTCited in: Definition and Epidemiology, Risk Factors and Prevention, Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers
  26. [26]

    Shipley WU, Seiferheld W, Lukka HR et al.. “Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.” The New England journal of medicine (2017). PMID: 28146658 ↗

    L1RCTCited in: Definition and Epidemiology, Staging
  27. [27]

    Hamdy FC, Donovan JL, Lane JA et al.. “10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.” The New England journal of medicine (2016). PMID: 27626136 ↗

    L1RCTCited in: Definition and Epidemiology, Clinical Presentation
  28. [28]

    Fizazi K, Shore N, Tammela TL et al.. “Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.” The New England journal of medicine (2020). PMID: 32905676 ↗

    L1RCTCited in: Definition and Epidemiology, Clinical Presentation
  29. [29]

    Aggarwal R, Huang J, Alumkal JJ et al.. “Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 29985747 ↗

    L4TRIAL_NONRANDOMCited in: Definition and Epidemiology, Special Populations
  30. [30]

    El-Taji O, Taktak S, Jones C et al.. “Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer: A Systematic Review and Meta-Analysis.” JAMA oncology (2024). PMID: 38842801 ↗

    L1SR_OBSCited in: Definition and Epidemiology, Management Overview
  31. [31]

    Baboudjian M, Gondran-Tellier B, Dariane C et al.. “Association Between 5α-Reductase Inhibitors and Prostate Cancer Mortality: A Systematic Review and Meta-analysis.” JAMA oncology (2023). PMID: 37079318 ↗

    L1SR_OBSCited in: Definition and Epidemiology, Clinical Presentation, Molecular Diagnostics and Biomarkers
  32. [32]

    Sushentsev N, Warren AY, Colling R et al.. “Active Monitoring, Surgery, and Radiotherapy for Cribriform-Positive and Cribriform-Negative Prostate Cancer: A Secondary Analysis of the PROTECT Randomized Clinical Trial.” JAMA oncology (2025). PMID: 41100113 ↗

    L2RCTCited in: Definition and Epidemiology, Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  33. [33]

    van As N, Griffin C, Tree A et al.. “Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer.” The New England journal of medicine (2024). PMID: 39413377 ↗

    L1TRIAL_NONRANDOMCited in: Definition and Epidemiology, Molecular Diagnostics and Biomarkers, Staging, Management Overview, Prognosis and Prognostic Factors
  34. [34]

    Clements A, Gao B, Yeap SHO et al.. “Metformin in prostate cancer: two for the price of one.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21421541 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology
  35. [35]

    Fallah J, Agrawal S, Gittleman H et al.. “FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 36469000 ↗

    L5RCTCited in: Definition and Epidemiology, Molecular Diagnostics and Biomarkers, History and Evolution of Treatment, Prognosis and Prognostic Factors
  36. [36]

    Yu EY, Narayan V, Esposito G et al.. “131I-LNTH-1095 Radioligand Therapy plus Enzalutamide versus Enzalutamide Alone in Men with PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase II Study.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 41779000 ↗

    L1RCTCited in: Definition and Epidemiology, History and Evolution of Treatment
  37. [37]

    Araújo N, Costa A, Lopes-Conceição L et al.. “Androgen-deprivation therapy and cognitive decline in the NEON-PC prospective study during the COVID-19 pandemic.” ESMO open (2022). PMID: 35344749 ↗

    L2COHORTCited in: Definition and Epidemiology, Clinical Presentation, Management Overview
  38. [38]

    Benderra MA, Serrano AG, Paillaud E et al.. “Prognostic value of comorbidities in older patients with cancer: the ELCAPA cohort study.” ESMO open (2023). PMID: 37832389 ↗

    L2COHORTCited in: Definition and Epidemiology, Prognosis and Prognostic Factors, Special Populations
  39. [39]

    Karpinski MJ, Hüsing J, Claassen K et al.. “Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study.” The Lancet. Oncology (2024). PMID: 39089299 ↗

    L3COHORTCited in: Definition and Epidemiology, Risk Factors and Prevention, Imaging, Staging
  40. [40]

    Bancroft EK, Page EC, Brook MN et al.. “A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study.” The Lancet. Oncology (2021). PMID: 34678156 ↗

    L2COHORTCited in: Definition and Epidemiology, Risk Factors and Prevention, Genetics and Hereditary Predisposition
  41. [41]

    Zaorsky NG, Sun Y, Nabid A et al.. “Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy for Localized Prostate Cancer: A Meta-Analysis.” JAMA oncology (2026). PMID: 41264309 ↗

    L1SR_OBSCited in: Definition and Epidemiology, Management Overview, Prognosis and Prognostic Factors, Special Populations
  42. [42]

    Yang L, Drake BF, Colditz GA. “Obesity and Other Cancers.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 27903157 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation
  43. [43]

    Meyerhardt JA, Ma J, Courneya KS. “Energetics in colorectal and prostate cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2010). PMID: 20644082 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Clinical Presentation
  44. [44]

    Tan DS, Mok TS, Rebbeck TR. “Cancer Genomics: Diversity and Disparity Across Ethnicity and Geography.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 26578615 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Genetics and Hereditary Predisposition, Clinical Presentation
  45. [45]

    Cooperberg MR, Carroll PR, Klotz L. “Active surveillance for prostate cancer: progress and promise.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 21825257 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation
  46. [46]

    Saad F, Adachi JD, Brown JP et al.. “Cancer treatment-induced bone loss in breast and prostate cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 18955443 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology
  47. [47]

    Fung C, Dale W, Mohile SG. “Prostate cancer in the elderly patient.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2014). PMID: 25071137 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology
  48. [48]

    Naeim A, Aapro M, Subbarao R et al.. “Supportive care considerations for older adults with cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2014). PMID: 25071112 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology
  49. [49]

    Candelieri-Surette D, Lee J, Lynch JA et al.. “Epidemiology of Metastatic Castration-Resistant Prostate Cancer in Veterans Nationwide.” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 40659047 ↗

    L4OTHERCited in: Definition and Epidemiology, Special Populations
  50. [50]

    Dong L, Lajkosz K, Sanchez-Salas R et al.. “Proportion of Gleason Score ≥8 Prostate Cancer on Biopsy and Tumor Aggressiveness in Matched Cohorts of East Asian and Non-East Asian Men.” Journal of the National Comprehensive Cancer Network : JNCCN (2024). PMID: 39546889 ↗

    L3OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors, Special Populations
  51. [51]

    Jiang S, Patel V, Stabellini N et al.. “Rurality Status and Cardiovascular Events/Survival in Older Men With Prostate Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 40073832 ↗

    L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Special Populations
  52. [52]

    Crawford TB, Nelson T, Karunamuni R et al.. “Association of HOXB13 G84E With Prostate Cancer Among 592,158 Men.” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 40953603 ↗

    L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Genetics and Hereditary Predisposition, Special Populations
  53. [53]

    Courtney PT, Deka R, Kotha NV et al.. “Metastasis and Mortality in Men With Low- and Intermediate-Risk Prostate Cancer on Active Surveillance.” Journal of the National Comprehensive Cancer Network : JNCCN (2022). PMID: 35130495 ↗

    L2OTHERCited in: Definition and Epidemiology
  54. [54]

    Scilipoti P, Bratt O, Garmo H et al.. “Long-Term Outcomes After Guideline-Recommended Treatment of Men With Prostate Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 40639404 ↗

    L2OTHERCited in: Definition and Epidemiology, Management Overview, Special Populations
  55. [55]

    Choudhury AD, Kantoff PW. “New agents in metastatic prostate cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2012). PMID: 23138168 ↗

    L5OTHERCited in: Definition and Epidemiology
  56. [56]

    Catalona WJ, Loeb S. “Prostate cancer screening and determining the appropriate prostate-specific antigen cutoff values.” Journal of the National Comprehensive Cancer Network : JNCCN (2010). PMID: 20141681 ↗

    L5OTHERCited in: Definition and Epidemiology, Molecular Diagnostics and Biomarkers
  57. [57]

    Aizer AA, Gu X, Chen MH et al.. “Cost implications and complications of overtreatment of low-risk prostate cancer in the United States.” Journal of the National Comprehensive Cancer Network : JNCCN (2015). PMID: 25583770 ↗

    L2OTHERCited in: Definition and Epidemiology, Staging
  58. [58]

    Iezzoni LI, Rao SR, Agaronnik ND et al.. “Cross-Sectional Analysis of the Associations Between Four Common Cancers and Disability.” Journal of the National Comprehensive Cancer Network : JNCCN (2020). PMID: 32755976 ↗

    L4OTHERCited in: Definition and Epidemiology
  59. [59]

    Dorff T, Horvath LG, Autio K et al.. “A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 38300720 ↗

    L4TRIAL_NONRANDOMCited in: Definition and Epidemiology, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  60. [60]

    Li Y, Cozzi PJ. “Targeting uPA/uPAR in prostate cancer.” Cancer treatment reviews (2007). PMID: 17658220 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Management Overview
  61. [61]

    Heidegger I, Tsaur I, Borgmann H et al.. “Hereditary prostate cancer - Primetime for genetic testing?” Cancer treatment reviews (2019). PMID: 31783313 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Genetics and Hereditary Predisposition, History and Evolution of Treatment
  62. [62]

    Snow O, Lallous N, Singh K et al.. “Androgen receptor plasticity and its implications for prostate cancer therapy.” Cancer treatment reviews (2019). PMID: 31698174 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Management Overview
  63. [63]

    Nomiya T, Tsuji H, Toyama S et al.. “Management of high-risk prostate cancer: radiation therapy and hormonal therapy.” Cancer treatment reviews (2013). PMID: 23648323 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Management Overview
  64. [64]

    Efstathiou JA, Morgans AK, Bland CS et al.. “Novel hormone therapy and coordination of care in high-risk biochemically recurrent prostate cancer.” Cancer treatment reviews (2023). PMID: 38035646 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Molecular Diagnostics and Biomarkers, Management Overview
  65. [65]

    Lobianco L, Calvanese G, D'Ausilio D et al.. “The emerging role of PARP inhibitors in prostate cancer: A narrative review.” Cancer treatment reviews (2025). PMID: 40848312 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology
  66. [66]

    Saad F, Shore N, Zhang T et al.. “Emerging therapeutic targets for patients with advanced prostate cancer.” Cancer treatment reviews (2019). PMID: 30913454 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology
  67. [67]

    Vignani F, Bertaglia V, Buttigliero C et al.. “Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer.” Cancer treatment reviews (2016). PMID: 26907461 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology
  68. [68]

    Deng X, He G, Liu J et al.. “Recent advances in bone-targeted therapies of metastatic prostate cancer.” Cancer treatment reviews (2014). PMID: 24767837 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology
  69. [69]

    Zaorsky NG, Shaikh T, Murphy CT et al.. “Comparison of outcomes and toxicities among radiation therapy treatment options for prostate cancer.” Cancer treatment reviews (2016). PMID: 27347670 ↗

    L2REVIEW_NARRATIVECited in: Definition and Epidemiology, Prognosis and Prognostic Factors
  70. [70]

    Mederos N, Friedlaender A, Peters S et al.. “Gender-specific aspects of epidemiology, molecular genetics and outcome: lung cancer.” ESMO open (2020). PMID: 33148544 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Clinical Presentation, History and Evolution of Treatment
  71. [71]

    Bray F, Parkin DM. “Cancer in sub-Saharan Africa in 2020: a review of current estimates of the national burden, data gaps, and future needs.” The Lancet. Oncology (2022). PMID: 35550275 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology
  72. [72]

    Beer AJ, Eiber M, Souvatzoglou M et al.. “Radionuclide and hybrid imaging of recurrent prostate cancer.” The Lancet. Oncology (2010). PMID: 20599424 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Imaging
  73. [73]

    Chiao EY, Coghill A, Kizub D et al.. “The effect of non-AIDS-defining cancers on people living with HIV.” The Lancet. Oncology (2021). PMID: 34087151 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention
  74. [74]

    Peshin S, Takrori E, Lal BM et al.. “Association Between Metabolic Syndrome and Prostate Cancer: A Systematic Review.” Cancers (2026). PMID: 42352487 ↗

    L2SR_OBSCited in: Definition and Epidemiology, Risk Factors and Prevention
  75. [75]

    Ho AS, Daskivich TJ, Sacks WL et al.. “Parallels Between Low-Risk Prostate Cancer and Thyroid Cancer: A Review.” JAMA oncology (2019). PMID: 30543358 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation, Imaging, History and Evolution of Treatment
  76. [76]

    Zaorsky NG, Churilla TM, Egleston BL et al.. “Causes of death among cancer patients.” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 27831506 ↗

    L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation
  77. [77]

    Kobayashi D, Takahashi O, Fukui T et al.. “Optimal prostate-specific antigen screening interval for prostate cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21948815 ↗

    L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention
  78. [78]

    Carioli G, La Vecchia C, Bertuccio P et al.. “Cancer mortality predictions for 2017 in Latin America.” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 28911064 ↗

    L2OTHERCited in: Definition and Epidemiology
  79. [79]

    Rombouts AJM, Hugen N, Elferink MAG et al.. “Incidence of second tumors after treatment with or without radiation for rectal cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 27993790 ↗

    L2OTHERCited in: Definition and Epidemiology
  80. [80]

    Carioli G, Malvezzi M, Bertuccio P et al.. “Cancer mortality in the elderly in 11 countries worldwide, 1970-2015.” Annals of oncology : official journal of the European Society for Medical Oncology (2019). PMID: 31147682 ↗

    L2OTHERCited in: Definition and Epidemiology
  81. [81]

    Carioli G, Bertuccio P, Boffetta P et al.. “European cancer mortality predictions for the year 2020 with a focus on prostate cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2020). PMID: 32321669 ↗

    L2OTHERCited in: Definition and Epidemiology, Clinical Presentation
  82. [82]

    Janssen-Heijnen ML, Houterman S, Lemmens VE et al.. “Prognosis for long-term survivors of cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 17693654 ↗

    L2OTHERCited in: Definition and Epidemiology, Clinical Presentation
  83. [83]

    Lou Y, Fan D, Chen T et al.. “The impact of abiraterone and enzalutamide on hypokalemia incidence in patients with prostate cancer: a systematic review and meta-analysis.” BMC cancer (2026). PMID: 42387420 ↗

    L1SR_OBSCited in: Definition and Epidemiology, Management Overview
  84. [84]

    Benker P, Hamann A, Leitzmann MF et al.. “Post-diagnosis physical activity in relation to mortality among prostate cancer survivors: a systematic review and meta-analysis.” Cancer causes & control : CCC (2026). PMID: 42348026 ↗

    L2SR_OBSCited in: Definition and Epidemiology
  85. [85]

    Özdemir BC, Dotto GP. “Sex Hormones and Anticancer Immunity.” Clinical cancer research : an official journal of the American Association for Cancer Research (2019). PMID: 30890551 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Management Overview
  86. [86]

    Bolton EM, Tuzova AV, Walsh AL et al.. “Noncoding RNAs in prostate cancer: the long and the short of it.” Clinical cancer research : an official journal of the American Association for Cancer Research (2013). PMID: 24146262 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Molecular Diagnostics and Biomarkers, History and Evolution of Treatment, Prognosis and Prognostic Factors
  87. [87]

    Friedenreich CM, Neilson HK, Farris MS et al.. “Physical Activity and Cancer Outcomes: A Precision Medicine Approach.” Clinical cancer research : an official journal of the American Association for Cancer Research (2016). PMID: 27407093 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Clinical Presentation
  88. [88]

    Biggar RJ. “Molecular pathways: digoxin use and estrogen-sensitive cancers--risks and possible therapeutic implications.” Clinical cancer research : an official journal of the American Association for Cancer Research (2012). PMID: 22368159 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention
  89. [89]

    Vessella RL, Corey E. “Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis.” Clinical cancer research : an official journal of the American Association for Cancer Research (2006). PMID: 17062715 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology
  90. [90]

    Tiangco BJ, Burog AILD, Garcia-Trinidad AM et al.. “Philippine Clinical Practice Guidelines for Periodic Health Examination: Screening for Neoplastic Diseases.” Acta medica Philippina (2026). PMID: 42382936 ↗

    L1GUIDELINECited in: Definition and Epidemiology, Risk Factors and Prevention
  91. [91]

    van der Gaag S, Vis A, Bartelink I et al.. “The DARO-flare trial: evaluating the impact of darolutamide on prostate-specific membrane antigen (PSMA) flare and its implications for imaging and staging of hormone-sensitive prostate cancer - study protocol.” BMJ open (2026). PMID: 42315278 ↗

    L5TRIAL_NONRANDOMCited in: Definition and Epidemiology, Imaging, Molecular Diagnostics and Biomarkers, Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors
  92. [92]

    Blay JY, Boucher S, Le Vu B et al.. “Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France.” ESMO open (2021). PMID: 33984676 ↗

    L2OTHERCited in: Definition and Epidemiology, Clinical Presentation
  93. [93]

    Mitchell JD, Laurie M, Xia Q et al.. “Risk profiles and incidence of cardiovascular events across different cancer types.” ESMO open (2023). PMID: 37979325 ↗

    L2OTHERCited in: Definition and Epidemiology, Clinical Presentation
  94. [94]

    Peretti U, Cavaliere A, Niger M et al.. “Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort.” ESMO open (2021). PMID: 33399070 ↗

    L4OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Genetics and Hereditary Predisposition, Clinical Presentation, History and Evolution of Treatment, Special Populations
  95. [95]

    Kulkarni AA, Rubin N, Tholkes A et al.. “Risk for stroke and myocardial infarction with abiraterone versus enzalutamide in metastatic prostate cancer patients.” ESMO open (2021). PMID: 34509804 ↗

    L2OTHERCited in: Definition and Epidemiology, Clinical Presentation
  96. [96]

    Dee EC, Laversanne M, Bhoo-Pathy N et al.. “Cancer incidence and mortality estimates in 2022 in southeast Asia: a comparative analysis.” The Lancet. Oncology (2025). PMID: 40024257 ↗

    L2OTHERCited in: Definition and Epidemiology
  97. [97]

    De Angelis R, Demuru E, Baili P et al.. “Complete cancer prevalence in Europe in 2020 by disease duration and country (EUROCARE-6): a population-based study.” The Lancet. Oncology (2024). PMID: 38307102 ↗

    L2OTHERCited in: Definition and Epidemiology
  98. [98]

    Nguyen T, Tallman S, Cho Y et al.. “Equity in cancer genomics in the UK: a cross-sectional analysis of a national cancer cohort.” The Lancet. Oncology (2025). PMID: 40513587 ↗

    L4OTHERCited in: Definition and Epidemiology, Genetics and Hereditary Predisposition
  99. [99]

    Stephens C, Shah R, Hussain A et al.. “Cancer-related mortality among solid organ transplant recipients: systematic review and meta-analysis.” Frontiers in transplantation (2026). PMID: 42405264 ↗

    L2SR_OBSCited in: Definition and Epidemiology, Risk Factors and Prevention
  100. [100]

    Simoni AH, Ording A, Hedegaard JN et al.. “Detection of prostate cancer by magnetic resonance imaging before biopsy - real-world evidence from a nationwide cohort study.” Scandinavian journal of urology (2026). PMID: 42411569 ↗

    L2COHORTCited in: Definition and Epidemiology, Clinical Presentation, Biopsy and Histologic Diagnosis, Imaging, Molecular Diagnostics and Biomarkers, Special Populations
  101. [101]

    Bae SH, Byun HJ, Jang HC et al.. “Risk of second primary cancer after radiotherapy for localized prostate cancer: A single-center Korean cohort study.” Investigative and clinical urology (2026). PMID: 42405711 ↗

    L3COHORTCited in: Definition and Epidemiology, Management Overview, Special Populations
  102. [102]

    Fitzmaurice C, Abate D, Abbasi N et al.. “Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study.” JAMA oncology (2019). PMID: 31560378 ↗

    L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention
  103. [103]

    Goddard KAB, Feuer EJ, Mandelblatt JS et al.. “Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020.” JAMA oncology (2025). PMID: 39636625 ↗

    L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Management Overview, Special Populations
  104. [104]

    Kishan AU, Ma TM, Lamb JM et al.. “Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial.” JAMA oncology (2023). PMID: 36633877 ↗

    L1OTHERCited in: Definition and Epidemiology, Imaging, Management Overview
  105. [105]

    Fitzmaurice C, Allen C, Barber RM et al.. “Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study.” JAMA oncology (2017). PMID: 27918777 ↗

    L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation
  106. [106]

    Unger JM, Till C, Tangen CM et al.. “Long-Term Adverse Effects and Complications After Prostate Cancer Treatment.” JAMA oncology (2024). PMID: 39509091 ↗

    L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation
  107. [107]

    Su ZT, Mamawala M, Landis PK et al.. “Diet Quality, Dietary Inflammatory Potential, and Risk of Prostate Cancer Grade Reclassification.” JAMA oncology (2024). PMID: 39418052 ↗

    L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation, Prognosis and Prognostic Factors
  108. [108]

    Patel NA, Barocas DA, Lin DW et al.. “Grade Group 1 Prostate Cancer Outcome by Biopsy Grade and Risk Group.” JAMA oncology (2025). PMID: 40742601 ↗

    L3OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Biopsy and Histologic Diagnosis, Prognosis and Prognostic Factors
  109. [109]

    . “Q&A: John Carpten on Cancer Disparities.” Cancer discovery (2020). PMID: 32948609 ↗

    L5OTHERCited in: Definition and Epidemiology
  110. [110]

    . “Mortality Similar for Prostate Cancer Therapies.” Cancer discovery (2016). PMID: 27920141 ↗

    L5OTHERCited in: Definition and Epidemiology, Molecular Diagnostics and Biomarkers, Special Populations
  111. [111]

    Huang FW, Mosquera JM, Garofalo A et al.. “Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations.” Cancer discovery (2017). PMID: 28515055 ↗

    L4OTHERCited in: Definition and Epidemiology
  112. [112]

    . “By the Numbers: Cancer Mortality, 2011-2015.” Cancer discovery (2018). PMID: 30076139 ↗

    L5OTHERCited in: Definition and Epidemiology
  113. [113]

    Lucas JM, Heinlein C, Kim T et al.. “The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis.” Cancer discovery (2014). PMID: 25122198 ↗

    L5OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention
  114. [114]

    Reina-Campos M, Linares JF, Duran A et al.. “Increased Serine and One-Carbon Pathway Metabolism by PKCλ/ι Deficiency Promotes Neuroendocrine Prostate Cancer.” Cancer cell (2019). PMID: 30827887 ↗

    L5OTHERCited in: Definition and Epidemiology
  115. [115]

    Zhao J, Zhao Q, Liu X et al.. “Comparative effectiveness and integrated safety of goserelin sustained-release microspheres versus implants in prostate cancer: a patient-based real-world study and systematic review with meta-analysis.” Frontiers in oncology (2026). PMID: 42388614 ↗

    L2SR_OBSCited in: Definition and Epidemiology
  116. [116]

    Partuzo JGR, Mora-Garijo B, Hwang J. “Genetics and Screening in Prostate Cancer.” The Surgical clinics of North America (2026). PMID: 42419315 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention, Genetics and Hereditary Predisposition, Clinical Presentation, Prognosis and Prognostic Factors
  117. [117]

    Tsiamis N, Toulgaridis F, Stefanou E et al.. “Cardiovascular complications of antineoplastic treatment in prostate cancer patients and compensatory strategies for clinical management.” European journal of internal medicine (2026). PMID: 42386405 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology
  118. [118]

    Bensalim I, Belyamani L, Boutayeb S et al.. “Mechanisms of resistance to androgen deprivation therapy in prostate cancer.” Molecular aspects of medicine (2026). PMID: 42314224 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology
  119. [119]

    Flavin R, Pettersson A, Hendrickson WK et al.. “SPINK1 protein expression and prostate cancer progression.” Clinical cancer research : an official journal of the American Association for Cancer Research (2014). PMID: 24687926 ↗

    L2OTHERCited in: Definition and Epidemiology, Biopsy and Histologic Diagnosis
  120. [120]

    Murtola TJ, Siltari A. “Statins for Prostate Cancer: When and How Much?” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 34281913 ↗

    L5OTHERCited in: Definition and Epidemiology
  121. [121]

    Polascik TJ, Passoni NM, Villers A et al.. “Modernizing the diagnostic and decision-making pathway for prostate cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2014). PMID: 25316814 ↗

    L5OTHERCited in: Definition and Epidemiology, Imaging
  122. [122]

    Gallagher DJ, Vijai J, Cronin AM et al.. “Susceptibility loci associated with prostate cancer progression and mortality.” Clinical cancer research : an official journal of the American Association for Cancer Research (2010). PMID: 20460480 ↗

    L2OTHERCited in: Definition and Epidemiology, Staging
  123. [123]

    Daly MB, Pal T, Berry MP et al.. “Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2021). PMID: 33406487 ↗

    L1GUIDELINECited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition, Management Overview, History and Evolution of Treatment
  124. [124]

    Cheng HH, Giri VN, Goggins M et al.. “NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026.” Journal of the National Comprehensive Cancer Network : JNCCN (2026). PMID: 41671423 ↗

    L1GUIDELINECited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition, Management Overview, History and Evolution of Treatment
  125. [125]

    Carroll PH, Mohler JL. “NCCN Guidelines Updates: Prostate Cancer and Prostate Cancer Early Detection.” Journal of the National Comprehensive Cancer Network : JNCCN (2018). PMID: 29784740 ↗

    L5GUIDELINECited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition, Biopsy and Histologic Diagnosis, Imaging, Molecular Diagnostics and Biomarkers, Staging, Prognosis and Prognostic Factors
  126. [126]

    Carroll PR, Parsons JK, Andriole G et al.. “NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016.” Journal of the National Comprehensive Cancer Network : JNCCN (2016). PMID: 27160230 ↗

    L1GUIDELINECited in: Risk Factors and Prevention
  127. [127]

    Olleik G, Kassouf W, Aprikian A et al.. “Evaluation of New Tests and Interventions for Prostate Cancer Management: A Systematic Review.” Journal of the National Comprehensive Cancer Network : JNCCN (2018). PMID: 30442734 ↗

    L5SR_OBSCited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition, Clinical Presentation, Biopsy and Histologic Diagnosis, Imaging, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  128. [128]

    Scher HI, Morris MJ, Stadler WM et al.. “Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 26903579 ↗

    L5GUIDELINECited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition, Histopathology and Molecular Biology, Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors
  129. [129]

    Yu EY, Rumble RB, Agarwal N et al.. “Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 39787437 ↗

    L1GUIDELINECited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition, Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment
  130. [130]

    Giri VN, Knudsen KE, Kelly WK et al.. “Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 29236593 ↗

    L5GUIDELINECited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition
  131. [131]

    Louie KS, Seigneurin A, Cathcart P et al.. “Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis.” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 25403590 ↗

    L1SR_OBSCited in: Risk Factors and Prevention, Biopsy and Histologic Diagnosis
  132. [132]

    Murthy V, Maitre P, Kannan S et al.. “Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 33497252 ↗

    L1RCTCited in: Risk Factors and Prevention, Clinical Presentation, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  133. [133]

    Zaorsky NG, Doyle LA, Yamoah K et al.. “High dose rate brachytherapy boost for prostate cancer: a systematic review.” Cancer treatment reviews (2013). PMID: 24231548 ↗

    L5SR_OBSCited in: Risk Factors and Prevention
  134. [134]

    Tang C, Sherry AD, Hwang H et al.. “Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration.” The Lancet. Oncology (2026). PMID: 41643695 ↗

    L1SR_OBSCited in: Risk Factors and Prevention
  135. [135]

    Fizazi K, Tran N, Fein L et al.. “Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.” The Lancet. Oncology (2019). PMID: 30987939 ↗

    L1RCTCited in: Risk Factors and Prevention, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  136. [136]

    Hofman MS, Emmett L, Sandhu S et al.. “Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial.” The Lancet. Oncology (2023). PMID: 38043558 ↗

    L1RCTCited in: Risk Factors and Prevention, Imaging, Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors
  137. [137]

    Azad AA, Bressel M, Tan H et al.. “Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study.” The Lancet. Oncology (2024). PMID: 39293461 ↗

    L1RCTCited in: Risk Factors and Prevention, Histopathology and Molecular Biology, Molecular Diagnostics and Biomarkers
  138. [138]

    Karpinski MJ, Civan C, Rauscher I et al.. “New prostate cancer risk groups by PSMA-PET (PPP3): an international, retrospective, registry-based cohort study.” The Lancet. Oncology (2026). PMID: 41819113 ↗

    L3COHORTCited in: Risk Factors and Prevention, Imaging
  139. [139]

    Fizazi K, Piulats JM, Reaume MN et al.. “Rucaparib or Physician's Choice in Metastatic Prostate Cancer.” The New England journal of medicine (2023). PMID: 36795891 ↗

    L1RCTCited in: Risk Factors and Prevention, Prognosis and Prognostic Factors
  140. [140]

    Hugosson J, Godtman RA, Wallstrom J et al.. “Results after Four Years of Screening for Prostate Cancer with PSA and MRI.” The New England journal of medicine (2024). PMID: 39321360 ↗

    L1RCTCited in: Risk Factors and Prevention, Clinical Presentation, Biopsy and Histologic Diagnosis, Imaging, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  141. [141]

    Hugosson J, Månsson M, Wallström J et al.. “Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only.” The New England journal of medicine (2022). PMID: 36477032 ↗

    L1RCTCited in: Risk Factors and Prevention, Clinical Presentation, Imaging, Molecular Diagnostics and Biomarkers
  142. [142]

    Eklund M, Jäderling F, Discacciati A et al.. “MRI-Targeted or Standard Biopsy in Prostate Cancer Screening.” The New England journal of medicine (2021). PMID: 34237810 ↗

    L1RCTCited in: Risk Factors and Prevention, Biopsy and Histologic Diagnosis, Imaging
  143. [143]

    Fazekas T, Shim SR, Basile G et al.. “Magnetic Resonance Imaging in Prostate Cancer Screening: A Systematic Review and Meta-Analysis.” JAMA oncology (2024). PMID: 38576242 ↗

    L1SR_OBSCited in: Risk Factors and Prevention, Imaging, Molecular Diagnostics and Biomarkers
  144. [144]

    Brand DH, Tree AC, Ostler P et al.. “Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.” The Lancet. Oncology (2019). PMID: 31540791 ↗

    L1TRIAL_NONRANDOMCited in: Risk Factors and Prevention, Management Overview, Prognosis and Prognostic Factors, Special Populations
  145. [145]

    Hofman MS, Violet J, Hicks RJ et al.. “[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.” The Lancet. Oncology (2018). PMID: 29752180 ↗

    L4TRIAL_NONRANDOMCited in: Risk Factors and Prevention, Molecular Diagnostics and Biomarkers
  146. [146]

    Buteau JP, Kostos L, Jackson PA et al.. “First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta-Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study.” The Lancet. Oncology (2025). PMID: 40617237 ↗

    L4TRIAL_NONRANDOMCited in: Risk Factors and Prevention, Clinical Presentation
  147. [147]

    Li H, Tai BC. “RNASEL gene polymorphisms and the risk of prostate cancer: a meta-analysis.” Clinical cancer research : an official journal of the American Association for Cancer Research (2006). PMID: 17020975 ↗

    L3SR_OBSCited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition, History and Evolution of Treatment
  148. [148]

    Turati F, Edefonti V, Bosetti C et al.. “Family history of cancer and the risk of cancer: a network of case-control studies.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 23884440 ↗

    L3CASE_CONTROLCited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition, Clinical Presentation
  149. [149]

    Di Maso M, Talamini R, Bosetti C et al.. “Red meat and cancer risk in a network of case-control studies focusing on cooking practices.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 24121119 ↗

    L3CASE_CONTROLCited in: Risk Factors and Prevention
  150. [150]

    Vidal AC, Howard LE, Moreira DM et al.. “Aspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE study.” Clinical cancer research : an official journal of the American Association for Cancer Research (2014). PMID: 25520389 ↗

    L2RCTCited in: Risk Factors and Prevention, Clinical Presentation
  151. [151]

    Daly MB, Pal T, Maxwell KN et al.. “NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024.” Journal of the National Comprehensive Cancer Network : JNCCN (2023). PMID: 37856201 ↗

    L1OTHERCited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition
  152. [152]

    Carroll PR, Vickers AJ. “Point/Counterpoint: early detection of prostate cancer: do the benefits outweigh the consequences?” Journal of the National Comprehensive Cancer Network : JNCCN (2014). PMID: 24853213 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Molecular Diagnostics and Biomarkers
  153. [153]

    Gonzalgo ML, Carter HB. “Update on PSA testing.” Journal of the National Comprehensive Cancer Network : JNCCN (2007). PMID: 17692178 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Molecular Diagnostics and Biomarkers
  154. [154]

    Klotz L. “Point: active surveillance for favorable risk prostate cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2007). PMID: 17692173 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Prognosis and Prognostic Factors
  155. [155]

    Matsubara N, de Bono J, Olmos D et al.. “Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 36318705 ↗

    L2TRIAL_NONRANDOMCited in: Risk Factors and Prevention
  156. [156]

    Olmos D, Lorente D, Alameda D et al.. “Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes.” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 38417742 ↗

    L3OTHERCited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition, Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors
  157. [157]

    Hu J, La Vecchia C, de Groh M et al.. “Dietary cholesterol intake and cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21543628 ↗

    L3OTHERCited in: Risk Factors and Prevention
  158. [158]

    Segal N, Ber Y, Benjaminov O et al.. “Imaging-based prostate cancer screening among BRCA mutation carriers-results from the first round of screening.” Annals of oncology : official journal of the European Society for Medical Oncology (2020). PMID: 32958357 ↗

    L2OTHERCited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition, Imaging
  159. [159]

    Yassa M, Saliou M, De Rycke Y et al.. “Male pattern baldness and the risk of prostate cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21324955 ↗

    L3OTHERCited in: Risk Factors and Prevention, Clinical Presentation
  160. [160]

    Montopoli M, Zumerle S, Vettor R et al.. “Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532).” Annals of oncology : official journal of the European Society for Medical Oncology (2020). PMID: 32387456 ↗

    L3OTHERCited in: Risk Factors and Prevention, Clinical Presentation
  161. [161]

    Rapp K, Klenk J, Ulmer H et al.. “Weight change and cancer risk in a cohort of more than 65,000 adults in Austria.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 18056917 ↗

    L2OTHERCited in: Risk Factors and Prevention
  162. [162]

    Bravi F, Scotti L, Bosetti C et al.. “Self-reported history of hypercholesterolaemia and gallstones and the risk of prostate cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2006). PMID: 16611646 ↗

    L3OTHERCited in: Risk Factors and Prevention
  163. [163]

    Klotz L, Vesprini D, Sethukavalan P et al.. “Long-term follow-up of a large active surveillance cohort of patients with prostate cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2014). PMID: 25512465 ↗

    L2OTHERCited in: Risk Factors and Prevention, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  164. [164]

    Castro E, Goh C, Olmos D et al.. “Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2013). PMID: 23569316 ↗

    L3OTHERCited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition, Clinical Presentation, Staging, Prognosis and Prognostic Factors
  165. [165]

    Wei EK, Wolin KY, Colditz GA. “Time course of risk factors in cancer etiology and progression.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2010). PMID: 20644083 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention
  166. [166]

    Giri VN, Knudsen KE, Kelly WK et al.. “Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 32516092 ↗

    L5OTHERCited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition
  167. [167]

    Nam RK, Toi A, Klotz LH et al.. “Assessing individual risk for prostate cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2007). PMID: 17704405 ↗

    L4OTHERCited in: Risk Factors and Prevention, Biopsy and Histologic Diagnosis
  168. [168]

    Morgans AK. “Optimization of Risk Stratification in Localized Prostate Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 29303624 ↗

    L5OTHERCited in: Risk Factors and Prevention
  169. [169]

    Beebe-Dimmer JL, Kapron AL, Fraser AM et al.. “Risk of Prostate Cancer Associated With Familial and Hereditary Cancer Syndromes.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 32208047 ↗

    L3OTHERCited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition
  170. [170]

    Nyberg T, Brook MN, Ficorella L et al.. “CanRisk-Prostate: A Comprehensive, Externally Validated Risk Model for the Prediction of Future Prostate Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 36493335 ↗

    L2OTHERCited in: Risk Factors and Prevention
  171. [171]

    Kim A, Moore NA, Dong T et al.. “Artificial intelligence in genitourinary oncology: publication trends and systematic review.” BJU international (2026). PMID: 42360093 ↗

    L1SR_OBSCited in: Risk Factors and Prevention
  172. [172]

    Créhange G, Chen CP, Hsu CC et al.. “Management of prostate cancer patients with lymph node involvement: a rapidly evolving paradigm.” Cancer treatment reviews (2012). PMID: 22703831 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Clinical Presentation
  173. [173]

    Stavrinides V, Parker CC, Moore CM. “When no treatment is the best treatment: Active surveillance strategies for low risk prostate cancers.” Cancer treatment reviews (2017). PMID: 28609648 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Clinical Presentation, Imaging
  174. [174]

    Russo A, Incorvaia L, Capoluongo E et al.. “Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies.” ESMO open (2022). PMID: 35597177 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Management Overview
  175. [175]

    Huntley C, Torr B, Sud A et al.. “Utility of polygenic risk scores in UK cancer screening: a modelling analysis.” The Lancet. Oncology (2023). PMID: 37178708 ↗

    L2REVIEW_NARRATIVECited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition
  176. [176]

    Cuzick J, Thorat MA, Andriole G et al.. “Prevention and early detection of prostate cancer.” The Lancet. Oncology (2014). PMID: 25281467 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers
  177. [177]

    McHugh JK, Bancroft EK, Saunders E et al.. “Assessment of a Polygenic Risk Score in Screening for Prostate Cancer.” The New England journal of medicine (2025). PMID: 40214032 ↗

    L2OTHERCited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition, Biopsy and Histologic Diagnosis, Imaging, Molecular Diagnostics and Biomarkers
  178. [178]

    Cheng HH, Shevach JW, Castro E et al.. “BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients: A Review.” JAMA oncology (2024). PMID: 39052257 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition, Management Overview
  179. [179]

    Tosoian JJ, Zhang Y, Xiao L et al.. “Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer.” JAMA oncology (2024). PMID: 38635241 ↗

    L2OTHERCited in: Risk Factors and Prevention, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  180. [180]

    Monda SM, Demus T, Jaime-Casas S et al.. “Trends in Surgical Overtreatment of Prostate Cancer.” JAMA oncology (2025). PMID: 40292607 ↗

    L2OTHERCited in: Risk Factors and Prevention, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  181. [181]

    Tilki D, Chen MH, Wu J et al.. “Persistent Prostate-Specific Antigen Following Radical Prostatectomy for Prostate Cancer and Mortality Risk.” JAMA oncology (2025). PMID: 40080000 ↗

    L2OTHERCited in: Risk Factors and Prevention, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  182. [182]

    Vickers AJ, Cooperberg M, Pavlovich CP et al.. “Prostate Cancer Mortality After Relabeling Low-Grade Prostate Cancer as Precancerous.” JAMA oncology (2026). PMID: 42166158 ↗

    L5OTHERCited in: Risk Factors and Prevention
  183. [183]

    Pickersgill NA, Peré MM, Vertosick EA et al.. “Prostate-Specific Antigen Levels Among Participants Receiving Annual Testing.” JAMA oncology (2025). PMID: 40965920 ↗

    L2OTHERCited in: Risk Factors and Prevention, Clinical Presentation, Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers
  184. [184]

    Chin YR, Yuan X, Balk SP et al.. “PTEN-deficient tumors depend on AKT2 for maintenance and survival.” Cancer discovery (2014). PMID: 24838891 ↗

    L5OTHERCited in: Risk Factors and Prevention
  185. [185]

    . “Shared Decision Making Emphasized for Prostate Screening.” Cancer discovery (2018). PMID: 29794067 ↗

    L5OTHERCited in: Risk Factors and Prevention, Special Populations
  186. [186]

    Heaphy CM, Yoon GS, Peskoe SB et al.. “Prostate cancer cell telomere length variability and stromal cell telomere length as prognostic markers for metastasis and death.” Cancer discovery (2013). PMID: 23779129 ↗

    L2OTHERCited in: Risk Factors and Prevention, Prognosis and Prognostic Factors, Special Populations
  187. [187]

    Platz EA, Yegnasubramanian S, Liu JO et al.. “A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment.” Cancer discovery (2011). PMID: 22140654 ↗

    L2OTHERCited in: Risk Factors and Prevention
  188. [188]

    Zhang Z, Zhou C, Li X et al.. “Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation.” Cancer cell (2020). PMID: 32220301 ↗

    L5OTHERCited in: Risk Factors and Prevention, Molecular Diagnostics and Biomarkers, Management Overview
  189. [189]

    Li X, Wang Y, Deng S et al.. “Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer.” Cancer cell (2023). PMID: 37478850 ↗

    L5OTHERCited in: Risk Factors and Prevention, Management Overview
  190. [190]

    Gerhauser C, Favero F, Risch T et al.. “Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories.” Cancer cell (2018). PMID: 30537516 ↗

    L4OTHERCited in: Risk Factors and Prevention, Histopathology and Molecular Biology, Clinical Presentation, Molecular Diagnostics and Biomarkers, History and Evolution of Treatment
  191. [191]

    Su W, Han HH, Wang Y et al.. “The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression.” Cancer cell (2019). PMID: 31327655 ↗

    L5OTHERCited in: Risk Factors and Prevention, Management Overview
  192. [192]

    Mirza W, Haider MH, Habib T et al.. “Hugo™ RAS versus da Vinci® for robot-assisted radical prostatectomy in localized prostate cancer: a GRADE-assessed systematic review and meta-analysis of prospective comparative studies.” BMC surgery (2026). PMID: 42332746 ↗

    L1SR_OBSCited in: Risk Factors and Prevention
  193. [193]

    May KF, Gulley JL, Drake CG et al.. “Prostate cancer immunotherapy.” Clinical cancer research : an official journal of the American Association for Cancer Research (2011). PMID: 21700764 ↗

    L5OTHERCited in: Risk Factors and Prevention
  194. [194]

    Guedes LB, Antonarakis ES, Schweizer MT et al.. “MSH2 Loss in Primary Prostate Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2017). PMID: 28790115 ↗

    L4OTHERCited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition, Biopsy and Histologic Diagnosis, Staging
  195. [195]

    Kaur H, Salles DC, Murali S et al.. “Genomic and Clinicopathologic Characterization of ATM-deficient Prostate Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 32694154 ↗

    L4OTHERCited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition, Prognosis and Prognostic Factors, Special Populations
  196. [196]

    McNevin CS, Keogh A, Mohammed Nur M et al.. “Prevalence of Mismatch Repair Deficiency in Primary Prostate Cancer in a Large Prospective Cohort.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40105779 ↗

    L4OTHERCited in: Risk Factors and Prevention, Biopsy and Histologic Diagnosis
  197. [197]

    Stopsack KH, Vijai J, Conry M et al.. “Germline DNA Damage Repair Variants and Prognosis of Patients with High-Risk or Metastatic Prostate Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 39450704 ↗

    L2OTHERCited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition, Clinical Presentation, Prognosis and Prognostic Factors
  198. [198]

    Barber L, Gerke T, Markt SC et al.. “Family History of Breast or Prostate Cancer and Prostate Cancer Risk.” Clinical cancer research : an official journal of the American Association for Cancer Research (2018). PMID: 30082473 ↗

    L2OTHERCited in: Risk Factors and Prevention
  199. [199]

    Murphy AB, Nyame Y, Martin IK et al.. “Vitamin D deficiency predicts prostate biopsy outcomes.” Clinical cancer research : an official journal of the American Association for Cancer Research (2014). PMID: 24789033 ↗

    L2OTHERCited in: Risk Factors and Prevention, Clinical Presentation, Biopsy and Histologic Diagnosis, Staging
  200. [200]

    Lindström S, Adami HO, Adolfsson J et al.. “Y chromosome haplotypes and prostate cancer in Sweden.” Clinical cancer research : an official journal of the American Association for Cancer Research (2008). PMID: 18927315 ↗

    L3OTHERCited in: Risk Factors and Prevention
  201. [201]

    Huh JW, Tanksley J, Chino J et al.. “Long-term Consequences of Pelvic Irradiation: Toxicities, Challenges, and Therapeutic Opportunities with Pharmacologic Mitigators.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 32098770 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition
  202. [202]

    Allott EH, Ebot EM, Stopsack KH et al.. “Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2019). PMID: 31754047 ↗

    L2OTHERCited in: Risk Factors and Prevention
  203. [203]

    Houssa N, Abdelalim S, Elmouki I. “Algebraic evaluation of optimization in tumors classification with numerical assessments via a flask-react web interface.” Frontiers in digital health (2026). PMID: 42434374 ↗

    L5OTHERCited in: Risk Factors and Prevention
  204. [204]

    Silvani C, Santangelo A, Stephens A et al.. “No racial disparities in prostate cancer-specific mortality after biochemical recurrence following radical prostatectomy or radiation therapy.” Prostate cancer and prostatic diseases (2026). PMID: 42432266 ↗

    L4OTHERCited in: Risk Factors and Prevention
  205. [205]

    Elewa AMT, Snousy MG, Alghamdi FM et al.. “Global prostate cancer risk associated with microplastic exposure: a statistical and machine learning analysis.” Frontiers in public health (2026). PMID: 42428925 ↗

    L2OTHERCited in: Risk Factors and Prevention
  206. [206]

    Presti J, Prausnitz S, Altschuler A et al.. “Informed Decision Making for Prostate Cancer Screening - A Prospective, Randomized Study of Two Novel Web-based, Electronic Visits.” The Journal of urology (2026). PMID: 42418618 ↗

    L1OTHERCited in: Risk Factors and Prevention
  207. [207]

    Geng JH, Yu CC, Huang CY et al.. “Exploring Genetic Contributions to Prostate Cancer Risk in an Asian Population-Based Study.” Cancer medicine (2026). PMID: 42415294 ↗

    L3OTHERCited in: Risk Factors and Prevention
  208. [208]

    Siavoshi M, Frochen S, Fakunle M et al.. “Prostate-Specific Antigen Screening Patterns and Metastatic Prostate Cancer in US Veterans.” JAMA network open (2026). PMID: 42406398 ↗

    L4OTHERCited in: Risk Factors and Prevention, Molecular Diagnostics and Biomarkers
  209. [209]

    Jung JH, Han GH, So B et al.. “An artificial intelligence model integrating clinico-laboratory data and single nucleotide polymorphism-based genomic risk for prostate cancer diagnosis in Korean men.” Investigative and clinical urology (2026). PMID: 42405708 ↗

    L4OTHERCited in: Risk Factors and Prevention
  210. [210]

    Kelly CM, Onuorah O, Gilbert E. “Within-sibling attenuation of polygenic risk score accuracy: investigating the effects of principal component analysis, LD score regression, and mixed model association in the UK Biobank.” Human genetics (2026). PMID: 42400756 ↗

    L5OTHERCited in: Risk Factors and Prevention
  211. [211]

    Mohler JL, Antonarakis ES, Armstrong AJ et al.. “Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 31085757 ↗

    L1GUIDELINECited in: Genetics and Hereditary Predisposition, Clinical Presentation, Management Overview, History and Evolution of Treatment
  212. [212]

    Schwartz MD, Peshkin BN, Isaacs C et al.. “Pilot Trial of Streamlined Genetic Education and Traceback Genetic Testing in Prostate Cancer Survivors.” Journal of the National Comprehensive Cancer Network : JNCCN (2023). PMID: 38081141 ↗

    L4RCTCited in: Genetics and Hereditary Predisposition
  213. [213]

    Khalaf DJ, Aragón IM, Annala M et al.. “HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies.” Annals of oncology : official journal of the European Society for Medical Oncology (2020). PMID: 32574722 ↗

    L2RCTCited in: Genetics and Hereditary Predisposition
  214. [214]

    Khemlina G, Ikeda S, Kurzrock R. “Molecular landscape of prostate cancer: implications for current clinical trials.” Cancer treatment reviews (2015). PMID: 26210103 ↗

    L5TRIAL_NONRANDOMCited in: Genetics and Hereditary Predisposition, Molecular Diagnostics and Biomarkers
  215. [215]

    Tobalina L, Armenia J, Irving E et al.. “A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance.” Annals of oncology : official journal of the European Society for Medical Oncology (2020). PMID: 33091561 ↗

    L2SR_OBSCited in: Genetics and Hereditary Predisposition
  216. [216]

    Cheng HH, Sokolova AO, Schaeffer EM et al.. “Germline and Somatic Mutations in Prostate Cancer for the Clinician.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 31085765 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition
  217. [217]

    Barnett GC, Coles CE, Elliott RM et al.. “Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study.” The Lancet. Oncology (2011). PMID: 22169268 ↗

    L2RCTCited in: Genetics and Hereditary Predisposition
  218. [218]

    Kaufman B, Shapira-Frommer R, Schmutzler RK et al.. “Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2014). PMID: 25366685 ↗

    L4TRIAL_NONRANDOMCited in: Genetics and Hereditary Predisposition, Prognosis and Prognostic Factors, Special Populations
  219. [219]

    Hearn JWD, Sweeney CJ, Almassi N et al.. “HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer.” JAMA oncology (2020). PMID: 32053149 ↗

    L2RCTCited in: Genetics and Hereditary Predisposition
  220. [220]

    Smith MR, Scher HI, Sandhu S et al.. “Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.” The Lancet. Oncology (2022). PMID: 35131040 ↗

    L4TRIAL_NONRANDOMCited in: Genetics and Hereditary Predisposition, Histopathology and Molecular Biology
  221. [221]

    Fong PC, Boss DS, Yap TA et al.. “Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.” The New England journal of medicine (2009). PMID: 19553641 ↗

    L4TRIAL_NONRANDOMCited in: Genetics and Hereditary Predisposition
  222. [222]

    Mateo J, Carreira S, Sandhu S et al.. “DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.” The New England journal of medicine (2015). PMID: 26510020 ↗

    L4TRIAL_NONRANDOMCited in: Genetics and Hereditary Predisposition
  223. [223]

    Goodall J, Mateo J, Yuan W et al.. “Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.” Cancer discovery (2017). PMID: 28450425 ↗

    L4TRIAL_NONRANDOMCited in: Genetics and Hereditary Predisposition, History and Evolution of Treatment, Prognosis and Prognostic Factors
  224. [224]

    Carreira S, Porta N, Arce-Gallego S et al.. “Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial.” Cancer discovery (2021). PMID: 34045297 ↗

    L4TRIAL_NONRANDOMCited in: Genetics and Hereditary Predisposition
  225. [225]

    Hussain M, Kocherginsky M, Agarwal N et al.. “Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway).” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 39115414 ↗

    L1RCTCited in: Genetics and Hereditary Predisposition, Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Special Populations
  226. [226]

    Aparicio AM, Tidwell RSS, Yadav SS et al.. “A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 38683200 ↗

    L1RCTCited in: Genetics and Hereditary Predisposition, History and Evolution of Treatment
  227. [227]

    Saad M, Mokrab Y, Halabi N et al.. “Genetic predisposition to cancer across people of different ancestries in Qatar: a population-based, cohort study.” The Lancet. Oncology (2022). PMID: 35150601 ↗

    L2COHORTCited in: Genetics and Hereditary Predisposition
  228. [228]

    Gheybi K, Jiang J, Mutambirwa SBA et al.. “Evaluating Germline Testing Panels in Southern African Males With Advanced Prostate Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2023). PMID: 36898365 ↗

    L4OTHERCited in: Genetics and Hereditary Predisposition
  229. [229]

    Korn SM, Qian Z, Zurl H et al.. “Geographic Variability in Germline Genetic Testing for Prostate Cancer: A Nationwide Medicare Claims Study With Evidence of Low Uptake.” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 41671443 ↗

    L2OTHERCited in: Genetics and Hereditary Predisposition
  230. [230]

    Crawford TB, Tayeb M, Barrett E et al.. “Pathogenic Germline Variants in a Racially Diverse Real-World Cohort of Patients With Prostate Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2026). PMID: 42229501 ↗

    L4OTHERCited in: Genetics and Hereditary Predisposition
  231. [231]

    Ciccarese C, Massari F, Iacovelli R et al.. “Prostate cancer heterogeneity: Discovering novel molecular targets for therapy.” Cancer treatment reviews (2017). PMID: 28231559 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition, Molecular Diagnostics and Biomarkers, Management Overview
  232. [232]

    Guida A, Mosillo C, Mammone G et al.. “The 5-WS of targeting DNA-damage repair (DDR) pathways in prostate cancer.” Cancer treatment reviews (2024). PMID: 38763054 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition
  233. [233]

    Loong HH, Shimizu T, Prawira A et al.. “Recommendations for the use of next-generation sequencing in patients with metastatic cancer in the Asia-Pacific region: a report from the APODDC working group.” ESMO open (2023). PMID: 37356359 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition
  234. [234]

    Lyu J, He F, Corcoran NM et al.. “Systematic Review of Genomic-Based Risk Stratification in Localised Prostate Cancer Treatment Optimisation: Clinical Impact and Health Economic Evidence.” Cancer medicine (2026). PMID: 41802997 ↗

    L2SR_OBSCited in: Genetics and Hereditary Predisposition
  235. [235]

    Stopsack KH, Mucci LA, Antonarakis ES et al.. “TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention?” Cancer discovery (2020). PMID: 32276929 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition, Management Overview
  236. [236]

    Olmos D, Lorente D, Jambrina A et al.. “BRCA1/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomes.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 40467032 ↗

    L2OTHERCited in: Genetics and Hereditary Predisposition, Management Overview, Prognosis and Prognostic Factors
  237. [237]

    Shenoy TR, Boysen G, Wang MY et al.. “CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair.” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 28383660 ↗

    L5OTHERCited in: Genetics and Hereditary Predisposition
  238. [238]

    Rose AM, Krishan A, Chakarova CF et al.. “MSR1 repeats modulate gene expression and affect risk of breast and prostate cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2018). PMID: 29509840 ↗

    L5OTHERCited in: Genetics and Hereditary Predisposition
  239. [239]

    Grasso CS, Cani AK, Hovelson DH et al.. “Integrative molecular profiling of routine clinical prostate cancer specimens.” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 25735316 ↗

    L4OTHERCited in: Genetics and Hereditary Predisposition, Biopsy and Histologic Diagnosis
  240. [240]

    Castro E, Jugurnauth-Little S, Karlsson Q et al.. “High burden of copy number alterations and c-MYC amplification in prostate cancer from BRCA2 germline mutation carriers.” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 26347108 ↗

    L3OTHERCited in: Genetics and Hereditary Predisposition
  241. [241]

    Lu C, Terbuch A, Dolling D et al.. “Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype.” Annals of oncology : official journal of the European Society for Medical Oncology (2020). PMID: 32387417 ↗

    L2OTHERCited in: Genetics and Hereditary Predisposition
  242. [242]

    Brandt A, Sundquist J, Hemminki K. “Risk for incident and fatal prostate cancer in men with a family history of any incident and fatal cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21467126 ↗

    L2OTHERCited in: Genetics and Hereditary Predisposition
  243. [243]

    Doornweerd BHJ, Rasmussen MW. “Early detection of urological malignancies in Lynch syndrome: a systematic review.” Familial cancer (2026). PMID: 42029790 ↗

    L1SR_OBSCited in: Genetics and Hereditary Predisposition
  244. [244]

    Li S, Silvestri V, Leslie G et al.. “Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35077220 ↗

    L2OTHERCited in: Genetics and Hereditary Predisposition
  245. [245]

    Mandelker D, Marra A, Zheng-Lin B et al.. “Genomic Profiling Reveals Germline Predisposition and Homologous Recombination Deficiency in Pancreatic Acinar Cell Carcinoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37607324 ↗

    L4OTHERCited in: Genetics and Hereditary Predisposition, Histopathology and Molecular Biology
  246. [246]

    Hampel H, Yurgelun MB. “Point/Counterpoint: Is It Time for Universal Germline Genetic Testing for All GI Cancers?” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35649230 ↗

    L5OTHERCited in: Genetics and Hereditary Predisposition
  247. [247]

    Abida W, Patnaik A, Campbell D et al.. “Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 32795228 ↗

    L4OTHERCited in: Genetics and Hereditary Predisposition
  248. [248]

    Sharifi N, Dahut WL, Figg WD. “The genetics of castration-resistant prostate cancer: what can the germline tell us?” Clinical cancer research : an official journal of the American Association for Cancer Research (2008). PMID: 18676736 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition
  249. [249]

    Shiota M, Naiki T, Hatano K et al.. “Genetic Predictors of Progression and Skin Rash in Japanese mCSPC Patients Treated With Apalutamide: CUARTET Study.” Cancer science (2026). PMID: 42050823 ↗

    L4TRIAL_NONRANDOMCited in: Genetics and Hereditary Predisposition
  250. [250]

    Triner D, Graf RP, Madison RW et al.. “Durable benefit from poly(ADP-ribose) polymerase inhibitors in metastatic prostate cancer in routine practice: biomarker associations and implications for optimal clinical next-generation sequencing testing.” ESMO open (2024). PMID: 39255537 ↗

    L2OTHERCited in: Genetics and Hereditary Predisposition, Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers, Management Overview, Special Populations
  251. [251]

    Rami A, Rashid NS, Zhong C et al.. “Association between DNA damage repair alterations and outcomes to 177Lu-PSMA-617 in advanced prostate cancer.” ESMO open (2025). PMID: 39847876 ↗

    L3OTHERCited in: Genetics and Hereditary Predisposition, Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors, Special Populations
  252. [252]

    Lindström LS, Hall P, Hartman M et al.. “Familial concordance in cancer survival: a Swedish population-based study.” The Lancet. Oncology (2007). PMID: 17921068 ↗

    L2OTHERCited in: Genetics and Hereditary Predisposition
  253. [253]

    Pritchard CC, Mateo J, Walsh MF et al.. “Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.” The New England journal of medicine (2016). PMID: 27433846 ↗

    L4OTHERCited in: Genetics and Hereditary Predisposition
  254. [254]

    Ewing CM, Ray AM, Lange EM et al.. “Germline mutations in HOXB13 and prostate-cancer risk.” The New England journal of medicine (2012). PMID: 22236224 ↗

    L3OTHERCited in: Genetics and Hereditary Predisposition
  255. [255]

    Zheng SL, Sun J, Wiklund F et al.. “Cumulative association of five genetic variants with prostate cancer.” The New England journal of medicine (2008). PMID: 18199855 ↗

    L3OTHERCited in: Genetics and Hereditary Predisposition
  256. [256]

    Tanegashima T, Shiota M, Doi A et al.. “GWAS from a multicenter prospective study of radium-223 in bone-metastatic castration-resistant prostate cancer.” EJNMMI research (2026). PMID: 42230449 ↗

    L2COHORTCited in: Genetics and Hereditary Predisposition
  257. [257]

    Zhao Z, Wu C, Fu S et al.. “Sport, genetic susceptibility, and the risk of benign prostatic hyperplasia: a large prospective cohort study.” World journal of urology (2026). PMID: 42223661 ↗

    L2COHORTCited in: Genetics and Hereditary Predisposition
  258. [258]

    Shevrin D, Yang M, Sabatini LM et al.. “A Real-World Prospective Study of Comprehensive Genomic Testing in Patients With Metastatic Castration-Resistant Prostate Cancer.” Clinical genitourinary cancer (2026). PMID: 42161163 ↗

    L4COHORTCited in: Genetics and Hereditary Predisposition
  259. [259]

    Zhang A, Zhu X, Li Z et al.. “Type 2 Diabetes, Glycemic Traits and Overall Cancer Risk: A Large-Scale Prospective Cohort Study.” Cancer medicine (2026). PMID: 42144703 ↗

    L2COHORTCited in: Genetics and Hereditary Predisposition
  260. [260]

    Goss LB, Liu M, Zheng Y et al.. “Polygenic Risk Score and Upgrading in Patients With Prostate Cancer Receiving Active Surveillance.” JAMA oncology (2025). PMID: 39666350 ↗

    L2OTHERCited in: Genetics and Hereditary Predisposition, Clinical Presentation, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  261. [261]

    Darst BF, Saunders E, Dadaev T et al.. “Germline Sequencing Analysis to Inform Clinical Gene Panel Testing for Aggressive Prostate Cancer.” JAMA oncology (2023). PMID: 37733366 ↗

    L4OTHERCited in: Genetics and Hereditary Predisposition
  262. [262]

    Almassi N, Reichard C, Li J et al.. “HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer.” JAMA oncology (2018). PMID: 29049452 ↗

    L2OTHERCited in: Genetics and Hereditary Predisposition
  263. [263]

    Nicolosi P, Ledet E, Yang S et al.. “Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines.” JAMA oncology (2019). PMID: 30730552 ↗

    L4OTHERCited in: Genetics and Hereditary Predisposition
  264. [264]

    Beltran H, Eng K, Mosquera JM et al.. “Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.” JAMA oncology (2015). PMID: 26181256 ↗

    L4OTHERCited in: Genetics and Hereditary Predisposition, Molecular Diagnostics and Biomarkers
  265. [265]

    Abida W, Cheng ML, Armenia J et al.. “Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.” JAMA oncology (2019). PMID: 30589920 ↗

    L4OTHERCited in: Genetics and Hereditary Predisposition, Biopsy and Histologic Diagnosis
  266. [266]

    Schweizer MT, Sivakumar S, Tukachinsky H et al.. “Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples and Metastatic Tissue or Cell-Free DNA.” JAMA oncology (2021). PMID: 34086042 ↗

    L4OTHERCited in: Genetics and Hereditary Predisposition
  267. [267]

    Antonarakis ES, Lu C, Luber B et al.. “Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.” JAMA oncology (2015). PMID: 26181238 ↗

    L2OTHERCited in: Genetics and Hereditary Predisposition
  268. [268]

    Maas P, Barrdahl M, Joshi AD et al.. “Breast Cancer Risk From Modifiable and Nonmodifiable Risk Factors Among White Women in the United States.” JAMA oncology (2016). PMID: 27228256 ↗

    L3OTHERCited in: Genetics and Hereditary Predisposition
  269. [269]

    Agarwal N, Hahn AW, Gill DM et al.. “Independent Validation of Effect of HSD3B1 Genotype on Response to Androgen-Deprivation Therapy in Prostate Cancer.” JAMA oncology (2017). PMID: 28208175 ↗

    L3OTHERCited in: Genetics and Hereditary Predisposition
  270. [270]

    Gasperini P, Alaimo A, Stringa B et al.. “Germline-Somatic Liaison Dictates Cancer Subtypes via de novo Steroid Biosynthesis.” Cancer discovery (2025). PMID: 40512155 ↗

    L5OTHERCited in: Genetics and Hereditary Predisposition, History and Evolution of Treatment
  271. [271]

    Yamaguchi TN, Houlahan KE, Zhu H et al.. “The Germline and Somatic Origins of Prostate Cancer Heterogeneity.” Cancer discovery (2025). PMID: 39945744 ↗

    L4OTHERCited in: Genetics and Hereditary Predisposition, History and Evolution of Treatment
  272. [272]

    Tolmeijer SH, Maurice-Dror C, Sandhu S et al.. “Germline CDK12 variants in aggressive prostate cancer.” Cancer discovery (2026). PMID: 42392870 ↗

    L4OTHERCited in: Genetics and Hereditary Predisposition, History and Evolution of Treatment
  273. [273]

    Papachristodoulou A, Rodriguez-Calero A, Panja S et al.. “NKX3.1 Localization to Mitochondria Suppresses Prostate Cancer Initiation.” Cancer discovery (2021). PMID: 33893149 ↗

    L5OTHERCited in: Genetics and Hereditary Predisposition
  274. [274]

    Yuan J, Houlahan KE, Ramanand SG et al.. “Prostate Cancer Transcriptomic Regulation by the Interplay of Germline Risk Alleles, Somatic Mutations, and 3D Genomic Architecture.” Cancer discovery (2022). PMID: 36108240 ↗

    L4OTHERCited in: Genetics and Hereditary Predisposition, Histopathology and Molecular Biology
  275. [275]

    . “Repair-Gene Mutations Uncovered in Metastatic Prostate Cancer.” Cancer discovery (2016). PMID: 27460689 ↗

    L5OTHERCited in: Genetics and Hereditary Predisposition
  276. [276]

    Hoffmann TJ, Van Den Eeden SK, Sakoda LC et al.. “A large multiethnic genome-wide association study of prostate cancer identifies novel risk variants and substantial ethnic differences.” Cancer discovery (2015). PMID: 26034056 ↗

    L3OTHERCited in: Genetics and Hereditary Predisposition, Molecular Diagnostics and Biomarkers, Special Populations
  277. [277]

    Kar SP, Beesley J, Amin Al Olama A et al.. “Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types.” Cancer discovery (2016). PMID: 27432226 ↗

    L3OTHERCited in: Genetics and Hereditary Predisposition
  278. [278]

    Leibold J, Ruscetti M, Cao Z et al.. “Somatic Tissue Engineering in Mouse Models Reveals an Actionable Role for WNT Pathway Alterations in Prostate Cancer Metastasis.” Cancer discovery (2020). PMID: 32376773 ↗

    L5OTHERCited in: Genetics and Hereditary Predisposition
  279. [279]

    Brenner JC, Chinnaiyan AM. “Disruptive events in the life of prostate cancer.” Cancer cell (2011). PMID: 21397854 ↗

    L5OTHERCited in: Genetics and Hereditary Predisposition, Molecular Diagnostics and Biomarkers
  280. [280]

    Noro T, Utsumi T, Ikeda R et al.. “Advances in Precision Diagnostics and Personalized Therapeutics for Prostate Cancer: An Integrated Precision Continuum from Risk-Adapted Detection to Biomarker-Directed Therapy and Dynamic Monitoring.” Cancers (2026). PMID: 42352444 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition
  281. [281]

    Bryce AH, Nash P, Roessler A et al.. “Rucaparib - drug evaluation: a PARP inhibitor for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer.” Future oncology (London, England) (2026). PMID: 42312474 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition
  282. [282]

    Craddock J, Hayes VM. “Epigenetic modulation of prostate cancer disparities in men with African ancestry.” Nature reviews. Urology (2026). PMID: 42249067 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition
  283. [283]

    Kishan AU, McGreevy K, Valle L et al.. “Validation and Derivation of miRNA-Based Germline Signatures Predicting Radiation Toxicity in Prostate Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40192540 ↗

    L3OTHERCited in: Genetics and Hereditary Predisposition, Imaging
  284. [284]

    Chen WS, Haynes WA, Waitz R et al.. “Autoantibody Landscape in Patients with Advanced Prostate Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 32967941 ↗

    L4OTHERCited in: Genetics and Hereditary Predisposition
  285. [285]

    Westphalen CB, Fine AD, André F et al.. “Pan-cancer Analysis of Homologous Recombination Repair-associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score.” Clinical cancer research : an official journal of the American Association for Cancer Research (2022). PMID: 34740923 ↗

    L2OTHERCited in: Genetics and Hereditary Predisposition
  286. [286]

    Sipeky C, Gao P, Zhang Q et al.. “Synergistic Interaction of HOXB13 and CIP2A Predisposes to Aggressive Prostate Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2018). PMID: 30181389 ↗

    L3OTHERCited in: Genetics and Hereditary Predisposition, Staging
  287. [287]

    Li L, Zhang L, Li Z et al.. “Evolving role of biomarkers beyond prostate‑specific antigen in refining prostate cancer screening: From blood‑based tests to urinary and genetic markers (Review).” Molecular medicine reports (2026). PMID: 42396659 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition, Biopsy and Histologic Diagnosis
  288. [288]

    Fizazi K, Flaig TW, Stöckle M et al.. “Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials.” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 26609008 ↗

    L2RCTCited in: Histopathology and Molecular Biology
  289. [289]

    Eggener SE, Rumble RB, Armstrong AJ et al.. “Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 31829902 ↗

    L1SR_OBSCited in: Histopathology and Molecular Biology, Staging
  290. [290]

    Khor LY, Bae K, Paulus R et al.. “MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19470936 ↗

    L2RCTCited in: Histopathology and Molecular Biology
  291. [291]

    Azzouzi AR, Vincendeau S, Barret E et al.. “Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial.” The Lancet. Oncology (2016). PMID: 28007457 ↗

    L1RCTCited in: Histopathology and Molecular Biology
  292. [292]

    de Bono JS, Mehra N, Scagliotti GV et al.. “Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.” The Lancet. Oncology (2021). PMID: 34388386 ↗

    L4TRIAL_NONRANDOMCited in: Histopathology and Molecular Biology
  293. [293]

    Kono M, Fujii T, Lim B et al.. “Androgen Receptor Function and Androgen Receptor-Targeted Therapies in Breast Cancer: A Review.” JAMA oncology (2017). PMID: 28301631 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology, Molecular Diagnostics and Biomarkers
  294. [294]

    Sutera PA, Shetty AC, Hakansson A et al.. “Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2023). PMID: 37164128 ↗

    L2OTHERCited in: Histopathology and Molecular Biology
  295. [295]

    Makena W, Nwankwo M, Idris A et al.. “Burden, clinical characteristics, and management patterns of prostate cancer in Nigeria: a systematic review and meta-analysis.” Frontiers in oncology (2026). PMID: 41982235 ↗

    L2SR_OBSCited in: Histopathology and Molecular Biology
  296. [296]

    Spencer BA, Miller DC, Litwin MS et al.. “Variations in quality of care for men with early-stage prostate cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 18669460 ↗

    L2OTHERCited in: Histopathology and Molecular Biology
  297. [297]

    Sperger JM, Emamekhoo H, McKay RR et al.. “Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 34197212 ↗

    L2OTHERCited in: Histopathology and Molecular Biology
  298. [298]

    Rades D, Fehlauer F, Schulte R et al.. “Prognostic factors for local control and survival after radiotherapy of metastatic spinal cord compression.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2006). PMID: 16849752 ↗

    L2OTHERCited in: Histopathology and Molecular Biology
  299. [299]

    Mohan HM, Aherne CM, Rogers AC et al.. “Molecular pathways: the role of NR4A orphan nuclear receptors in cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2012). PMID: 22566377 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  300. [300]

    Sweeney CJ, Krishna V, Krishna V et al.. “Development and Validation of a Computational Histology Artificial Intelligence-Powered Biomarker in Metastatic Hormone-Sensitive Prostate Cancer on Randomized Phase III Trials.” JCO precision oncology (2026). PMID: 42418739 ↗

    L2TRIAL_NONRANDOMCited in: Histopathology and Molecular Biology, Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors
  301. [301]

    Zhao SG, Chang SL, Spratt DE et al.. “Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis.” The Lancet. Oncology (2016). PMID: 27743920 ↗

    L2OTHERCited in: Histopathology and Molecular Biology
  302. [302]

    Rahbar K, Bögemann M, Papavasilis P et al.. “Clinical Utility of PROSTest: A Prospective Study Suggesting Reduction in Unnecessary MRI and Biopsy in Men Evaluated for Prostate Cancer.” Cancers (2026). PMID: 41827804 ↗

    L2COHORTCited in: Histopathology and Molecular Biology
  303. [303]

    Leapman MS, Wang R, Ma S et al.. “Regional Adoption of Commercial Gene Expression Testing for Prostate Cancer.” JAMA oncology (2021). PMID: 33237277 ↗

    L2OTHERCited in: Histopathology and Molecular Biology
  304. [304]

    Spratt DE, Chan T, Waldron L et al.. “Racial/Ethnic Disparities in Genomic Sequencing.” JAMA oncology (2016). PMID: 27366979 ↗

    L2OTHERCited in: Histopathology and Molecular Biology
  305. [305]

    Evans JR, Zhao SG, Chang SL et al.. “Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.” JAMA oncology (2016). PMID: 26746117 ↗

    L2OTHERCited in: Histopathology and Molecular Biology
  306. [306]

    Beltran H, Rickman DS, Park K et al.. “Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.” Cancer discovery (2011). PMID: 22389870 ↗

    L5OTHERCited in: Histopathology and Molecular Biology, Management Overview
  307. [307]

    Vasciaveo A, Arriaga JM, de Almeida FN et al.. “OncoLoop: A Network-Based Precision Cancer Medicine Framework.” Cancer discovery (2023). PMID: 36374194 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  308. [308]

    Zhang Y, Gong M, Yuan H et al.. “Chimeric transcript generated by cis-splicing of adjacent genes regulates prostate cancer cell proliferation.” Cancer discovery (2012). PMID: 22719019 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  309. [309]

    . “Small-Cell Prostate Cancer Variety Surprisingly Common.” Cancer discovery (2018). PMID: 30072408 ↗

    L5OTHERCited in: Histopathology and Molecular Biology, Molecular Diagnostics and Biomarkers
  310. [310]

    Goel HL, Chang C, Pursell B et al.. “VEGF/neuropilin-2 regulation of Bmi-1 and consequent repression of IGF-IR define a novel mechanism of aggressive prostate cancer.” Cancer discovery (2012). PMID: 22777769 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  311. [311]

    Lunardi A, Varmeh S, Chen M et al.. “Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis.” Cancer discovery (2015). PMID: 25653093 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  312. [312]

    Bishop JL, Thaper D, Vahid S et al.. “The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.” Cancer discovery (2016). PMID: 27784708 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  313. [313]

    Dhimolea E, de Matos Simoes R, Kansara D et al.. “An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence.” Cancer cell (2021). PMID: 33417832 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  314. [314]

    Casanova-Salas I, Aguilar D, Cordoba-Terreros S et al.. “Circulating tumor extracellular vesicles to monitor metastatic prostate cancer genomics and transcriptomic evolution.” Cancer cell (2024). PMID: 38981440 ↗

    L2OTHERCited in: Histopathology and Molecular Biology, Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers, History and Evolution of Treatment
  315. [315]

    Russo JW, Balk SP. “Initiation and Evolution of Early Onset Prostate Cancer.” Cancer cell (2018). PMID: 30537509 ↗

    L5OTHERCited in: Histopathology and Molecular Biology, History and Evolution of Treatment
  316. [316]

    Cato L, de Tribolet-Hardy J, Lee I et al.. “ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer.” Cancer cell (2019). PMID: 30773341 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  317. [317]

    Patel LR, Barton MC. “TRIM-ing Ligand Dependence in Castration-Resistant Prostate Cancer.” Cancer cell (2016). PMID: 27300431 ↗

    L5OTHERCited in: Histopathology and Molecular Biology, History and Evolution of Treatment
  318. [318]

    Dardenne E, Beltran H, Benelli M et al.. “N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.” Cancer cell (2016). PMID: 27728805 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  319. [319]

    Lei Q, Jiao J, Xin L et al.. “NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss.” Cancer cell (2006). PMID: 16697957 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  320. [320]

    Hieronymus H, Lamb J, Ross KN et al.. “Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators.” Cancer cell (2006). PMID: 17010675 ↗

    L5OTHERCited in: Histopathology and Molecular Biology, Molecular Diagnostics and Biomarkers
  321. [321]

    Aytes A, Mitrofanova A, Lefebvre C et al.. “Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy.” Cancer cell (2014). PMID: 24823640 ↗

    L5OTHERCited in: Histopathology and Molecular Biology, Prognosis and Prognostic Factors
  322. [322]

    Carver BS, Chapinski C, Wongvipat J et al.. “Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.” Cancer cell (2011). PMID: 21575859 ↗

    L5OTHERCited in: Histopathology and Molecular Biology, Imaging, Molecular Diagnostics and Biomarkers
  323. [323]

    Xu K, Shimelis H, Linn DE et al.. “Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination.” Cancer cell (2009). PMID: 19345326 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  324. [324]

    Wang L, Liu R, Li W et al.. “Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate.” Cancer cell (2009). PMID: 19800578 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  325. [325]

    Memarzadeh S, Xin L, Mulholland DJ et al.. “Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor.” Cancer cell (2007). PMID: 18068633 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  326. [326]

    Augello MA, Liu D, Deonarine LD et al.. “CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis.” Cancer cell (2019). PMID: 30930119 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  327. [327]

    Krishna M, Garg P, Horne D et al.. “Inflammation-driven transcriptional reprogramming in prostate cancer: Convergence of NFκB, JAK/STAT3, and epigenetic remodeling in castration-resistant disease.” Cancer letters (2026). PMID: 42229824 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  328. [328]

    Munari E, Antonini P, Cima L et al.. “The evolution of prostate cancer grading: from Gleason score to risk taxonomy and the artificial intelligence revolution.” Virchows Archiv : an international journal of pathology (2026). PMID: 42115324 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  329. [329]

    Peng J, Xie C, Xie Z et al.. “RNA methylation in urological cancers: regulatory logic, biological functions, and clinical relevance.” Frontiers in immunology (2026). PMID: 42093977 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  330. [330]

    Cimadamore A, Lopez-Beltran A, Montironi R et al.. “Molecular Pathology of Genitourinary Tumors: Diagnostic, Prognostic, and Therapeutic Implications.” Surgical pathology clinics (2026). PMID: 42091277 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  331. [331]

    Caramella Pereira F, De Marzo AM. “The molecular pathology of prostate cancer: an update for practising pathologists.” Histopathology (2026). PMID: 41943889 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  332. [332]

    Sklinda K, Rajca M, Kasprowicz M et al.. “Radiomics-Based Characterization of Aggressive Prostate Cancer Variants: Diagnostic Challenges and Opportunities.” Cancers (2026). PMID: 41827718 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  333. [333]

    Xie Q, Zhao H, Yang X et al.. “The emerging role of m6A methylation in prostate-related diseases: mechanisms and clinical implications.” Frontiers in immunology (2026). PMID: 41766860 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  334. [334]

    McKay RR, Nazari SS, Elliott A et al.. “Molecular Characterization of KLK2 RNA Expression in Prostate Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 41817312 ↗

    L4OTHERCited in: Histopathology and Molecular Biology, Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors, Special Populations
  335. [335]

    Boysen G, Rodrigues DN, Rescigno P et al.. “SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity.” Clinical cancer research : an official journal of the American Association for Cancer Research (2018). PMID: 30068710 ↗

    L2OTHERCited in: Histopathology and Molecular Biology, Clinical Presentation, Staging, Prognosis and Prognostic Factors, Special Populations
  336. [336]

    Leclerc BG, Charlebois R, Chouinard G et al.. “CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2015). PMID: 26253870 ↗

    L2OTHERCited in: Histopathology and Molecular Biology
  337. [337]

    Ku AT, Shankavaram U, Trostel SY et al.. “Radiogenomic Profiling of Prostate Tumors prior to External Beam Radiotherapy Converges on a Transcriptomic Signature of TGF-β Activity Driving Tumor Recurrence.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 41037000 ↗

    L2OTHERCited in: Histopathology and Molecular Biology, Imaging
  338. [338]

    Lopez SM, Agoulnik AI, Zhang M et al.. “Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression.” Clinical cancer research : an official journal of the American Association for Cancer Research (2016). PMID: 26968201 ↗

    L4OTHERCited in: Histopathology and Molecular Biology
  339. [339]

    Le Magnen C, Bubendorf L, Rentsch CA et al.. “Characterization and clinical relevance of ALDHbright populations in prostate cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2013). PMID: 23969936 ↗

    L4OTHERCited in: Histopathology and Molecular Biology
  340. [340]

    Peng S, Hu P, Xiao YT et al.. “Single-Cell Analysis Reveals EP4 as a Target for Restoring T-Cell Infiltration and Sensitizing Prostate Cancer to Immunotherapy.” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 34740924 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  341. [341]

    Maranto C, Udhane V, Hoang DT et al.. “STAT5A/B Blockade Sensitizes Prostate Cancer to Radiation through Inhibition of RAD51 and DNA Repair.” Clinical cancer research : an official journal of the American Association for Cancer Research (2018). PMID: 29483142 ↗

    L5OTHERCited in: Histopathology and Molecular Biology, Staging
  342. [342]

    Yin Y, Zhang Q, Zhang H et al.. “Molecular Signature to Risk-Stratify Prostate Cancer of Intermediate Risk.” Clinical cancer research : an official journal of the American Association for Cancer Research (2016). PMID: 27803045 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  343. [343]

    Grubmüller B, Baltzer P, Hartenbach S et al.. “PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact.” Clinical cancer research : an official journal of the American Association for Cancer Research (2018). PMID: 30139879 ↗

    L2OTHERCited in: Histopathology and Molecular Biology, Staging
  344. [344]

    Dylgjeri E, McNair C, Goodwin JF et al.. “Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic Strategies.” Clinical cancer research : an official journal of the American Association for Cancer Research (2019). PMID: 31266833 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  345. [345]

    Choi SY, Xue H, Wu R et al.. “The MCT4 Gene: A Novel, Potential Target for Therapy of Advanced Prostate Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2016). PMID: 26755530 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  346. [346]

    Ketola K, Munuganti RSN, Davies A et al.. “Targeting Prostate Cancer Subtype 1 by Forkhead Box M1 Pathway Inhibition.” Clinical cancer research : an official journal of the American Association for Cancer Research (2017). PMID: 28899970 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  347. [347]

    Kothari V, Goodwin JF, Zhao SG et al.. “DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway.” Clinical cancer research : an official journal of the American Association for Cancer Research (2019). PMID: 31266829 ↗

    L2OTHERCited in: Histopathology and Molecular Biology
  348. [348]

    Heidari P, Jadvar H, Kako B et al.. “Novel Theranostic Targets for Prostate Cancer Beyond Prostate-Specific Membrane Antigen.” PET clinics (2026). PMID: 41951504 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  349. [349]

    Pratap Nair R, Du W, Mei L et al.. “Artificial intelligence for detection, grading, and prognostication in prostate cancer pathology: A scoping review.” Histology and histopathology (2026). PMID: 41808601 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  350. [350]

    Pereira M, Vale N. “Gene Expression-Guided Drug Repurposing in Oncology: Insights from Antiretroviral Agents in Prostate and Bladder Cancer.” Genes (2026). PMID: 41751568 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  351. [351]

    Iida K, Tashiro K, Urabe F et al.. “Large-scale Genomic Landscape and Clinical Outcomes of De Novo and Treatment-emergent Neuroendocrine Prostate Cancer.” European urology open science (2026). PMID: 42433303 ↗

    L3OTHERCited in: Histopathology and Molecular Biology
  352. [352]

    Ge S, Liu X, Zeng X et al.. “Hsa_circ_0003258 drives serine biosynthesis and docetaxel resistance in prostate cancer by enhancing IGF2BP3-mediated PSAT1 mRNA stability.” Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy (2026). PMID: 42364255 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  353. [353]

    Sharkey AR, Bassett P, Subesinghe M et al.. “[68Ga]Ga-PSMA-11 PET/CT for baseline staging of high-risk prostate cancer: A real-world study.” BJUI compass (2026). PMID: 42358655 ↗

    L3OTHERCited in: Histopathology and Molecular Biology
  354. [354]

    Watanabe R, Chosei M, Sakaue T et al.. “Single-Cell Analysis Reveals Pre-Existing Basal-Associated Epithelial States in Metastatic Hormone-Naïve Prostate Cancer.” International journal of molecular sciences (2026). PMID: 42353123 ↗

    L4OTHERCited in: Histopathology and Molecular Biology
  355. [355]

    Chen Z, Zhou F, Tian J et al.. “A diagnostic signature derived from NK cell related genes in prostate cancer: insights from integrated scRNA-seq and bulk RNA-seq analyses with functional validation of KIT.” Frontiers in immunology (2026). PMID: 42317356 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  356. [356]

    Mohler JL, Armstrong AJ, Bahnson RR et al.. “Prostate Cancer, Version 1.2016.” Journal of the National Comprehensive Cancer Network : JNCCN (2016). PMID: 26733552 ↗

    L1GUIDELINECited in: Clinical Presentation, Imaging, Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors
  357. [357]

    Spratt DE, Srinivas S, Adra N et al.. “NCCN Guidelines® Insights: Prostate Cancer, Version 5.2026.” Journal of the National Comprehensive Cancer Network : JNCCN (2026). PMID: 42134408 ↗

    L1GUIDELINECited in: Clinical Presentation, Imaging, Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors
  358. [358]

    Schaeffer E, Srinivas S, Antonarakis ES et al.. “NCCN Guidelines Insights: Prostate Cancer, Version 1.2021.” Journal of the National Comprehensive Cancer Network : JNCCN (2021). PMID: 33545689 ↗

    L1GUIDELINECited in: Clinical Presentation, Imaging, Staging, History and Evolution of Treatment, Prognosis and Prognostic Factors
  359. [359]

    Horwich A, Hugosson J, de Reijke T et al.. “Prostate cancer: ESMO Consensus Conference Guidelines 2012.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 23303340 ↗

    L1GUIDELINECited in: Clinical Presentation, Imaging
  360. [360]

    Pettersson A, Robinson D, Garmo H et al.. “Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study.” Annals of oncology : official journal of the European Society for Medical Oncology (2018). PMID: 29161337 ↗

    L2COHORTCited in: Clinical Presentation
  361. [361]

    Velicer CM, Ulrich CM. “Vitamin and mineral supplement use among US adults after cancer diagnosis: a systematic review.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 18235127 ↗

    L2SR_OBSCited in: Clinical Presentation
  362. [362]

    Kanesvaran R, Castro E, Wong A et al.. “Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer.” ESMO open (2022). PMID: 35797737 ↗

    L1GUIDELINECited in: Clinical Presentation, Management Overview, History and Evolution of Treatment
  363. [363]

    Maiorano BA, De Giorgi U, Roviello G et al.. “Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis.” ESMO open (2022). PMID: 36152486 ↗

    L1SR_OBSCited in: Clinical Presentation, Management Overview
  364. [364]

    Vale CL, Fisher DJ, Godolphin PJ et al.. “Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials.” The Lancet. Oncology (2023). PMID: 37414011 ↗

    L1SR_OBSCited in: Clinical Presentation, Prognosis and Prognostic Factors
  365. [365]

    Aggarwal R, Zhang T, Small EJ et al.. “Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes.” Journal of the National Comprehensive Cancer Network : JNCCN (2014). PMID: 24812138 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  366. [366]

    Sentana-Lledo D, Saraf A, Morgans AK. “Symptom Burden and Survivorship Care for Patients With Prostate Cancer on Androgen Deprivation Therapy.” Journal of the National Comprehensive Cancer Network : JNCCN (2024). PMID: 39705803 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  367. [367]

    Higano CS. “Intermittent versus continuous androgen deprivation therapy.” Journal of the National Comprehensive Cancer Network : JNCCN (2014). PMID: 24812139 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  368. [368]

    McNeely ML, Courneya KS. “Exercise programs for cancer-related fatigue: evidence and clinical guidelines.” Journal of the National Comprehensive Cancer Network : JNCCN (2010). PMID: 20870638 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  369. [369]

    Fizazi K, Herrmann K, Krause BJ et al.. “Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial.” The Lancet. Oncology (2023). PMID: 37269841 ↗

    L1RCTCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Special Populations
  370. [370]

    Corn PG, Heath EI, Zurita A et al.. “Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial.” The Lancet. Oncology (2019). PMID: 31515154 ↗

    L1RCTCited in: Clinical Presentation, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  371. [371]

    Ost P, Siva S, Brabrand S et al.. “Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V-STORM): a phase 2, open-label, randomised controlled trial.” The Lancet. Oncology (2025). PMID: 40339593 ↗

    L1RCTCited in: Clinical Presentation, Imaging, Management Overview, History and Evolution of Treatment, Special Populations
  372. [372]

    Fizazi K, Morris MJ, Shore ND et al.. “Health-related quality of life, pain, and symptomatic skeletal events with [177Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial.” The Lancet. Oncology (2025). PMID: 40441170 ↗

    L1RCTCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, History and Evolution of Treatment, Prognosis and Prognostic Factors
  373. [373]

    Carrie C, Magné N, Burban-Provost P et al.. “Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial.” The Lancet. Oncology (2019). PMID: 31629656 ↗

    L1RCTCited in: Clinical Presentation, Imaging, Staging, Prognosis and Prognostic Factors
  374. [374]

    Gafita A, Calais J, Grogan TR et al.. “Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study.” The Lancet. Oncology (2021). PMID: 34246328 ↗

    L3COHORTCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, Staging
  375. [375]

    Marvaso G, Corrao G, Zaffaroni M et al.. “ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial.” The Lancet. Oncology (2025). PMID: 40049196 ↗

    L1RCTCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers
  376. [376]

    Bryant RJ, Marian IR, Williams R et al.. “Local anaesthetic transperineal biopsy versus transrectal prostate biopsy in prostate cancer detection (TRANSLATE): a multicentre, randomised, controlled trial.” The Lancet. Oncology (2025). PMID: 40139210 ↗

    L1RCTCited in: Clinical Presentation, Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers
  377. [377]

    Dinneen E, Almeida-Magana R, Al-Hammouri T et al.. “Effect of NeuroSAFE-guided RARP versus standard RARP on erectile function and urinary continence in patients with localised prostate cancer (NeuroSAFE PROOF): a multicentre, patient-blinded, randomised, controlled phase 3 trial.” The Lancet. Oncology (2025). PMID: 40147459 ↗

    L1RCTCited in: Clinical Presentation
  378. [378]

    Smith MR, Hussain M, Saad F et al.. “Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.” The New England journal of medicine (2022). PMID: 35179323 ↗

    L1RCTCited in: Clinical Presentation, Management Overview, History and Evolution of Treatment, Special Populations
  379. [379]

    Kasivisvanathan V, Rannikko AS, Borghi M et al.. “MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis.” The New England journal of medicine (2018). PMID: 29552975 ↗

    L1RCTCited in: Clinical Presentation, Biopsy and Histologic Diagnosis, Imaging, History and Evolution of Treatment, Special Populations
  380. [380]

    de Bono JS, Logothetis CJ, Molina A et al.. “Abiraterone and increased survival in metastatic prostate cancer.” The New England journal of medicine (2011). PMID: 21612468 ↗

    L1RCTCited in: Clinical Presentation, Prognosis and Prognostic Factors
  381. [381]

    Scher HI, Fizazi K, Saad F et al.. “Increased survival with enzalutamide in prostate cancer after chemotherapy.” The New England journal of medicine (2012). PMID: 22894553 ↗

    L1RCTCited in: Clinical Presentation, Prognosis and Prognostic Factors
  382. [382]

    Donovan JL, Hamdy FC, Lane JA et al.. “Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.” The New England journal of medicine (2016). PMID: 27626365 ↗

    L1RCTCited in: Clinical Presentation
  383. [383]

    Brahmer JR, Drake CG, Wollner I et al.. “Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2010). PMID: 20516446 ↗

    L4TRIAL_NONRANDOMCited in: Clinical Presentation
  384. [384]

    Klotz L, Chin J, Black PC et al.. “Comparison of Multiparametric Magnetic Resonance Imaging-Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for Biopsy-Naive Men at Risk for Prostate Cancer: A Phase 3 Randomized Clinical Trial.” JAMA oncology (2021). PMID: 33538782 ↗

    L1RCTCited in: Clinical Presentation, Biopsy and Histologic Diagnosis, Imaging, History and Evolution of Treatment
  385. [385]

    Dess RT, Hartman HE, Mahal BA et al.. “Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality.” JAMA oncology (2019). PMID: 31120534 ↗

    L2RCTCited in: Clinical Presentation
  386. [386]

    Sharma P, Pachynski RK, Narayan V et al.. “Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial.” Cancer cell (2020). PMID: 32916128 ↗

    L4RCTCited in: Clinical Presentation, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  387. [387]

    Pabst KM, Weber MM, Laschinsky C et al.. “[68Ga]Ga-FAPI-46 PET accuracy for cancer imaging with histopathology validation: a single-centre, single-arm, interventional, phase 2 trial.” The Lancet. Oncology (2025). PMID: 40774265 ↗

    L4TRIAL_NONRANDOMCited in: Clinical Presentation, Imaging, Staging
  388. [388]

    Jiao J, Ma S, Wu P et al.. “Transrectal Ultrasound-Guided Prostate Biopsy with and without PSMA-PET-Targeted Prostate Biopsy for Prostate Cancer Diagnosis.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40788181 ↗

    L2RCTCited in: Clinical Presentation, Biopsy and Histologic Diagnosis, Imaging, History and Evolution of Treatment, Special Populations
  389. [389]

    Marshall CH. “Acting on Actionable Mutations in Metastatic Prostate Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37098244 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  390. [390]

    Wala J, Nguyen P, Pomerantz M. “Early Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37267579 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  391. [391]

    Maitland NJ, Collins AT. “Prostate cancer stem cells: a new target for therapy.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 18539965 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  392. [392]

    Rubin MA, Maher CA, Chinnaiyan AM. “Common gene rearrangements in prostate cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 21859993 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  393. [393]

    Schaeffer EM, Srinivas S, Adra N et al.. “NCCN Guidelines® Insights: Prostate Cancer, Version 3.2024.” Journal of the National Comprehensive Cancer Network : JNCCN (2024). PMID: 38626801 ↗

    L1OTHERCited in: Clinical Presentation, Imaging, Management Overview
  394. [394]

    Schaeffer EM, Srinivas S, Adra N et al.. “NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023.” Journal of the National Comprehensive Cancer Network : JNCCN (2022). PMID: 36509074 ↗

    L1OTHERCited in: Clinical Presentation, Imaging
  395. [395]

    Belge Bilgin G, Lucien-Matteoni F, Chaudhuri AA et al.. “Current and future directions in theranostics for neuroendocrine prostate cancer.” Cancer treatment reviews (2025). PMID: 40239461 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Management Overview
  396. [396]

    Briganti A, Suardi N, Gallina A et al.. “Predicting the risk of bone metastasis in prostate cancer.” Cancer treatment reviews (2013). PMID: 23896177 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, History and Evolution of Treatment, Prognosis and Prognostic Factors
  397. [397]

    Tsaur I, Heidegger I, Kretschmer A et al.. “Aggressive variants of prostate cancer - Are we ready to apply specific treatment right now?” Cancer treatment reviews (2019). PMID: 30875581 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Molecular Diagnostics and Biomarkers
  398. [398]

    Mosillo C, Iacovelli R, Ciccarese C et al.. “De novo metastatic castration sensitive prostate cancer: State of art and future perspectives.” Cancer treatment reviews (2018). PMID: 30121492 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, History and Evolution of Treatment, Prognosis and Prognostic Factors
  399. [399]

    Berruti A, Bracarda S, Caffo O et al.. “nmCRPC, a look in the continuous care of prostate cancer patients: state of art and future perspectives.” Cancer treatment reviews (2023). PMID: 36822009 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Imaging, Molecular Diagnostics and Biomarkers, History and Evolution of Treatment, Prognosis and Prognostic Factors
  400. [400]

    Ah-Thiane L, Sargos P, Chapet O et al.. “Managing postoperative biochemical relapse in prostate cancer, from the perspective of the Francophone group of Urological radiotherapy (GFRU).” Cancer treatment reviews (2023). PMID: 37734178 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Molecular Diagnostics and Biomarkers
  401. [401]

    Boukaram C, Hannoun-Levi JM. “Management of prostate cancer recurrence after definitive radiation therapy.” Cancer treatment reviews (2010). PMID: 20100637 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  402. [402]

    Saad F. “New research findings on zoledronic acid: survival, pain, and anti-tumour effects.” Cancer treatment reviews (2007). PMID: 18061356 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  403. [403]

    Vajda A, Marignol L, Foley R et al.. “Clinical potential of gene-directed enzyme prodrug therapy to improve radiation therapy in prostate cancer patients.” Cancer treatment reviews (2011). PMID: 21481534 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  404. [404]

    von Deimling M, Rajwa P, Tilki D et al.. “The current role of precision surgery in oligometastatic prostate cancer.” ESMO open (2022). PMID: 36208497 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Imaging, Management Overview, History and Evolution of Treatment
  405. [405]

    Larose C, Samhani C, Piché ME et al.. “Should Male Pattern Baldness Be Considered in Prostate Cancer Risk Assessment? A Systematic Review and Meta-analysis.” European urology focus (2026). PMID: 42392953 ↗

    L1SR_OBSCited in: Clinical Presentation
  406. [406]

    Wong HPN, Lau RS, Kyaw L et al.. “Elevated prostate specific antigen due to indwelling urethral catheterisation: myth or fact? A systematic review and meta-analysis.” World journal of urology (2026). PMID: 42370958 ↗

    L1SR_OBSCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers
  407. [407]

    Lindenberg ML, Turkbey B, Mena E et al.. “Imaging Locally Advanced, Recurrent, and Metastatic Prostate Cancer: A Review.” JAMA oncology (2017). PMID: 28097325 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Imaging, Prognosis and Prognostic Factors
  408. [408]

    Vathiotis I, Banerjee A, Sen U et al.. “Histologic Transformation in Cancer: The Path for Clinical Translation.” Cancer discovery (2025). PMID: 40904097 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  409. [409]

    Cannoletta D, Brembilla G, Longoni M et al.. “Impact of prostate mpMRI quality on diagnostic accuracy in prostate cancer: a prospective study.” BJU international (2026). PMID: 42417115 ↗

    L2COHORTCited in: Clinical Presentation
  410. [410]

    Sayyid RK, Tiwari R, Zhang B et al.. “Association of Cumulative Proton Pump Inhibitor Use with Prostate Cancer Risk and Outcomes: A Population-Based Cohort Study.” Cancer research communications (2026). PMID: 42378436 ↗

    L2COHORTCited in: Clinical Presentation
  411. [411]

    Francolini G, Di Cataldo V, Caini S et al.. “SBRT plus abiraterone acetate and ADT versus abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer (ARTO): long-term, unplanned overall survival analysis of an open-label, randomised, phase 2 trial.” The Lancet. Oncology (2026). PMID: 42372744 ↗

    L1RCTCited in: Clinical Presentation, Management Overview, History and Evolution of Treatment, Special Populations
  412. [412]

    Haberkorn U, Eder M, Kopka K et al.. “New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy.” Clinical cancer research : an official journal of the American Association for Cancer Research (2016). PMID: 26728408 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Imaging
  413. [413]

    Zadra G, Priolo C, Patnaik A et al.. “New strategies in prostate cancer: targeting lipogenic pathways and the energy sensor AMPK.” Clinical cancer research : an official journal of the American Association for Cancer Research (2010). PMID: 20423984 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  414. [414]

    Chien CH, Chuang CK, Wu CT et al.. “Theory-based dyadic co-learning intervention to enhance family resilience in men with prostate cancer and their spouses in Taiwan: protocol for a randomised controlled trial.” BMJ open (2026). PMID: 42366001 ↗

    L5TRIAL_NONRANDOMCited in: Clinical Presentation, Management Overview, Special Populations
  415. [415]

    Procopio G, Chiuri VE, Giordano M et al.. “Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study.” ESMO open (2022). PMID: 35405438 ↗

    L2OTHERCited in: Clinical Presentation, Special Populations
  416. [416]

    Manfredi C, Franco A, Ditonno F et al.. “Prevalence and Factors Associated With Prostate Cancer Among Transgender Women.” JAMA oncology (2024). PMID: 39361307 ↗

    L2OTHERCited in: Clinical Presentation
  417. [417]

    Björnebo L, Nordström T, Discacciati A et al.. “Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality.” JAMA oncology (2022). PMID: 35587340 ↗

    L2OTHERCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers
  418. [418]

    Chesner LN, Polesso F, Graff JN et al.. “Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer.” Cancer discovery (2025). PMID: 39652470 ↗

    L5OTHERCited in: Clinical Presentation, Management Overview
  419. [419]

    Arbet J, Yamaguchi TN, Shiah YJ et al.. “The Landscape of Prostate Tumour Methylation.” Cancer discovery (2026). PMID: 42307031 ↗

    L4OTHERCited in: Clinical Presentation
  420. [420]

    Franceschini GM, Quaini O, Mizuno K et al.. “Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation.” Cancer discovery (2024). PMID: 38197680 ↗

    L4OTHERCited in: Clinical Presentation, Biopsy and Histologic Diagnosis
  421. [421]

    . “Algorithms May Assist Expert Pathologists in Prostate Cancer Diagnosis.” Cancer discovery (2020). PMID: 31953243 ↗

    L5OTHERCited in: Clinical Presentation, Biopsy and Histologic Diagnosis
  422. [422]

    Huang J, Duran A, Reina-Campos M et al.. “Adipocyte p62/SQSTM1 Suppresses Tumorigenesis through Opposite Regulations of Metabolism in Adipose Tissue and Tumor.” Cancer cell (2018). PMID: 29634950 ↗

    L5OTHERCited in: Clinical Presentation, Prognosis and Prognostic Factors
  423. [423]

    Kazan O, Arikan Y, Basaran A et al.. “Comparison of three-lobe and en-bloc techniques during the holmium laser enucleation of the prostate learning curve: a prospective, multicenter, cohort study.” Revista da Associacao Medica Brasileira (1992) (2026). PMID: 42385050 ↗

    L2COHORTCited in: Clinical Presentation, Management Overview, Prognosis and Prognostic Factors, Special Populations
  424. [424]

    Agrotis G, Purysko A, Padhani A et al.. “Integrating MRI-based tumour staging within the TNM classification system in modern prostate cancer management.” Insights into imaging (2026). PMID: 42426432 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Imaging, Staging
  425. [425]

    Lenis AT, Ravichandran V, Brown S et al.. “Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 38949888 ↗

    L2OTHERCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, Management Overview, Special Populations
  426. [426]

    Rescigno P, Gurel B, Pereira R et al.. “Characterizing CDK12-Mutated Prostate Cancers.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 32988971 ↗

    L4OTHERCited in: Clinical Presentation, Prognosis and Prognostic Factors
  427. [427]

    Dallos MC, Obradovic AZ, McCann P et al.. “Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 39269310 ↗

    L2OTHERCited in: Clinical Presentation, Special Populations
  428. [428]

    Hage Chehade C, Graf RP, Ozay ZI et al.. “Association of Homologous Recombination Repair Alterations with Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40522300 ↗

    L2OTHERCited in: Clinical Presentation, Prognosis and Prognostic Factors
  429. [429]

    Pokrivcak T, Poprach A, Lakomy R et al.. “Primary prostatic seminoma: a rare case report and structured literature review highlighting tumor marker discordance.” Therapeutic advances in medical oncology (2026). PMID: 42428049 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Biopsy and Histologic Diagnosis, Imaging
  430. [430]

    Lengyelova E, Patel M, Morrish G et al.. “Optimization of Administered Activity for 64 Cu-SAR-bisPSMA PET Imaging in Primary Prostate Cancer: Results from a Phase I Retrospective Study (PROPELLER Sub-study).” World journal of nuclear medicine (2026). PMID: 42395167 ↗

    L4COHORTCited in: Clinical Presentation
  431. [431]

    Carroll PR, Parsons JK, Andriole G et al.. “NCCN Clinical Practice Guidelines Prostate Cancer Early Detection, Version 2.2015.” Journal of the National Comprehensive Cancer Network : JNCCN (2015). PMID: 26656522 ↗

    L1GUIDELINECited in: Biopsy and Histologic Diagnosis, History and Evolution of Treatment
  432. [432]

    Fizazi K, Clarke NW, De Santis M et al.. “Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 41120017 ↗

    L1RCTCited in: Biopsy and Histologic Diagnosis, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  433. [433]

    Ost P, Reynders D, Decaestecker K et al.. “Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 29240541 ↗

    L1RCTCited in: Biopsy and Histologic Diagnosis, Imaging, Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors, Special Populations
  434. [434]

    Taneja SS, Morton R, Barnette G et al.. “Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2013). PMID: 23295793 ↗

    L1RCTCited in: Biopsy and Histologic Diagnosis
  435. [435]

    Zhang AY, Grogan JS, Mahon KL et al.. “A prospective multicentre phase III validation study of AZGP1 as a biomarker in localized prostate cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 28486686 ↗

    L2TRIAL_NONRANDOMCited in: Biopsy and Histologic Diagnosis
  436. [436]

    Lane JA, Donovan JL, Davis M et al.. “Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial.” The Lancet. Oncology (2014). PMID: 25163905 ↗

    L1RCTCited in: Biopsy and Histologic Diagnosis
  437. [437]

    Vickers AJ, Savage C, O'Brien MF et al.. “Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 19064972 ↗

    L2SR_OBSCited in: Biopsy and Histologic Diagnosis
  438. [438]

    Tendler S, Dunphy MP, Agee M et al.. “Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial.” The Lancet. Oncology (2024). PMID: 38950555 ↗

    L4TRIAL_NONRANDOMCited in: Biopsy and Histologic Diagnosis, Imaging
  439. [439]

    Ahmed HU, Hindley RG, Dickinson L et al.. “Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study.” The Lancet. Oncology (2012). PMID: 22512844 ↗

    L2TRIAL_NONRANDOMCited in: Biopsy and Histologic Diagnosis, Staging
  440. [440]

    Ahdoot M, Wilbur AR, Reese SE et al.. “MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis.” The New England journal of medicine (2020). PMID: 32130814 ↗

    L2TRIAL_NONRANDOMCited in: Biopsy and Histologic Diagnosis, Imaging, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  441. [441]

    Vickers A, Cronin A, Roobol M et al.. “Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2010). PMID: 20421547 ↗

    L2RCTCited in: Biopsy and Histologic Diagnosis
  442. [442]

    Thompson IM, Pauler Ankerst D, Chi C et al.. “Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2007). PMID: 17634486 ↗

    L2RCTCited in: Biopsy and Histologic Diagnosis, Staging
  443. [443]

    Buethe DD, Pow-Sang J. “Enrollment criteria controversies for active surveillance and triggers for conversion to treatment in prostate cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2012). PMID: 22956809 ↗

    L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers
  444. [444]

    Grey ADR, Scott R, Shah B et al.. “Multiparametric ultrasound versus multiparametric MRI to diagnose prostate cancer (CADMUS): a prospective, multicentre, paired-cohort, confirmatory study.” The Lancet. Oncology (2022). PMID: 35240084 ↗

    L2RCTCited in: Biopsy and Histologic Diagnosis
  445. [445]

    Stocking JJ, Fiandalo MV, Pop EA et al.. “Characterization of Prostate Cancer in a Functional Eunuch.” Journal of the National Comprehensive Cancer Network : JNCCN (2016). PMID: 27587619 ↗

    L4CASE_REPORTCited in: Biopsy and Histologic Diagnosis
  446. [446]

    Urban D, Rischin D, Angel C et al.. “Abiraterone in metastatic salivary duct carcinoma.” Journal of the National Comprehensive Cancer Network : JNCCN (2015). PMID: 25736005 ↗

    L4CASE_REPORTCited in: Biopsy and Histologic Diagnosis, Imaging
  447. [447]

    Yu W, Hurley J, Roberts D et al.. “Exosome-based liquid biopsies in cancer: opportunities and challenges.” Annals of oncology : official journal of the European Society for Medical Oncology (2021). PMID: 33548389 ↗

    L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers
  448. [448]

    Vergis R, Corbishley CM, Norman AR et al.. “Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study.” The Lancet. Oncology (2008). PMID: 18343725 ↗

    L2COHORTCited in: Biopsy and Histologic Diagnosis
  449. [449]

    Tangen CM, Goodman PJ, Till C et al.. “Biases in Recommendations for and Acceptance of Prostate Biopsy Significantly Affect Assessment of Prostate Cancer Risk Factors: Results From Two Large Randomized Clinical Trials.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 27998216 ↗

    L2REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis
  450. [450]

    Moses KA, Sprenkle PC, Bahler C et al.. “NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023.” Journal of the National Comprehensive Cancer Network : JNCCN (2023). PMID: 36898362 ↗

    L1OTHERCited in: Biopsy and Histologic Diagnosis
  451. [451]

    Munbauhal G, Seisen T, Gomez FD et al.. “Current perspectives of sentinel lymph node dissection at the time of radical surgery for prostate cancer.” Cancer treatment reviews (2016). PMID: 27768918 ↗

    L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis, Imaging
  452. [452]

    Sargos P, Guerif S, Latorzeff I et al.. “Definition of lymph node areas for radiotherapy of prostate cancer: A critical literature review by the French Genito-Urinary Group and the French Association of Urology (GETUG-AFU).” Cancer treatment reviews (2015). PMID: 26508669 ↗

    L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis
  453. [453]

    Petrioli R, Fiaschi AI, Francini E et al.. “The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer.” Cancer treatment reviews (2008). PMID: 18620815 ↗

    L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers, Staging, Special Populations
  454. [454]

    Suartz CV, Micheleto JPC, Condotta BE et al.. “NeuroSAFE-guided robot-assisted radical prostatectomy versus standard RARP: systematic review and meta-analysis of comparative studies.” Journal of robotic surgery (2026). PMID: 42126466 ↗

    L2SR_OBSCited in: Biopsy and Histologic Diagnosis
  455. [455]

    Linch M, Goh G, Hiley C et al.. “Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters.” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 28961847 ↗

    L4OTHERCited in: Biopsy and Histologic Diagnosis
  456. [456]

    Jain S, Lyons CA, Walker SM et al.. “Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy.” Annals of oncology : official journal of the European Society for Medical Oncology (2018). PMID: 29045551 ↗

    L2OTHERCited in: Biopsy and Histologic Diagnosis
  457. [457]

    Domingo-Domenech J, Fernandez PL, Filella X et al.. “Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 17998285 ↗

    L2OTHERCited in: Biopsy and Histologic Diagnosis
  458. [458]

    Al-Monajjed R, Albers P, Boschheidgen M et al.. “PRIMA: randomized prospective multicenter non-inferiority study for primary diagnosis of clinically significant PRostate cancer by PSA and MR IMAging-study protocol for a randomized diagnostic accuracy trial.” Trials (2026). PMID: 42032761 ↗

    L5TRIAL_NONRANDOMCited in: Biopsy and Histologic Diagnosis
  459. [459]

    Wade J, Rosario DJ, Macefield RC et al.. “Psychological impact of prostate biopsy: physical symptoms, anxiety, and depression.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2013). PMID: 24145343 ↗

    L2OTHERCited in: Biopsy and Histologic Diagnosis
  460. [460]

    Leapman MS, Cowan JE, Nguyen HG et al.. “Active Surveillance in Younger Men With Prostate Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 28346806 ↗

    L2OTHERCited in: Biopsy and Histologic Diagnosis
  461. [461]

    Vigneswaran HT, Eklund M, Discacciati A et al.. “Stockholm3 in a Multiethnic Cohort for Prostate Cancer Detection (SEPTA): A Prospective Multicentered Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 39038251 ↗

    L2OTHERCited in: Biopsy and Histologic Diagnosis
  462. [462]

    Stark JR, Perner S, Stampfer MJ et al.. “Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3?” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19433685 ↗

    L2OTHERCited in: Biopsy and Histologic Diagnosis, Staging
  463. [463]

    Haffner MC, Morris MJ, Ding CC et al.. “Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 39589343 ↗

    L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  464. [464]

    Michalski K, Lorenzini T, Jedamzik T et al.. “Liquid Biopsy Biomarkers in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Prostate-Specific Membrane Antigen Radioligand Therapy: Protocol for a Prospective, Longitudinal Multicenter Observational Study.” JMIR research protocols (2026). PMID: 42054640 ↗

    L5TRIAL_NONRANDOMCited in: Biopsy and Histologic Diagnosis
  465. [465]

    Ström P, Kartasalo K, Olsson H et al.. “Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study.” The Lancet. Oncology (2020). PMID: 31926806 ↗

    L2OTHERCited in: Biopsy and Histologic Diagnosis
  466. [466]

    Nordström T, Discacciati A, Bergman M et al.. “Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.” The Lancet. Oncology (2021). PMID: 34391509 ↗

    L1OTHERCited in: Biopsy and Histologic Diagnosis
  467. [467]

    Rouvière O, Puech P, Renard-Penna R et al.. “Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study.” The Lancet. Oncology (2018). PMID: 30470502 ↗

    L2OTHERCited in: Biopsy and Histologic Diagnosis
  468. [468]

    Klemann N, Røder MA, Helgstrand JT et al.. “Risk of prostate cancer diagnosis and mortality in men with a benign initial transrectal ultrasound-guided biopsy set: a population-based study.” The Lancet. Oncology (2017). PMID: 28094199 ↗

    L2OTHERCited in: Biopsy and Histologic Diagnosis, Staging
  469. [469]

    Bulten W, Pinckaers H, van Boven H et al.. “Automated deep-learning system for Gleason grading of prostate cancer using biopsies: a diagnostic study.” The Lancet. Oncology (2020). PMID: 31926805 ↗

    L2OTHERCited in: Biopsy and Histologic Diagnosis
  470. [470]

    Hamm CA, Asbach P, Pöhlmann A et al.. “Oncological Safety of MRI-Informed Biopsy Decision-Making in Men With Suspected Prostate Cancer.” JAMA oncology (2025). PMID: 39666360 ↗

    L2OTHERCited in: Biopsy and Histologic Diagnosis, Imaging
  471. [471]

    Eldred-Evans D, Burak P, Connor MJ et al.. “Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography: The IP1-PROSTAGRAM Study.” JAMA oncology (2021). PMID: 33570542 ↗

    L2OTHERCited in: Biopsy and Histologic Diagnosis, Imaging
  472. [472]

    Klaassen Z, Stock S, Waller J et al.. “Association of the COVID-19 Pandemic With Rates of Prostate Cancer Biopsies and Diagnoses in Black vs White US Veterans.” JAMA oncology (2022). PMID: 35389461 ↗

    L2OTHERCited in: Biopsy and Histologic Diagnosis
  473. [473]

    Roth JA, Gulati R, Gore JL et al.. “Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies.” JAMA oncology (2016). PMID: 27010943 ↗

    L2OTHERCited in: Biopsy and Histologic Diagnosis, Staging
  474. [474]

    Nagpal K, Foote D, Tan F et al.. “Development and Validation of a Deep Learning Algorithm for Gleason Grading of Prostate Cancer From Biopsy Specimens.” JAMA oncology (2020). PMID: 32701148 ↗

    L2OTHERCited in: Biopsy and Histologic Diagnosis
  475. [475]

    McKiernan J, Donovan MJ, O'Neill V et al.. “A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy.” JAMA oncology (2016). PMID: 27032035 ↗

    L2OTHERCited in: Biopsy and Histologic Diagnosis
  476. [476]

    Mehralivand S, Shih JH, Rais-Bahrami S et al.. “A Magnetic Resonance Imaging-Based Prediction Model for Prostate Biopsy Risk Stratification.” JAMA oncology (2018). PMID: 29470570 ↗

    L2OTHERCited in: Biopsy and Histologic Diagnosis, Imaging
  477. [477]

    Tilki D, Chen MH, Wu J et al.. “Surgery vs Radiotherapy in the Management of Biopsy Gleason Score 9-10 Prostate Cancer and the Risk of Mortality.” JAMA oncology (2019). PMID: 30452521 ↗

    L2OTHERCited in: Biopsy and Histologic Diagnosis
  478. [478]

    . “Beware Liquid Biopsies to Guide PARP Blockade.” Cancer discovery (2020). PMID: 33208392 ↗

    L5OTHERCited in: Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers
  479. [479]

    Ciani Y, Nardella C, Demichelis F. “Casting a wider net: The clinical potential of EV transcriptomics in multi-analyte liquid biopsy.” Cancer cell (2024). PMID: 38981437 ↗

    L5OTHERCited in: Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers
  480. [480]

    Doğan M, Aydin C, Ekici M et al.. “The effect of povidone-iodine-enhanced rectal enema on procedure-related infectious complications before transrectal ultrasound-guided prostate biopsy: A prospective randomized study.” Medicine (2026). PMID: 42152336 ↗

    L1RCTCited in: Biopsy and Histologic Diagnosis
  481. [481]

    Truong HTT, Kwon WA, Woo HJ et al.. “Deciphering the Heterogeneity of Cancer-Associated Fibroblasts in Prostate Cancer: From Stromal Biology to Clinical Translation.” Cancers (2026). PMID: 42192959 ↗

    L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis
  482. [482]

    Kayaalp M, Yekedüz E, Ürün Y. “Role of liquid biopsy in genitourinary (GU) cancers.” Expert review of molecular diagnostics (2026). PMID: 42130297 ↗

    L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis
  483. [483]

    Chiu CL, Zhang D, Zhao H et al.. “Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 39879384 ↗

    L5OTHERCited in: Biopsy and Histologic Diagnosis
  484. [484]

    Brighi N, Wetterskog D, Vainauskas O et al.. “Liquid Biopsy Identifies Taxane Resistance and Clonal Selection in Castration-Resistant Prostate Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 41081632 ↗

    L2OTHERCited in: Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors, Special Populations
  485. [485]

    Feng S, Agoulnik IU, Bogatcheva NV et al.. “Relaxin promotes prostate cancer progression.” Clinical cancer research : an official journal of the American Association for Cancer Research (2007). PMID: 17363522 ↗

    L5OTHERCited in: Biopsy and Histologic Diagnosis
  486. [486]

    Owiredu J, Ersoy-Fazlioglu B, Poluben L et al.. “Increased ErbB2 Signaling Is an Early Adaptation to Androgen Signaling Inhibition and Persists in Castration-Resistant Prostate Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40795068 ↗

    L5OTHERCited in: Biopsy and Histologic Diagnosis
  487. [487]

    Urabe F, Matsuzaki J, Yamamoto Y et al.. “Large-scale Circulating microRNA Profiling for the Liquid Biopsy of Prostate Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2019). PMID: 30808771 ↗

    L3OTHERCited in: Biopsy and Histologic Diagnosis
  488. [488]

    Koumakpayi IH, Diallo JS, Le Page C et al.. “Expression and nuclear localization of ErbB3 in prostate cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2006). PMID: 16675564 ↗

    L4OTHERCited in: Biopsy and Histologic Diagnosis
  489. [489]

    Zhang Z, Zhai J, Ma Q et al.. “Pathological complete response to perioperative treatment with darolutamide plus ADT in locally advanced prostate cancer without PTEN or RB1 loss: a case report.” Frontiers in pharmacology (2026). PMID: 42318353 ↗

    L4CASE_REPORTCited in: Biopsy and Histologic Diagnosis
  490. [490]

    He QM, Tang JJ, Hao C et al.. “Bilateral renal metastasis following radical prostatectomy for prostate cancer: a case report.” Frontiers in medicine (2026). PMID: 42292172 ↗

    L4CASE_REPORTCited in: Biopsy and Histologic Diagnosis
  491. [491]

    Kim KM, Kim JH, Chung MJ. “Clonal relationship in a rare pulmonary mixed tumor: shared ALK fusion in atypical carcinoid and adenocarcinoma-a case report.” Translational lung cancer research (2026). PMID: 42170278 ↗

    L4CASE_REPORTCited in: Biopsy and Histologic Diagnosis
  492. [492]

    Trabulsi EJ, Rumble RB, Jadvar H et al.. “Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 31940221 ↗

    L1GUIDELINECited in: Imaging
  493. [493]

    Clarke NW, Ali A, Ingleby FC et al.. “Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2019). PMID: 31560068 ↗

    L1RCTCited in: Imaging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  494. [494]

    Kishan AU, Valle LF, Wilhalme H et al.. “177Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 41223345 ↗

    L1RCTCited in: Imaging
  495. [495]

    McKay RR, Ye H, Xie W et al.. “Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 30811282 ↗

    L1RCTCited in: Imaging
  496. [496]

    Roach M, Bae K, Speight J et al.. “Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 18172188 ↗

    L1RCTCited in: Imaging
  497. [497]

    Mollica V, Marchetti A, Fraccascia N et al.. “A prospective study on the early evaluation of response to androgen receptor-targeted agents with 11C-Choline, 68Ga-PSMA, and 18F-FACBC PET in metastatic castration-resistant prostate cancer: a single-center experience.” ESMO open (2024). PMID: 38718704 ↗

    L2RCTCited in: Imaging, Management Overview, History and Evolution of Treatment, Special Populations
  498. [498]

    Petrylak DP, Vaishampayan UN, Patel KR et al.. “A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide.” ESMO open (2021). PMID: 33744812 ↗

    L1RCTCited in: Imaging, History and Evolution of Treatment
  499. [499]

    Kneebone A, Fraser-Browne C, Duchesne GM et al.. “Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial.” The Lancet. Oncology (2020). PMID: 33002437 ↗

    L1RCTCited in: Imaging, Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors, Special Populations
  500. [500]

    Emmett L, Papa N, Subramaniam S et al.. “Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial.” The Lancet. Oncology (2025). PMID: 40752515 ↗

    L1RCTCited in: Imaging
  501. [501]

    Carrier M, Lazo-Langner A, Shivakumar S et al.. “Screening for Occult Cancer in Unprovoked Venous Thromboembolism.” The New England journal of medicine (2015). PMID: 26095467 ↗

    L1RCTCited in: Imaging
  502. [502]

    Schöder H, Hope TA, Knopp M et al.. “Considerations on Integrating Prostate-Specific Membrane Antigen Positron Emission Tomography Imaging Into Clinical Prostate Cancer Trials by National Clinical Trials Network Cooperative Groups.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35015566 ↗

    L5TRIAL_NONRANDOMCited in: Imaging
  503. [503]

    Kyriakopoulos CE, Heath EI, Ferrari A et al.. “Exploring Spatial-Temporal Changes in 18F-Sodium Fluoride PET/CT and Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 32897830 ↗

    L2TRIAL_NONRANDOMCited in: Imaging
  504. [504]

    Harmon SA, Perk T, Lin C et al.. “Quantitative Assessment of Early [18F]Sodium Fluoride Positron Emission Tomography/Computed Tomography Response to Treatment in Men With Metastatic Prostate Cancer to Bone.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 28654366 ↗

    L2TRIAL_NONRANDOMCited in: Imaging
  505. [505]

    Agrotis G, Ursprung S, van der Steen C et al.. “Pretreatment MRI as a Prognostic Factor After Radical Prostatectomy: A Systematic Review and Meta-Analysis.” JAMA oncology (2026). PMID: 41926088 ↗

    L1SR_OBSCited in: Imaging
  506. [506]

    Belliveau C, Saad F, Duplan D et al.. “Prostate-Specific Membrane Antigen PET-Guided Intensification of Salvage Radiotherapy After Radical Prostatectomy: A Phase 2 Randomized Clinical Trial.” JAMA oncology (2025). PMID: 41037308 ↗

    L1RCTCited in: Imaging, Molecular Diagnostics and Biomarkers
  507. [507]

    Hope TA, Eiber M, Armstrong WR et al.. “Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial.” JAMA oncology (2021). PMID: 34529005 ↗

    L2TRIAL_NONRANDOMCited in: Imaging, Management Overview, Special Populations
  508. [508]

    Fendler WP, Calais J, Eiber M et al.. “Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial.” JAMA oncology (2019). PMID: 30920593 ↗

    L2TRIAL_NONRANDOMCited in: Imaging, Molecular Diagnostics and Biomarkers, Management Overview, Special Populations
  509. [509]

    Mookerji N, Pfanner T, Hui A et al.. “Fluorine-18 Prostate-Specific Membrane Antigen-1007 PET/CT vs Multiparametric MRI for Locoregional Staging of Prostate Cancer.” JAMA oncology (2024). PMID: 38949926 ↗

    L2TRIAL_NONRANDOMCited in: Imaging, Staging, History and Evolution of Treatment, Prognosis and Prognostic Factors
  510. [510]

    Morris MJ, Flynn J, Zhao B et al.. “Automated Imaging as an Adjunct to Serum and Clinical Biomarkers: A New Validated Prediction Tool for Metastatic Castration-Resistant Prostate Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 41324553 ↗

    L2RCTCited in: Imaging
  511. [511]

    Nikitas J, Smith CP, Armstrong WR et al.. “Five-Year Outcomes After Prostate-Specific Membrane Antigen PET/CT-Guided Salvage Radiotherapy Following Radical Prostatectomy.” Journal of the National Comprehensive Cancer Network : JNCCN (2026). PMID: 41698328 ↗

    L3OTHERCited in: Imaging, Special Populations
  512. [512]

    Mason BR, Eastham JA, Davis BJ et al.. “Current Status of MRI and PET in the NCCN Guidelines for Prostate Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 31085758 ↗

    L5OTHERCited in: Imaging
  513. [513]

    Borkenhagen JF, Eastwood D, Kilari D et al.. “Digital Rectal Examination Remains a Key Prognostic Tool for Prostate Cancer: A National Cancer Database Review.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 31319388 ↗

    L3REVIEW_NARRATIVECited in: Imaging
  514. [514]

    Ellis WJ, Lange PH. “Point: open radical prostatectomy should not be abandoned.” Journal of the National Comprehensive Cancer Network : JNCCN (2007). PMID: 17692171 ↗

    L5REVIEW_NARRATIVECited in: Imaging
  515. [515]

    Morris MJ, Rowe SP, Gorin MA et al.. “Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study.” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 33622706 ↗

    L2TRIAL_NONRANDOMCited in: Imaging, Molecular Diagnostics and Biomarkers, Special Populations
  516. [516]

    Jin Y, Yuan T, Chen Z. “Magnetic Resonance Imaging-Based Artificial Intelligence in Predicting Prostate Cancer Biochemical Recurrence: Systematic Review and Meta-Analysis.” Journal of medical Internet research (2026). PMID: 42412916 ↗

    L1SR_OBSCited in: Imaging
  517. [517]

    Ulaner GA, Parihar AS, Calais J et al.. “Liver Background Uptake of Prostate-specific Membrane Antigen-targeted PET Radiotracers: A Systematic Review and Meta-Analysis.” Radiology. Imaging cancer (2026). PMID: 42313080 ↗

    L1SR_OBSCited in: Imaging
  518. [518]

    Buch-Olsen KM, Hansen S, Vilstrup MH et al.. “Progression-free Survival Following Primary Staging with [18F]PSMA-1007-PET/ceCT Versus Na[18F]F-PET/ceCT in Prostate Cancer: Results from the PRISMA-PET Randomized Controlled Trial.” European urology open science (2026). PMID: 42255253 ↗

    L1RCTCited in: Imaging
  519. [519]

    Catton CN, Lukka H, Martin J. “Prostate Cancer Radiotherapy: An Evolving Paradigm.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 30138084 ↗

    L5OTHERCited in: Imaging
  520. [520]

    Speight JL, Roach M. “Advances in the treatment of localized prostate cancer: the role of anatomic and functional imaging in men managed with radiotherapy.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2007). PMID: 17350948 ↗

    L5REVIEW_NARRATIVECited in: Imaging
  521. [521]

    Onik G, Miessau M, Bostwick DG. “Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19652073 ↗

    L2OTHERCited in: Imaging
  522. [522]

    Lecouvet FE, Geukens D, Stainier A et al.. “Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2007). PMID: 17664475 ↗

    L2OTHERCited in: Imaging
  523. [523]

    Panikar SS, Bansal D, Crandall J et al.. “Exploratory FDG PET/CT Imaging in mCRPC Patients Treated with Sipuleucel-T ± IL-7: A Phase II Trial Subanalysis.” International journal of molecular sciences (2026). PMID: 42278652 ↗

    L4TRIAL_NONRANDOMCited in: Imaging
  524. [524]

    Lancia A, Zilli T, Achard V et al.. “Oligometastatic prostate cancer: The game is afoot.” Cancer treatment reviews (2019). PMID: 30684842 ↗

    L5REVIEW_NARRATIVECited in: Imaging, Management Overview, History and Evolution of Treatment
  525. [525]

    Calais J, Eulau SM, Gardner L et al.. “Incorporating radioligand therapy in clinical practice in the United States for patients with prostate cancer.” Cancer treatment reviews (2023). PMID: 36933329 ↗

    L5REVIEW_NARRATIVECited in: Imaging, Molecular Diagnostics and Biomarkers
  526. [526]

    Bollineni VR, Kramer G, Liu Y et al.. “A literature review of the association between diffusion-weighted MRI derived apparent diffusion coefficient and tumour aggressiveness in pelvic cancer.” Cancer treatment reviews (2015). PMID: 25892290 ↗

    L5REVIEW_NARRATIVECited in: Imaging
  527. [527]

    Saha A, Bosma JS, Twilt JJ et al.. “Artificial intelligence and radiologists in prostate cancer detection on MRI (PI-CAI): an international, paired, non-inferiority, confirmatory study.” The Lancet. Oncology (2024). PMID: 38876123 ↗

    L2OTHERCited in: Imaging, Prognosis and Prognostic Factors
  528. [528]

    Wu S, Hong G, Xu A et al.. “Artificial intelligence-based model for lymph node metastases detection on whole slide images in bladder cancer: a retrospective, multicentre, diagnostic study.” The Lancet. Oncology (2023). PMID: 36893772 ↗

    L2OTHERCited in: Imaging
  529. [529]

    De Meerleer G, Berghen C, Briganti A et al.. “Elective nodal radiotherapy in prostate cancer.” The Lancet. Oncology (2021). PMID: 34339655 ↗

    L5REVIEW_NARRATIVECited in: Imaging
  530. [530]

    Ibrahim EA, Alper E. “When PSMA is not enough: the diagnostic blind spots of PSMA PET/CT and the added value of [¹⁸F]FDG in high-risk prostate cancer: dual-tracer cohort study.” Cancer imaging : the official publication of the International Cancer Imaging Society (2026). PMID: 42393801 ↗

    L2COHORTCited in: Imaging, History and Evolution of Treatment
  531. [531]

    Evans MJ. “Measuring oncogenic signaling pathways in cancer with PET: an emerging paradigm from studies in castration-resistant prostate cancer.” Cancer discovery (2012). PMID: 23043150 ↗

    L5REVIEW_NARRATIVECited in: Imaging
  532. [532]

    Ulmert D, Evans MJ, Holland JP et al.. “Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen.” Cancer discovery (2012). PMID: 22576209 ↗

    L5OTHERCited in: Imaging, Molecular Diagnostics and Biomarkers
  533. [533]

    Bidkar AP, Peter R, Wadhwa A et al.. “Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac Therapy.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 39945595 ↗

    L5OTHERCited in: Imaging, Management Overview
  534. [534]

    Wang S, Li J, Hua J et al.. “Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 33293372 ↗

    L5OTHERCited in: Imaging
  535. [535]

    Chakraborty G, Nandakumar S, Hirani R et al.. “The Impact of PIK3R1 Mutations and Insulin-PI3K-Glycolytic Pathway Regulation in Prostate Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2022). PMID: 35670774 ↗

    L2OTHERCited in: Imaging
  536. [536]

    Veach DR, Storey CM, Lückerath K et al.. “PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates.” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 33441295 ↗

    L5OTHERCited in: Imaging
  537. [537]

    Penet MF, Kakkad S, Pathak AP et al.. “Structure and Function of a Prostate Cancer Dissemination-Permissive Extracellular Matrix.” Clinical cancer research : an official journal of the American Association for Cancer Research (2016). PMID: 27799248 ↗

    L5OTHERCited in: Imaging
  538. [538]

    Glumac PM, Gallant JP, Shapovalova M et al.. “Exploitation of CD133 for the Targeted Imaging of Lethal Prostate Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2019). PMID: 31732520 ↗

    L5OTHERCited in: Imaging
  539. [539]

    Wadhwa A, Wang S, Patiño-Escobar B et al.. “CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 38109209 ↗

    L5OTHERCited in: Imaging
  540. [540]

    van der Velden KJM, Bosch D, Vassilev Z et al.. “Real-world use of PSMA imaging in metastatic castration-sensitive prostate cancer: Findings from the CAPRI-3 registry.” European journal of nuclear medicine and molecular imaging (2026). PMID: 42429819 ↗

    L2OTHERCited in: Imaging
  541. [541]

    Stamouli I, Gatos I, Kalathas T et al.. “A computer-aided diagnosis tool in prostate cancer patients with biochemical recurrence using 18F-PSMA PET/CT imaging.” Medical physics (2026). PMID: 42415410 ↗

    L3OTHERCited in: Imaging
  542. [542]

    Nakhostin-Ansari A, Khera Z, Becker D et al.. “Telehealth Utilization for Prostate Cancer Management in the Veteran Affairs Healthcare System: A Study from 2016 to 2023.” Journal of general internal medicine (2026). PMID: 42414805 ↗

    L2OTHERCited in: Imaging
  543. [543]

    Zoroğlu H, Madendere S, Tarım K et al.. “Comparison of MRI-guided in-bore and fusion biopsy for small PI-RADS 4 prostate lesions.” World journal of urology (2026). PMID: 42406173 ↗

    L2OTHERCited in: Imaging
  544. [544]

    Hassen WA, Karsan FA, Abbas F et al.. “Modification and implementation of NCCN guidelines on prostate cancer in the Middle East and North Africa region.” Journal of the National Comprehensive Cancer Network : JNCCN (2010). PMID: 20697128 ↗

    L1GUIDELINECited in: Molecular Diagnostics and Biomarkers, Staging, Prognosis and Prognostic Factors
  545. [545]

    Fizazi K, Chi KN, Shore ND et al.. “Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 40680993 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  546. [546]

    Armstrong AJ, Morris MJ, Abida W et al.. “Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2026). PMID: 41744290 ↗

    L1GUIDELINECited in: Molecular Diagnostics and Biomarkers
  547. [547]

    Aggarwal R, Heller G, Hillman DW et al.. “PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19).” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38261983 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, Management Overview
  548. [548]

    Francolini G, Allegra AG, Detti B et al.. “Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO).” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37733977 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers
  549. [549]

    Szmulewitz RZ, Peer CJ, Ibraheem A et al.. “Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 29590007 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers
  550. [550]

    Denmeade SR, Wang H, Agarwal N et al.. “TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 33617303 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers
  551. [551]

    Rathkopf DE, Patel MR, Choudhury AD et al.. “Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 39293515 ↗

    L4TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors, Special Populations
  552. [552]

    Stein MN, Vinceneux A, Robbrecht D et al.. “Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40450573 ↗

    L4TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers, Special Populations
  553. [553]

    Antonarakis ES, Piulats JM, Gross-Goupil M et al.. “Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 31774688 ↗

    L4TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers
  554. [554]

    Tagawa ST, Thomas C, Sartor AO et al.. “Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37922438 ↗

    L4TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers
  555. [555]

    Buteau JP, Martin AJ, Emmett L et al.. “PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial.” The Lancet. Oncology (2022). PMID: 36261050 ↗

    L2RCTCited in: Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors
  556. [556]

    Emmett L, Subramaniam S, Crumbaker M et al.. “[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial.” The Lancet. Oncology (2024). PMID: 38621400 ↗

    L2RCTCited in: Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  557. [557]

    Emmett L, Subramaniam S, Crumbaker M et al.. “Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial.” The Lancet. Oncology (2025). PMID: 39956124 ↗

    L2RCTCited in: Molecular Diagnostics and Biomarkers
  558. [558]

    Smith MR, Saad F, Chowdhury S et al.. “Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.” The New England journal of medicine (2018). PMID: 29420164 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  559. [559]

    James ND, de Bono JS, Spears MR et al.. “Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.” The New England journal of medicine (2017). PMID: 28578639 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Special Populations
  560. [560]

    Hussain M, Fizazi K, Saad F et al.. “Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.” The New England journal of medicine (2018). PMID: 29949494 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  561. [561]

    Parker CC, Petersen PM, Cook AD et al.. “Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047).” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 38583574 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  562. [562]

    Chowdhury S, Bjartell A, Agarwal N et al.. “Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2023). PMID: 36858151 ↗

    L2RCTCited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment
  563. [563]

    Tripathi A, Chen Y, Jarrard DF et al.. “Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 40854410 ↗

    L2RCTCited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment, Special Populations
  564. [564]

    Berthold DR, Pond GR, Soban F et al.. “Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 18182665 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors, Special Populations
  565. [565]

    Buyyounouski MK, Pugh SL, Chen RC et al.. “Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms: The NRG-GU003 Phase 3 Randomized Clinical Trial.” JAMA oncology (2024). PMID: 38483412 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Special Populations
  566. [566]

    Annala M, Vandekerkhove G, Khalaf D et al.. “Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.” Cancer discovery (2018). PMID: 29367197 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  567. [567]

    Sweeney CJ, Chen YH, Carducci M et al.. “Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.” The New England journal of medicine (2015). PMID: 26244877 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, Management Overview
  568. [568]

    Jones LW, Moskowitz CS, Lee CP et al.. “Neoadjuvant Exercise Therapy in Prostate Cancer: A Phase 1, Decentralized Nonrandomized ControlledTrial.” JAMA oncology (2024). PMID: 39023900 ↗

    L4TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors, Special Populations
  569. [569]

    Miyamoto DT, Lee RJ, Kalinich M et al.. “An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer.” Cancer discovery (2018). PMID: 29301747 ↗

    L4TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  570. [570]

    Montgomery B, Tretiakova MS, Joshua AM et al.. “Neoadjuvant Enzalutamide Prior to Prostatectomy.” Clinical cancer research : an official journal of the American Association for Cancer Research (2016). PMID: 28151719 ↗

    L2RCTCited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment, Special Populations
  571. [571]

    Sathekge MM, Lawal IO, Bal C et al.. “Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study.” The Lancet. Oncology (2024). PMID: 38218192 ↗

    L4COHORTCited in: Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors, Special Populations
  572. [572]

    Yamoah K, Trivedi P, Awasthi S et al.. “A Prospective Validation of the Decipher Genomic Classifier in Men With Early Localized Prostate Cancer: The VANDAAM Study.” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 41671436 ↗

    L2OTHERCited in: Molecular Diagnostics and Biomarkers, Special Populations
  573. [573]

    Mehrens D, Kramer KKM, Unterrainer LM et al.. “Cost-Effectiveness Analysis of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2023). PMID: 36634610 ↗

    L2OTHERCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  574. [574]

    McCloskey SA, Kuettel MR. “Counterpoint: prostate cancer life expectancy can not be accurately predicted from currently available tools.” Journal of the National Comprehensive Cancer Network : JNCCN (2007). PMID: 17692176 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers
  575. [575]

    Magnani CJ, Li K, Seto T et al.. “PSA Testing Use and Prostate Cancer Diagnostic Stage After the 2012 U.S. Preventive Services Task Force Guideline Changes.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 31319390 ↗

    L2OTHERCited in: Molecular Diagnostics and Biomarkers, Staging
  576. [576]

    Pomykala KL, Hadaschik BA, Sartor O et al.. “Next generation radiotheranostics promoting precision medicine.” Annals of oncology : official journal of the European Society for Medical Oncology (2023). PMID: 36924989 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers
  577. [577]

    McGrail DJ, Pilié PG, Rashid NU et al.. “High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.” Annals of oncology : official journal of the European Society for Medical Oncology (2021). PMID: 33736924 ↗

    L4OTHERCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  578. [578]

    De Vincentis G, Gerritsen W, Gschwend JE et al.. “Advances in targeted alpha therapy for prostate cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2019). PMID: 31418764 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers
  579. [579]

    Fizazi K. “The role of Src in prostate cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 17426060 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Staging
  580. [580]

    Zeng J, Chen MH, Wu J et al.. “Testosterone and docetaxel treatment effect on mortality risk in nonmetastatic high-risk prostate cancer: A predictive biomarker analysis.” Cancer (2026). PMID: 42175549 ↗

    L2RCTCited in: Molecular Diagnostics and Biomarkers
  581. [581]

    Krauss DJ, Karrison T, Martinez AA et al.. “Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37104748 ↗

    L1OTHERCited in: Molecular Diagnostics and Biomarkers
  582. [582]

    Hoshi S, Izumi K, Meguro S et al.. “Efficacy and Safety of Enzalutamide and Abiraterone in CRPC Patients With a History of Other Cancers: A Sub-Analysis of the ENABLE Study for PCa.” International journal of urology : official journal of the Japanese Urological Association (2026). PMID: 42161369 ↗

    L2RCTCited in: Molecular Diagnostics and Biomarkers
  583. [583]

    Giunta EF, Brighi N, Gurioli G et al.. “177Lu-PSMA therapy in metastatic prostate cancer: An updated review of prognostic and predictive biomarkers.” Cancer treatment reviews (2024). PMID: 38422894 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  584. [584]

    Seisen T, Rouprêt M, Gomez F et al.. “A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer.” Cancer treatment reviews (2016). PMID: 27327958 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment
  585. [585]

    Sridhar N, Iwase T, Xie X et al.. “Paving the path ForwARd: Advances and challenges in androgen receptor targeting in breast cancer.” Cancer treatment reviews (2025). PMID: 40424861 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers
  586. [586]

    Esposito A, Bardelli A, Criscitiello C et al.. “Monitoring tumor-derived cell-free DNA in patients with solid tumors: clinical perspectives and research opportunities.” Cancer treatment reviews (2013). PMID: 24184333 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers
  587. [587]

    Lipton A. “Biochemical bone markers in breast cancer.” Cancer treatment reviews (2006). PMID: 16680834 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers
  588. [588]

    Smith MR. “Markers of bone metabolism in prostate cancer.” Cancer treatment reviews (2006). PMID: 16680835 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers
  589. [589]

    Dathathri E, Nanou A, Bidard FC et al.. “Blood tumor load: combining biomarkers to increase the proportion of informative patients.” ESMO open (2025). PMID: 40532363 ↗

    L4OTHERCited in: Molecular Diagnostics and Biomarkers, Special Populations
  590. [590]

    Brighi N, Conteduca V, Gurioli G et al.. “Longitudinal assessment of plasma androgen receptor copy number predicts overall survival in subsequent treatment lines in castration-resistant prostate cancer: analysis from a prospective trial.” ESMO open (2023). PMID: 37866028 ↗

    L2OTHERCited in: Molecular Diagnostics and Biomarkers
  591. [591]

    Moussa H, Tourigny R, Robitaille K et al.. “Cohort profile: BioCaPPE (Biomarkers of Prostate Cancer/Prevention and Environment) - a Canadian multicentre prospective study of lifestyle and candidate biomarkers in relation to prostate cancer risk.” BMJ open (2026). PMID: 42209010 ↗

    L2COHORTCited in: Molecular Diagnostics and Biomarkers
  592. [592]

    Asanuma H, Fujita N, Kato S et al.. “Efficacy, Safety, and Cost-Effectiveness of Reduced versus Full Initial Doses of Androgen Receptor Signaling Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Study.” The Prostate (2026). PMID: 42190045 ↗

    L4COHORTCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  593. [593]

    Jayaram A, Rashid M, Reid AHM et al.. “Combined ctDNA and serum PSA for dynamic monitoring of metastatic prostate cancer starting first-line treatment: a prospective national cohort study.” Nature cancer (2026). PMID: 42141175 ↗

    L2COHORTCited in: Molecular Diagnostics and Biomarkers
  594. [594]

    Kelly WK, Danila DC, Lin CC et al.. “Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study.” Cancer discovery (2024). PMID: 37861461 ↗

    L4OTHERCited in: Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors
  595. [595]

    Sharifi MN, Sperger JM, Taylor AK et al.. “High-purity CTC RNA sequencing identifies prostate cancer lineage phenotypes prognostic for clinical outcomes.” Cancer discovery (2025). PMID: 39912912 ↗

    L2OTHERCited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  596. [596]

    Logothetis CJ, Gallick GE, Maity SN et al.. “Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer.” Cancer discovery (2013). PMID: 23811619 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors
  597. [597]

    Heitzer E, Speicher MR. “Digital Circulating Tumor Cell Analyses for Prostate Cancer Precision Oncology.” Cancer discovery (2018). PMID: 29500328 ↗

    L5OTHERCited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment
  598. [598]

    . “CTCs Could Shorten Drug Trials.” Cancer discovery (2015). PMID: 25883015 ↗

    L5OTHERCited in: Molecular Diagnostics and Biomarkers
  599. [599]

    Stegeman S, Amankwah E, Klein K et al.. “A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer.” Cancer discovery (2015). PMID: 25691096 ↗

    L3OTHERCited in: Molecular Diagnostics and Biomarkers, Staging, Special Populations
  600. [600]

    Miyamoto DT, Lee RJ, Stott SL et al.. “Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer.” Cancer discovery (2012). PMID: 23093251 ↗

    L4OTHERCited in: Molecular Diagnostics and Biomarkers
  601. [601]

    Herschman HR, Czernin J. “A spotlight from prostate cancer.” Cancer discovery (2012). PMID: 22576205 ↗

    L5OTHERCited in: Molecular Diagnostics and Biomarkers
  602. [602]

    Taylor BS, Schultz N, Hieronymus H et al.. “Integrative genomic profiling of human prostate cancer.” Cancer cell (2010). PMID: 20579941 ↗

    L4OTHERCited in: Molecular Diagnostics and Biomarkers, Special Populations
  603. [603]

    Sinha A, Huang V, Livingstone J et al.. “The Proteogenomic Landscape of Curable Prostate Cancer.” Cancer cell (2019). PMID: 30889379 ↗

    L4OTHERCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors, Special Populations
  604. [604]

    Takeda DY, Sowalsky AG. “Unpacking circulating tumor DNA lends insight into prostate cancer biology and the clonal dynamics of metastasis.” Cancer cell (2022). PMID: 36179684 ↗

    L5OTHERCited in: Molecular Diagnostics and Biomarkers
  605. [605]

    Andersen RJ, Mawji NR, Wang J et al.. “Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor.” Cancer cell (2010). PMID: 20541699 ↗

    L5OTHERCited in: Molecular Diagnostics and Biomarkers
  606. [606]

    Jani CT, Tran E, Zhang N et al.. “Characterizing Longitudinal Molecular Changes in ctDNA in Patients with Metastatic Castration-Resistant Prostate Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 41746190 ↗

    L3OTHERCited in: Molecular Diagnostics and Biomarkers
  607. [607]

    Anselmino N, Labanca E, Shepherd PDA et al.. “Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 38488813 ↗

    L5OTHERCited in: Molecular Diagnostics and Biomarkers
  608. [608]

    Sartor O. “Circulating Tumor DNA Biomarkers for Response Assessment in Prostate Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 37265409 ↗

    L5OTHERCited in: Molecular Diagnostics and Biomarkers
  609. [609]

    Danila DC, Fleisher M, Scher HI. “Circulating tumor cells as biomarkers in prostate cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2011). PMID: 21680546 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers
  610. [610]

    Blinka S, Yu EY. “Drug Targets in Prostate Cancer: An Appetite for KLK2-Mediated Destruction.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40924642 ↗

    L5OTHERCited in: Molecular Diagnostics and Biomarkers
  611. [611]

    Franco JV, Hwang EC, Jung JH et al.. “Prostate-specific antigen (PSA) test for prostate cancer screening.” The Cochrane database of systematic reviews (2026). PMID: 42134821 ↗

    L1SR_OBSCited in: Molecular Diagnostics and Biomarkers
  612. [612]

    Paganoni E, Sabbadini P, D'Avolio A et al.. “Failure of a LHRH agonist in metastatic prostate cancer: a case report and review of literature.” Cancer chemotherapy and pharmacology (2026). PMID: 42159776 ↗

    L4CASE_REPORTCited in: Molecular Diagnostics and Biomarkers
  613. [613]

    Padden-Modi M, Taprogge J, Dutey-Magni P et al.. “Predictive imaging biomarkers on whole-body diffusion-weighted MRI (WB-DWMRI) and [68Ga]GaPSMA-PET/CT for [177Lu]LuPSMA therapy in metastatic prostate cancer (mCRPC).” Cancer imaging : the official publication of the International Cancer Imaging Society (2026). PMID: 42381110 ↗

    L4OTHERCited in: Molecular Diagnostics and Biomarkers
  614. [614]

    Mahmud S, Dwyer Orr L, Cline M et al.. “Biomarker testing patterns among patients newly diagnosed with metastatic non-small cell lung cancer, prostate cancer, and bladder cancer.” The oncologist (2026). PMID: 42366674 ↗

    L3OTHERCited in: Molecular Diagnostics and Biomarkers
  615. [615]

    Hodgson K, Blencoe L, Smith E et al.. “Comprehensive Profiling Reveals Sialyl-Tn Upregulation and Prognostic Value in Prostate Cancer.” Pathology international (2026). PMID: 42332379 ↗

    L4OTHERCited in: Molecular Diagnostics and Biomarkers
  616. [616]

    Cheng Y, Huang H, Wang M et al.. “Magnetic resonance imaging-targeted biopsy with index lesion ipsilateral or bilateral systematic biopsy in prostate cancer: A multicenter, paired, noninferiority, observational trial.” Cancer (2026). PMID: 42319125 ↗

    L2OTHERCited in: Molecular Diagnostics and Biomarkers
  617. [617]

    Mohler JL, Kantoff PW, Armstrong AJ et al.. “Prostate cancer, version 1.2014.” Journal of the National Comprehensive Cancer Network : JNCCN (2013). PMID: 24335682 ↗

    L1GUIDELINECited in: Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors
  618. [618]

    Loblaw DA, Virgo KS, Nam R et al.. “Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2007). PMID: 17404365 ↗

    L1GUIDELINECited in: Staging
  619. [619]

    Coyle C, Cafferty FH, Vale C et al.. “Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis.” Annals of oncology : official journal of the European Society for Medical Oncology (2016). PMID: 27681864 ↗

    L1SR_OBSCited in: Staging
  620. [620]

    Sternberg CN, Molina A, North S et al.. “Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy.” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 23152362 ↗

    L1RCTCited in: Staging
  621. [621]

    van Soest RJ, Templeton AJ, Vera-Badillo FE et al.. “Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials.” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 25515657 ↗

    L2RCTCited in: Staging
  622. [622]

    Lorente D, Mateo J, Templeton AJ et al.. “Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use.” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 25538172 ↗

    L2RCTCited in: Staging
  623. [623]

    Mostaghel EA, Nelson PS, Lange P et al.. “Targeted androgen pathway suppression in localized prostate cancer: a pilot study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2013). PMID: 24323034 ↗

    L1RCTCited in: Staging
  624. [624]

    Zaorsky NG, Ohri N, Showalter TN et al.. “Systematic review of hypofractionated radiation therapy for prostate cancer.” Cancer treatment reviews (2013). PMID: 23453861 ↗

    L5SR_OBSCited in: Staging, Management Overview, Prognosis and Prognostic Factors
  625. [625]

    Higano CS. “New developments in the treatment of castration-resistant prostate cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2014). PMID: 24853214 ↗

    L5REVIEW_NARRATIVECited in: Staging, Prognosis and Prognostic Factors
  626. [626]

    Ryan CJ, Smith MR, Fizazi K et al.. “Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.” The Lancet. Oncology (2015). PMID: 25601341 ↗

    L1RCTCited in: Staging
  627. [627]

    Zapatero A, Guerrero A, Maldonado X et al.. “High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial.” The Lancet. Oncology (2022). PMID: 35427469 ↗

    L1RCTCited in: Staging
  628. [628]

    Zapatero A, Guerrero A, Maldonado X et al.. “High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.” The Lancet. Oncology (2015). PMID: 25702876 ↗

    L1RCTCited in: Staging
  629. [629]

    Bill-Axelson A, Holmberg L, Garmo H et al.. “Radical Prostatectomy or Watchful Waiting in Prostate Cancer - 29-Year Follow-up.” The New England journal of medicine (2018). PMID: 30575473 ↗

    L1RCTCited in: Staging
  630. [630]

    Wilt TJ, Jones KM, Barry MJ et al.. “Follow-up of Prostatectomy versus Observation for Early Prostate Cancer.” The New England journal of medicine (2017). PMID: 28700844 ↗

    L1RCTCited in: Staging
  631. [631]

    Bill-Axelson A, Holmberg L, Ruutu M et al.. “Radical prostatectomy versus watchful waiting in early prostate cancer.” The New England journal of medicine (2011). PMID: 21542742 ↗

    L1RCTCited in: Staging
  632. [632]

    Rathkopf DE, Beer TM, Loriot Y et al.. “Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial.” JAMA oncology (2018). PMID: 29522174 ↗

    L1RCTCited in: Staging
  633. [633]

    Mucci LA, Powolny A, Giovannucci E et al.. “Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19858401 ↗

    L2COHORTCited in: Staging
  634. [634]

    Stranne J, Axen E, Bratt O et al.. “The Swedish national guidelines on prostate cancer: recurrent, metastatic and castration resistant disease.” Scandinavian journal of urology (2026). PMID: 42012147 ↗

    L1GUIDELINECited in: Staging
  635. [635]

    Soeterik TFW, Miszczyk M, Peters M et al.. “Nomogram-based risk classification for predicting response to metastasis-directed stereotactic body radiotherapy in PSMA PET-staged oligorecurrent prostate cancer (PORTAL): an international, retrospective cohort study.” The Lancet. Oncology (2026). PMID: 41713474 ↗

    L2COHORTCited in: Staging
  636. [636]

    Stolzenbach LF, Rosiello G, Pecoraro A et al.. “Prostate Cancer Grade and Stage Misclassification in Active Surveillance Candidates: Black Versus White Patients.” Journal of the National Comprehensive Cancer Network : JNCCN (2020). PMID: 33152695 ↗

    L2OTHERCited in: Staging, Prognosis and Prognostic Factors
  637. [637]

    Banegas MP, Yabroff KR, O'Keeffe-Rosetti MC et al.. “Medical Care Costs Associated With Cancer in Integrated Delivery Systems.” Journal of the National Comprehensive Cancer Network : JNCCN (2018). PMID: 29632060 ↗

    L2OTHERCited in: Staging
  638. [638]

    Lichtensztajn DY, Leppert JT, Brooks JD et al.. “Undertreatment of High-Risk Localized Prostate Cancer in the California Latino Population.” Journal of the National Comprehensive Cancer Network : JNCCN (2018). PMID: 30442735 ↗

    L2OTHERCited in: Staging
  639. [639]

    Muralidhar V, Nguyen PL, Mahal BA et al.. “Practice Patterns and Outcomes Among Patients With N0M0 Prostate Cancer and a Very High Prostate-Specific Antigen Level.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 31390585 ↗

    L2OTHERCited in: Staging
  640. [640]

    Quek RG, Ward KC, Master VA et al.. “Association between urologist characteristics and radiation oncologist consultation for patients with locoregional prostate cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2015). PMID: 25736007 ↗

    L2OTHERCited in: Staging
  641. [641]

    Fossati N, Nguyen DP, Trinh QD et al.. “The Impact of Insurance Status on Tumor Characteristics and Treatment Selection in Contemporary Patients With Prostate Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2015). PMID: 26553765 ↗

    L2OTHERCited in: Staging
  642. [642]

    Ciccarese C, Santoni M, Brunelli M et al.. “AR-V7 and prostate cancer: The watershed for treatment selection?” Cancer treatment reviews (2015). PMID: 26827690 ↗

    L5REVIEW_NARRATIVECited in: Staging, Management Overview, Prognosis and Prognostic Factors
  643. [643]

    Falci C, Morello E, Droz JP. “Treatment of prostate cancer in unfit senior adult patients.” Cancer treatment reviews (2009). PMID: 19487081 ↗

    L5REVIEW_NARRATIVECited in: Staging, Prognosis and Prognostic Factors, Special Populations
  644. [644]

    Zumsteg ZS, Zelefsky MJ. “Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: the standard of care?” The Lancet. Oncology (2012). PMID: 22652234 ↗

    L5REVIEW_NARRATIVECited in: Staging
  645. [645]

    Mahal BA, Chen MH, Bennett CL et al.. “High PSA anxiety and low health literacy skills: drivers of early use of salvage ADT among men with biochemically recurrent prostate cancer after radiotherapy?” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 25926039 ↗

    L2OTHERCited in: Staging
  646. [646]

    Kote-Jarai Z, Mikropoulos C, Leongamornlert DA et al.. “Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes.” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 25595936 ↗

    L3OTHERCited in: Staging
  647. [647]

    Kuykendal AR, Hendrix LH, Salloum RG et al.. “Guideline-discordant androgen deprivation therapy in localized prostate cancer: patterns of use in the medicare population and cost implications.” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 23277483 ↗

    L2OTHERCited in: Staging
  648. [648]

    Sushentsev N, Warren AY, Colling R et al.. “Long-term outcomes of cribriform-positive and cribriform-negative prostate cancer treated with radical prostatectomy in the ProtecT trial.” BJU international (2026). PMID: 41896701 ↗

    L2RCTCited in: Staging
  649. [649]

    Downer MK, Kenfield SA, Stampfer MJ et al.. “Alcohol Intake and Risk of Lethal Prostate Cancer in the Health Professionals Follow-Up Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 31026211 ↗

    L2OTHERCited in: Staging
  650. [650]

    Larsen SB, Dehlendorff C, Skriver C et al.. “Postdiagnosis Statin Use and Mortality in Danish Patients With Prostate Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 28806117 ↗

    L2OTHERCited in: Staging
  651. [651]

    Gutt R, Tonlaar N, Kunnavakkam R et al.. “Statin use and risk of prostate cancer recurrence in men treated with radiation therapy.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2010). PMID: 20421534 ↗

    L3OTHERCited in: Staging
  652. [652]

    Chan JM, Oh WK, Xie W et al.. “Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19528373 ↗

    L4OTHERCited in: Staging
  653. [653]

    Stalmeier PF, van Tol-Geerdink JJ, van Lin EN et al.. “Doctors' and patients' preferences for participation and treatment in curative prostate cancer radiotherapy.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2007). PMID: 17634489 ↗

    L4OTHERCited in: Staging
  654. [654]

    Hemminki K, Sundquist J, Brandt A. “Familial mortality and familial incidence in cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 21205747 ↗

    L2OTHERCited in: Staging
  655. [655]

    Morgan E, Bardot A, Langselius O et al.. “International disruptions to cancer diagnosis and stage at presentation during the COVID-19 pandemic in 2020: an International Cancer Benchmarking Partnership (ICBP) population-based study.” The Lancet. Oncology (2026). PMID: 42225103 ↗

    L2OTHERCited in: Staging
  656. [656]

    Downing A, Wright P, Hounsome L et al.. “Quality of life in men living with advanced and localised prostate cancer in the UK: a population-based study.” The Lancet. Oncology (2019). PMID: 30713036 ↗

    L4OTHERCited in: Staging
  657. [657]

    Hwang WL, Tendulkar RD, Niemierko A et al.. “Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features.” JAMA oncology (2018). PMID: 29372236 ↗

    L3OTHERCited in: Staging
  658. [658]

    Chamie K, Williams SB, Hu JC. “Population-Based Assessment of Determining Treatments for Prostate Cancer.” JAMA oncology (2015). PMID: 26182305 ↗

    L3OTHERCited in: Staging
  659. [659]

    Nead KT, Gaskin G, Chester C et al.. “Association Between Androgen Deprivation Therapy and Risk of Dementia.” JAMA oncology (2017). PMID: 27737437 ↗

    L2OTHERCited in: Staging
  660. [660]

    Loeb S, Folkvaljon Y, Curnyn C et al.. “Uptake of Active Surveillance for Very-Low-Risk Prostate Cancer in Sweden.” JAMA oncology (2017). PMID: 27768168 ↗

    L4OTHERCited in: Staging
  661. [661]

    Nguyen AT, Luu M, Mallen-St Clair J et al.. “Comparison of Survival After Transoral Robotic Surgery vs Nonrobotic Surgery in Patients With Early-Stage Oropharyngeal Squamous Cell Carcinoma.” JAMA oncology (2020). PMID: 32816023 ↗

    L3OTHERCited in: Staging
  662. [662]

    Okuyama A, Nakamura F, Higashi T. “Prescription of Prophylactic Antiemetic Drugs for Patients Receiving Chemotherapy With Minimal and Low Emetic Risk.” JAMA oncology (2017). PMID: 27812688 ↗

    L4OTHERCited in: Staging
  663. [663]

    Can U, Goktas C, Coskun A et al.. “Perineal versus retropubic radical prostatectomy in localized prostate cancer: extended analysis of a prospective randomized cohort.” Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica (2026). PMID: 41914230 ↗

    L1RCTCited in: Staging
  664. [664]

    Arita Y, Zheng X, Wen F et al.. “Standardizing PSMA PET/CT reporting in prostate cancer: from structured frameworks to AI-assisted interpretation.” Abdominal radiology (New York) (2026). PMID: 42319425 ↗

    L5REVIEW_NARRATIVECited in: Staging
  665. [665]

    Morgans AK, Pieczonka CM, Yu EYW et al.. “Future opportunities and nuances with the use of PSMA PET in prostate cancer (MD PET 1).” Theranostics (2026). PMID: 42094603 ↗

    L5REVIEW_NARRATIVECited in: Staging
  666. [666]

    Imam S, Yuh B. “Managing Clinical N1 Prostate Cancer.” The Urologic clinics of North America (2026). PMID: 41986020 ↗

    L5REVIEW_NARRATIVECited in: Staging
  667. [667]

    Elkun Y, Gupta R, De Almeida Luz M et al.. “Role of Pelvic Lymph Node Dissection for Clinically Localized Prostate Cancer: Should It be Done?” The Urologic clinics of North America (2026). PMID: 41986017 ↗

    L5REVIEW_NARRATIVECited in: Staging
  668. [668]

    Agrotis G, Jäderling F, Lakhani A et al.. “ESR Essentials: MRI-based T-staging in prostate cancer-practice recommendations by the European Society of Urogenital Radiology.” European radiology (2026). PMID: 41720935 ↗

    L1REVIEW_NARRATIVECited in: Staging
  669. [669]

    Altay MS, Kocatürk H, Bedir B et al.. “Impact of positive surgical margin location on biochemical recurrence in pT3 prostate cancer after robot-assisted radical prostatectomy: a retrospective cohort study.” BMC urology (2026). PMID: 41639660 ↗

    L3COHORTCited in: Staging
  670. [670]

    Lu D, Sinnott JA, Valdimarsdóttir U et al.. “Stress-Related Signaling Pathways in Lethal and Nonlethal Prostate Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2015). PMID: 26490316 ↗

    L3OTHERCited in: Staging
  671. [671]

    Stopsack KH, Nandakumar S, Wibmer AG et al.. “Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 32220891 ↗

    L3OTHERCited in: Staging
  672. [672]

    Nava Rodrigues D, Casiraghi N, Romanel A et al.. “RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2018). PMID: 30257982 ↗

    L4OTHERCited in: Staging
  673. [673]

    Labbé DP, Sweeney CJ, Brown M et al.. “TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup.” Clinical cancer research : an official journal of the American Association for Cancer Research (2017). PMID: 28899973 ↗

    L3OTHERCited in: Staging
  674. [674]

    Coumans FA, Ligthart ST, Uhr JW et al.. “Challenges in the enumeration and phenotyping of CTC.” Clinical cancer research : an official journal of the American Association for Cancer Research (2012). PMID: 23014524 ↗

    L2OTHERCited in: Staging
  675. [675]

    Cho H, Byun SS, Son NH et al.. “Impact of Circulating Tumor Cell-Expressed Prostate-Specific Membrane Antigen and Prostate-Specific Antigen Transcripts in Different Stages of Prostate Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 38587547 ↗

    L2OTHERCited in: Staging
  676. [676]

    Fendler WP, Weber M, Iravani A et al.. “Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2019). PMID: 31511295 ↗

    L4OTHERCited in: Staging
  677. [677]

    Penney KL, Salinas CA, Pomerantz M et al.. “Evaluation of 8q24 and 17q risk loci and prostate cancer mortality.” Clinical cancer research : an official journal of the American Association for Cancer Research (2009). PMID: 19366828 ↗

    L3OTHERCited in: Staging
  678. [678]

    Milano AF. “Prostate Cancer - 20-Year Comparative Mortality and Survival Analysis by Age, Race/Ethnicity, Stage, Grade, Disease Duration and Cohort Entry Period: A Systematic Review of 648,114 cases for Diagnosis Years 1975-2022.” Journal of insurance medicine (New York, N.Y.) (2026). PMID: 42307551 ↗

    L5SR_OBSCited in: Staging, Prognosis and Prognostic Factors, Special Populations
  679. [679]

    Schaeffer EM, Srinivas S, Adra N et al.. “Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2023). PMID: 37856213 ↗

    L1GUIDELINECited in: Management Overview, History and Evolution of Treatment
  680. [680]

    Spratt DE, Srinivas S, Adra N et al.. “Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 41213253 ↗

    L1GUIDELINECited in: Management Overview, History and Evolution of Treatment
  681. [681]

    Mohler JL, Kantoff PW, Armstrong AJ et al.. “Prostate cancer, version 2.2014.” Journal of the National Comprehensive Cancer Network : JNCCN (2014). PMID: 24812137 ↗

    L1GUIDELINECited in: Management Overview, History and Evolution of Treatment
  682. [682]

    Mosele MF, Westphalen CB, Stenzinger A et al.. “Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group.” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 38834388 ↗

    L1GUIDELINECited in: Management Overview, History and Evolution of Treatment
  683. [683]

    Tombal B, Choudhury A, Saad F et al.. “Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 40450503 ↗

    L1RCTCited in: Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  684. [684]

    Chi KN, Sandhu S, Smith MR et al.. “Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2023). PMID: 37399894 ↗

    L1RCTCited in: Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors
  685. [685]

    Graff JN, Burotto M, Fong PC et al.. “Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 40383193 ↗

    L1RCTCited in: Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  686. [686]

    Gratzke C, Özgüroğlu M, Peer A et al.. “Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 40383194 ↗

    L1RCTCited in: Management Overview, History and Evolution of Treatment, Special Populations
  687. [687]

    Armstrong AJ, Szmulewitz RZ, Petrylak DP et al.. “ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 31329516 ↗

    L1RCTCited in: Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  688. [688]

    Chi KN, Chowdhury S, Bjartell A et al.. “Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 33914595 ↗

    L1RCTCited in: Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors
  689. [689]

    Chi KN, Rathkopf D, Smith MR et al.. “Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 36952634 ↗

    L1RCTCited in: Management Overview, History and Evolution of Treatment
  690. [690]

    Armstrong AJ, Azad AA, Iguchi T et al.. “Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35420921 ↗

    L1RCTCited in: Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors
  691. [691]

    Kyriakopoulos CE, Chen YH, Carducci MA et al.. “Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 29384722 ↗

    L1RCTCited in: Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors
  692. [692]

    Hussain M, Tombal B, Saad F et al.. “Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 36795843 ↗

    L1RCTCited in: Management Overview, History and Evolution of Treatment
  693. [693]

    Klopp AH, Yeung AR, Deshmukh S et al.. “Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation Therapy: NRG Oncology-RTOG 1203.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 29989857 ↗

    L1RCTCited in: Management Overview, History and Evolution of Treatment
  694. [694]

    Rao A, Scher HI, De Porre P et al.. “Impact of clinical versus radiographic progression on clinical outcomes in metastatic castration-resistant prostate cancer.” ESMO open (2020). PMID: 33184097 ↗

    L2RCTCited in: Management Overview, History and Evolution of Treatment
  695. [695]

    Saad F, Clarke NW, Oya M et al.. “Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.” The Lancet. Oncology (2023). PMID: 37714168 ↗

    L1RCTCited in: Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  696. [696]

    de Bono J, Mateo J, Fizazi K et al.. “Olaparib for Metastatic Castration-Resistant Prostate Cancer.” The New England journal of medicine (2020). PMID: 32343890 ↗

    L1RCTCited in: Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  697. [697]

    Chi KN, Agarwal N, Bjartell A et al.. “Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.” The New England journal of medicine (2019). PMID: 31150574 ↗

    L1RCTCited in: Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  698. [698]

    Topalian SL, Hodi FS, Brahmer JR et al.. “Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.” The New England journal of medicine (2012). PMID: 22658127 ↗

    L4RCTCited in: Management Overview, History and Evolution of Treatment
  699. [699]

    Freedland SJ, de Almeida Luz M, De Giorgi U et al.. “Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.” The New England journal of medicine (2023). PMID: 37851874 ↗

    L1RCTCited in: Management Overview, History and Evolution of Treatment
  700. [700]

    Fizazi K, Tran N, Fein L et al.. “Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.” The New England journal of medicine (2017). PMID: 28578607 ↗

    L1RCTCited in: Management Overview, History and Evolution of Treatment, Special Populations
  701. [701]

    Phillips R, Shi WY, Deek M et al.. “Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial.” JAMA oncology (2020). PMID: 32215577 ↗

    L1RCTCited in: Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  702. [702]

    Kang DW, Fairey AS, Boulé NG et al.. “Effects of Exercise on Cardiorespiratory Fitness and Biochemical Progression in Men With Localized Prostate Cancer Under Active Surveillance: The ERASE Randomized Clinical Trial.” JAMA oncology (2021). PMID: 34410322 ↗

    L1RCTCited in: Management Overview, History and Evolution of Treatment
  703. [703]

    Ali A, Hoyle A, Haran ÁM et al.. “Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.” JAMA oncology (2021). PMID: 33599706 ↗

    L2RCTCited in: Management Overview, History and Evolution of Treatment, Special Populations
  704. [704]

    Spratt DE, George DJ, Shore ND et al.. “Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer.” JAMA oncology (2024). PMID: 38451492 ↗

    L2RCTCited in: Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  705. [705]

    Schram AM, Takebe N, Chen A et al.. “A phase I study of AZD8186 in combination with docetaxel in patients with PTEN-mutated or PIK3CB-mutated advanced solid tumors.” ESMO open (2025). PMID: 40939237 ↗

    L4TRIAL_NONRANDOMCited in: Management Overview, Special Populations
  706. [706]

    Alonso-Gordoa T, Goodman M, Vulsteke C et al.. “A phase II study (AARDVARC) of AZD4635 in combination with durvalumab and cabazitaxel in patients with progressive, metastatic, castration-resistant prostate cancer.” ESMO open (2024). PMID: 38838502 ↗

    L4TRIAL_NONRANDOMCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations
  707. [707]

    Lauer UM, Awada A, Postel-Vinay S et al.. “Final results from the phase Ia/Ib study of the novel bromodomain and extra-terminal domain inhibitor, BI 894999, in patients with advanced solid tumors or diffuse large B-cell lymphoma.” ESMO open (2025). PMID: 40203516 ↗

    L4TRIAL_NONRANDOMCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations
  708. [708]

    Kishan AU, Sun Y, Hartman H et al.. “Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis.” The Lancet. Oncology (2022). PMID: 35051385 ↗

    L1SR_OBSCited in: Management Overview, Special Populations
  709. [709]

    Ravi Kumar AS, Hansen AR. “Prostate Cancer Working Group 4 Recap.” European urology focus (2026). PMID: 42321089 ↗

    L1GUIDELINECited in: Management Overview, History and Evolution of Treatment
  710. [710]

    Saxena M, Marron TU, Kodysh J et al.. “PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting.” Cancer discovery (2025). PMID: 40094414 ↗

    L4TRIAL_NONRANDOMCited in: Management Overview
  711. [711]

    Song L, Rini C, Zhang Y et al.. “Evaluating a Tailored Web-Based eHealth Intervention for Symptom Management in Couples Managing Prostate Cancer During the COVID-19 Pandemic: Randomized Clinical Trial.” Journal of medical Internet research (2026). PMID: 42430132 ↗

    L1RCTCited in: Management Overview, History and Evolution of Treatment, Special Populations
  712. [712]

    McKay RR, Xie W, Ajmera A et al.. “Patient-reported outcomes in castration-resistant prostate cancer with bone metastases treated with radium-223 with or without olaparib.” Cancer (2026). PMID: 42319132 ↗

    L1RCTCited in: Management Overview, History and Evolution of Treatment, Special Populations
  713. [713]

    Olszanski AJ. “Principles of immunotherapy.” Journal of the National Comprehensive Cancer Network : JNCCN (2015). PMID: 25995426 ↗

    L5OTHERCited in: Management Overview
  714. [714]

    Pugh TJ, Nguyen BN, Kanke JE et al.. “Radiation therapy modalities in prostate cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2013). PMID: 23584344 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  715. [715]

    Aggarwal R, Rottey S, Bernard-Tessier A et al.. “Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40689871 ↗

    L4TRIAL_NONRANDOMCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations
  716. [716]

    Wi SJ, Kim DH, Kim SH et al.. “Integrative Traditional East Asian Medicine-Based Adjunctive Therapies for Patients With Prostate Cancer Undergoing Standard Cancer Treatment: Protocol for a Systematic Review and Meta-Analysis of Randomized Controlled Trials.” JMIR research protocols (2026). PMID: 42398929 ↗

    L5SR_MA_RCTCited in: Management Overview
  717. [717]

    Dai C, Dehm SM, Sharifi N. “Targeting the Androgen Signaling Axis in Prostate Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37429011 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  718. [718]

    Te Molder LPW, Sedelaar JPM, Bomers JGR et al.. “(Cost-)effectiveness of focal therapy versus radical therapy (standard of care) in the treatment of men with intermediate-risk prostate cancer: study protocol for the ENFORCE focal randomised controlled trial.” BMJ open (2026). PMID: 42419881 ↗

    L5TRIAL_NONRANDOMCited in: Management Overview, Prognosis and Prognostic Factors
  719. [719]

    Claps M, Mennitto A, Guadalupi V et al.. “Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes.” Cancer treatment reviews (2020). PMID: 32574991 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  720. [720]

    Gravis G, Audenet F, Irani J et al.. “Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature.” Cancer treatment reviews (2016). PMID: 27665366 ↗

    L5REVIEW_NARRATIVECited in: Management Overview, Prognosis and Prognostic Factors
  721. [721]

    Giugliano F, Giordano E, Gilardi L et al.. “Radioligand Therapy in Metastatic Breast Cancer: Harnessing Precision Oncology.” Cancer treatment reviews (2025). PMID: 40228448 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  722. [722]

    Markowski MC, Carducci MA. “Early use of chemotherapy in metastatic prostate cancer.” Cancer treatment reviews (2016). PMID: 27720577 ↗

    L5REVIEW_NARRATIVECited in: Management Overview, History and Evolution of Treatment
  723. [723]

    Muñoz-Carrillo FJ, Garcia de Herreros M, Carrillo D et al.. “Exercise in patients with metastatic prostate cancer: A comprehensive review.” Cancer treatment reviews (2025). PMID: 40712215 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  724. [724]

    Galletti G, Leach BI, Lam L et al.. “Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer.” Cancer treatment reviews (2017). PMID: 28527407 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  725. [725]

    Bolek H, Yazgan SC, Yekedüz E et al.. “Androgen receptor pathway inhibitors and drug-drug interactions in prostate cancer.” ESMO open (2024). PMID: 39426080 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  726. [726]

    Efstathiou E, Merseburger A, Liew A et al.. “Perception of cure in prostate cancer: human-led and artificial intelligence-assisted landscape review and linguistic analysis of literature, social media and policy documents.” ESMO open (2024). PMID: 38744101 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  727. [727]

    Abdel-Wahab M, Giammarile F, Carrara M et al.. “Radiotherapy and theranostics: a Lancet Oncology Commission.” The Lancet. Oncology (2024). PMID: 39362232 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  728. [728]

    Hussain M, Fizazi K, Shore ND et al.. “Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes: A Review.” JAMA oncology (2024). PMID: 38722620 ↗

    L5REVIEW_NARRATIVECited in: Management Overview, Prognosis and Prognostic Factors
  729. [729]

    Nolan-Stevaux O, Li C, Liang L et al.. “AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer.” Cancer discovery (2024). PMID: 37861452 ↗

    L5OTHERCited in: Management Overview
  730. [730]

    Welti J, Sharp A, Brooks N et al.. “Targeting the p300/CBP Axis in Lethal Prostate Cancer.” Cancer discovery (2021). PMID: 33431496 ↗

    L5OTHERCited in: Management Overview
  731. [731]

    Wu YM, Su F, Kalyana-Sundaram S et al.. “Identification of targetable FGFR gene fusions in diverse cancers.” Cancer discovery (2013). PMID: 23558953 ↗

    L4OTHERCited in: Management Overview
  732. [732]

    Xu Y, Yang Y, Wang Z et al.. “ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer.” Cancer discovery (2024). PMID: 38591846 ↗

    L5OTHERCited in: Management Overview
  733. [733]

    Linder S, Hoogstraat M, Stelloo S et al.. “Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence.” Cancer discovery (2022). PMID: 35754340 ↗

    L2OTHERCited in: Management Overview
  734. [734]

    Zhou L, DeMarco KD, Murphy KC et al.. “p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy.” Cancer discovery (2026). PMID: 41135083 ↗

    L5OTHERCited in: Management Overview
  735. [735]

    Hage Chehade C, Gebrael G, Agarwal N. “Bispecific T-cell Engagers in Metastatic Castration-Resistant Prostate Cancer.” Cancer discovery (2024). PMID: 38213299 ↗

    L5OTHERCited in: Management Overview
  736. [736]

    . “PROTAC Shrinks Mutated Prostate Tumors.” Cancer discovery (2022). PMID: 35491637 ↗

    L5OTHERCited in: Management Overview
  737. [737]

    Santasusagna S, Zhu S, Jawalagatti V et al.. “Master Transcription Factor Reprogramming Unleashes Selective Translation Promoting Castration Resistance and Immune Evasion in Lethal Prostate Cancer.” Cancer discovery (2023). PMID: 37676710 ↗

    L5OTHERCited in: Management Overview
  738. [738]

    Wang H, Li N, Liu Q et al.. “Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer.” Cancer cell (2023). PMID: 37352863 ↗

    L5OTHERCited in: Management Overview
  739. [739]

    Hawley JE, Obradovic AZ, Dallos MC et al.. “Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer.” Cancer cell (2023). PMID: 37922910 ↗

    L2OTHERCited in: Management Overview
  740. [740]

    Guo J, Li N, Liu Q et al.. “KMT2C deficiency drives transdifferentiation of double-negative prostate cancer and confer resistance to AR-targeted therapy.” Cancer cell (2025). PMID: 40280125 ↗

    L5OTHERCited in: Management Overview
  741. [741]

    Colucci M, Zumerle S, Bressan S et al.. “Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells.” Cancer cell (2024). PMID: 38428412 ↗

    L5OTHERCited in: Management Overview
  742. [742]

    Guccini I, Revandkar A, D'Ambrosio M et al.. “Senescence Reprogramming by TIMP1 Deficiency Promotes Prostate Cancer Metastasis.” Cancer cell (2020). PMID: 33186519 ↗

    L5OTHERCited in: Management Overview
  743. [743]

    Bluemn EG, Coleman IM, Lucas JM et al.. “Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling.” Cancer cell (2017). PMID: 29017058 ↗

    L4OTHERCited in: Management Overview
  744. [744]

    Calì B, Troiani M, Bressan S et al.. “Coagulation factor X promotes resistance to androgen-deprivation therapy in prostate cancer.” Cancer cell (2024). PMID: 39303726 ↗

    L5OTHERCited in: Management Overview
  745. [745]

    Kuzuoglu-Ozturk D, Nguyen HG, Xue L et al.. “Small-molecule RNA therapeutics to target prostate cancer.” Cancer cell (2025). PMID: 40118049 ↗

    L5OTHERCited in: Management Overview
  746. [746]

    Seed G, Beije N, Yuan W et al.. “Elucidating acquired PARP inhibitor resistance in advanced prostate cancer.” Cancer cell (2024). PMID: 39577422 ↗

    L2OTHERCited in: Management Overview
  747. [747]

    Orme JJ, Huang H. “Microenvironment-Mediated Resistance to Anti-Androgen Therapy.” Cancer cell (2020). PMID: 32781041 ↗

    L5OTHERCited in: Management Overview
  748. [748]

    Reina-Campos M, Diaz-Meco MT, Moscat J. “The Dual Roles of the Atypical Protein Kinase Cs in Cancer.” Cancer cell (2019). PMID: 31474570 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  749. [749]

    Tomioka-Inagawa R, Tomioka M, Tatenuma T et al.. “Incidence and Short- to Intermediate-Term Oncological Outcomes of Pathological T0 Prostate Cancer After Robot-Assisted Radical Prostatectomy: A Multicenter, Retrospective Cohort Study in Japan (MSUG94 Group).” Current oncology (Toronto, Ont.) (2026). PMID: 42346203 ↗

    L3COHORTCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations
  750. [750]

    Shen F, Smith R, McDevitt T et al.. “Human Kallikrein 2: A Novel Lineage-Specific Surface Target in Prostate Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40627156 ↗

    L5OTHERCited in: Management Overview
  751. [751]

    Aparicio AM, Harzstark AL, Corn PG et al.. “Platinum-based chemotherapy for variant castrate-resistant prostate cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2013). PMID: 23649003 ↗

    L4OTHERCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations
  752. [752]

    Chou J, Robinson TM, Egusa EA et al.. “Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 39321214 ↗

    L5OTHERCited in: Management Overview
  753. [753]

    Nayak S, Norris JD, Ammirante M et al.. “Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, for the Treatment of Advanced Prostate Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 40788283 ↗

    L5OTHERCited in: Management Overview
  754. [754]

    Chaudagar K, Hieromnimon HM, Khurana R et al.. “Reversal of Lactate and PD-1-mediated Macrophage Immunosuppression Controls Growth of PTEN/p53-deficient Prostate Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 36862086 ↗

    L5OTHERCited in: Management Overview
  755. [755]

    Schatz CA, Zitzmann-Kolbe S, Moen I et al.. “Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 38593212 ↗

    L5OTHERCited in: Management Overview
  756. [756]

    Deegen P, Thomas O, Nolan-Stevaux O et al.. “The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 33504551 ↗

    L5OTHERCited in: Management Overview, Prognosis and Prognostic Factors
  757. [757]

    Sperger JM, Helzer KT, Stahlfeld CN et al.. “Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 36939530 ↗

    L4OTHERCited in: Management Overview
  758. [758]

    Bilusic M, Madan RA, Gulley JL. “Immunotherapy of Prostate Cancer: Facts and Hopes.” Clinical cancer research : an official journal of the American Association for Cancer Research (2017). PMID: 28663235 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  759. [759]

    Cheng H, Wan Z, Liang J et al.. “Efficacy of Modified Extraperitoneal Laparoscopic Intrafascial Radical Prostatectomy in Prostate Cancer and Analysis of Factors Influencing Postoperative Urinary Continence Recovery.” APMIS : acta pathologica, microbiologica, et immunologica Scandinavica (2026). PMID: 42425916 ↗

    L3OTHERCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations
  760. [760]

    Childs DS, Hahn AW, Ravi P et al.. “Advances in systemic therapies for advanced prostate cancer.” BMJ (Clinical research ed.) (2026). PMID: 42419784 ↗

    L5REVIEW_NARRATIVECited in: Management Overview, History and Evolution of Treatment
  761. [761]

    Friedrich NA, Das SK, Luu M et al.. “Integrating Natural Language Processing With ChatGPT to Improve Quality of Artificial Intelligence Summaries of Prostate Cancer Consultations.” JCO clinical cancer informatics (2026). PMID: 42418754 ↗

    L4OTHERCited in: Management Overview
  762. [762]

    Kamran SC, Borges M, Michalski J et al.. “Participant Heterogeneity in the Prostate Cancer Biobank of the NRG: An Obstacle to Broadening the Reach of Precision Oncology.” JCO precision oncology (2026). PMID: 42418740 ↗

    L4OTHERCited in: Management Overview, Special Populations
  763. [763]

    Slootbeek PHJ, Quint YM, Kokke JJR et al.. “Shallow Whole-Genome Sequencing to Assess Genomic Instability and Predict Treatment Response in Metastatic Castration-Resistant Prostate Cancer.” JCO precision oncology (2026). PMID: 42418738 ↗

    L4OTHERCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations
  764. [764]

    Grujić M, Živković Radojević M, Alaverdashvili T et al.. “Endocrine-driven inflammatory-epigenetic adaptation as a proposed axis of radioresistance in endocrine-exposed prostate cancer: a translational hypothesis.” Frontiers in endocrinology (2026). PMID: 42416899 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  765. [765]

    Dong A, Hu W, Lu Z et al.. “A succinylation-based classifier predicts chemotherapy response in prostate cancer and reveals KAT2A as a therapeutic target.” Clinical and translational medicine (2026). PMID: 42415249 ↗

    L3OTHERCited in: Management Overview
  766. [766]

    . “Prostate cancer early detection. Clinical practice guidelines in oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2004). PMID: 19795604 ↗

    L1GUIDELINECited in: History and Evolution of Treatment
  767. [767]

    Christensen MH, Petersen LJ. “Radionuclide treatment of painful bone metastases in patients with breast cancer: a systematic review.” Cancer treatment reviews (2011). PMID: 21683530 ↗

    L2SR_MA_RCTCited in: History and Evolution of Treatment
  768. [768]

    Bardia A, Messersmith WA, Kio EA et al.. “Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2021). PMID: 33741442 ↗

    L4TRIAL_NONRANDOMCited in: History and Evolution of Treatment
  769. [769]

    de Wit R, Wülfing C, Castellano D et al.. “Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study.” ESMO open (2021). PMID: 34450475 ↗

    L2RCTCited in: History and Evolution of Treatment, Prognosis and Prognostic Factors
  770. [770]

    Gu W, Han W, Luo H et al.. “Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial.” The Lancet. Oncology (2022). PMID: 36075260 ↗

    L1RCTCited in: History and Evolution of Treatment
  771. [771]

    Tang C, Sherry AD, Haymaker C et al.. “Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial.” JAMA oncology (2023). PMID: 37022702 ↗

    L1RCTCited in: History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  772. [772]

    Vogelzang NJ, Beer TM, Gerritsen W et al.. “Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial.” JAMA oncology (2022). PMID: 35142815 ↗

    L1RCTCited in: History and Evolution of Treatment
  773. [773]

    Mariados NF, Orio PF, Schiffman Z et al.. “Hyaluronic Acid Spacer for Hypofractionated Prostate Radiation Therapy: A Randomized Clinical Trial.” JAMA oncology (2023). PMID: 36757690 ↗

    L1RCTCited in: History and Evolution of Treatment
  774. [774]

    Dev H, Linch M, Narahari K et al.. “Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib ± Degarelix in Primary Prostate Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40358364 ↗

    L1RCTCited in: History and Evolution of Treatment
  775. [775]

    McHugh D, Dallos M, Teo MY et al.. “Accelerating Drug Development in Hormone-Naïve Prostate Cancer through Multimodal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical Trial.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 41263694 ↗

    L1RCTCited in: History and Evolution of Treatment
  776. [776]

    Winquist E, Hotte SJ, Chi K et al.. “Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 39513948 ↗

    L1RCTCited in: History and Evolution of Treatment
  777. [777]

    Honma Y, Monden N, Yamazaki K et al.. “Apalutamide and Goserelin for Androgen Receptor-Positive Salivary Gland Carcinoma: A Phase II Nonrandomized Clinical Trial, YATAGARASU.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 38940667 ↗

    L4TRIAL_NONRANDOMCited in: History and Evolution of Treatment, Prognosis and Prognostic Factors
  778. [778]

    Saad F, Sternberg CN, Mulders PFA et al.. “The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer.” Cancer treatment reviews (2018). PMID: 29787892 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  779. [779]

    Sonpavde G, Hutson TE, Berry WR. “Hormone refractory prostate cancer: Management and advances.” Cancer treatment reviews (2006). PMID: 16458434 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment, Prognosis and Prognostic Factors
  780. [780]

    Oudard S. “Progress in emerging therapies for advanced prostate cancer.” Cancer treatment reviews (2012). PMID: 23107383 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  781. [781]

    Tucci M, Caffo O, Buttigliero C et al.. “Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era.” Cancer treatment reviews (2019). PMID: 30738364 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  782. [782]

    Somoto T, Utsumi T, Ikeda R et al.. “Evolving Systemic Therapy for Prostate Cancer: Pivotal Clinical Trials, Biomarker-Driven Combinations, and Practical Sequencing in the ARSI-PARP-Radioligand Era.” Cancers (2026). PMID: 42352498 ↗

    L5TRIAL_NONRANDOMCited in: History and Evolution of Treatment
  783. [783]

    Corona G, Morgado LA, Capogrosso P et al.. “Testosterone Therapy After Radical Prostatectomy: Insights From a Systematic Review and Meta-Analysis.” Andrology (2026). PMID: 42334104 ↗

    L1SR_OBSCited in: History and Evolution of Treatment
  784. [784]

    Gerlach A, Ras HM, Bonar W et al.. “Multiple primary head and neck cancers: a scenario-based framework for diagnosis and modern multidisciplinary management.” Frontiers in oncology (2026). PMID: 42326328 ↗

    L4SR_OBSCited in: History and Evolution of Treatment
  785. [785]

    Xie Y, Huang H, Chen X et al.. “Prostate cancer research on social media platforms: a bibliometric and thematic analysis.” Frontiers in oncology (2026). PMID: 42311243 ↗

    L5SR_OBSCited in: History and Evolution of Treatment
  786. [786]

    Serio RN, Scheben A, Lu B et al.. “Clonal Lineage Tracing with Somatic Delivery of Recordable Barcodes Reveals Migration Histories of Metastatic Prostate Cancer.” Cancer discovery (2024). PMID: 38969342 ↗

    L5OTHERCited in: History and Evolution of Treatment
  787. [787]

    Han M, Li F, Zhang Y et al.. “FOXA2 drives lineage plasticity and KIT pathway activation in neuroendocrine prostate cancer.” Cancer cell (2022). PMID: 36332622 ↗

    L5OTHERCited in: History and Evolution of Treatment
  788. [788]

    Chen CC, Tran W, Song K et al.. “Temporal evolution reveals bifurcated lineages in aggressive neuroendocrine small cell prostate cancer trans-differentiation.” Cancer cell (2023). PMID: 37995683 ↗

    L5OTHERCited in: History and Evolution of Treatment
  789. [789]

    Pearson JD, Huang K, Pacal M et al.. “Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity.” Cancer cell (2021). PMID: 34270926 ↗

    L5OTHERCited in: History and Evolution of Treatment
  790. [790]

    Vanden Abeele F, Skryma R, Shuba Y et al.. “Bcl-2-dependent modulation of Ca(2+) homeostasis and store-operated channels in prostate cancer cells.” Cancer cell (2002). PMID: 12086875 ↗

    L5OTHERCited in: History and Evolution of Treatment
  791. [791]

    Shen MM. “Chromoplexy: a new category of complex rearrangements in the cancer genome.” Cancer cell (2013). PMID: 23680143 ↗

    L5OTHERCited in: History and Evolution of Treatment
  792. [792]

    Takahashi S, Miura M, Higashiyama H. “Transurethral ultrasound ablation for prostate cancer: MRI-based pre-treatment planning and post-treatment assessment-what the radiologist needs to know.” Abdominal radiology (New York) (2026). PMID: 42380349 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  793. [793]

    Chow R, Lage DE, Williams GR et al.. “Representation and Outcomes of Older Adults in Practice-Changing Oncology Trials in the Era of Novel Therapies: A Guideline Appraisal.” Journal of the National Comprehensive Cancer Network : JNCCN (2022). PMID: 34991068 ↗

    L1SR_OBSCited in: Prognosis and Prognostic Factors, Special Populations
  794. [794]

    Eisenberger M, Hardy-Bessard AC, Kim CS et al.. “Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 28809610 ↗

    L1RCTCited in: Prognosis and Prognostic Factors
  795. [795]

    Oudard S, Fizazi K, Sengeløv L et al.. “Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 28753384 ↗

    L1RCTCited in: Prognosis and Prognostic Factors, Special Populations
  796. [796]

    Smith M, Parker C, Saad F et al.. “Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.” The Lancet. Oncology (2019). PMID: 30738780 ↗

    L1RCTCited in: Prognosis and Prognostic Factors
  797. [797]

    de Wit R, de Bono J, Sternberg CN et al.. “Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.” The New England journal of medicine (2019). PMID: 31566937 ↗

    L1RCTCited in: Prognosis and Prognostic Factors
  798. [798]

    Iannantuono GM, Chandran E, Floudas CS et al.. “Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trials.” Cancer treatment reviews (2023). PMID: 37716332 ↗

    L1TRIAL_NONRANDOMCited in: Prognosis and Prognostic Factors
  799. [799]

    Tombal B, Sternberg CN, Hussain M et al.. “Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.” ESMO open (2022). PMID: 35714477 ↗

    L2SR_OBSCited in: Prognosis and Prognostic Factors
  800. [800]

    Ni X, Luu M, Ma W et al.. “Impact of Asian Race on Prognosis in De Novo Metastatic Prostate Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2023). PMID: 37433430 ↗

    L2OTHERCited in: Prognosis and Prognostic Factors
  801. [801]

    Zhu Y, Wei Y, Zeng H et al.. “Inherited Mutations in Chinese Men With Prostate Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2021). PMID: 34653963 ↗

    L4OTHERCited in: Prognosis and Prognostic Factors
  802. [802]

    Schaly B, Mendez LC, Khawaja M et al.. “Investigating Setup Error Differences between Conventional and Ultra-Hypofractionated Whole Pelvis Radiation Therapy: A Secondary Analysis from the HOPE Randomized Clinical Trial.” Journal of applied clinical medical physics (2026). PMID: 42219614 ↗

    L1RCTCited in: Prognosis and Prognostic Factors
  803. [803]

    Quinn DI, Sandler HM, Horvath LG et al.. “The evolution of chemotherapy for the treatment of prostate cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 29045523 ↗

    L5REVIEW_NARRATIVECited in: Prognosis and Prognostic Factors
  804. [804]

    Aggarwal R, Italiano A, Domchek SM et al.. “Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study.” Cancer research communications (2026). PMID: 42219553 ↗

    L4TRIAL_NONRANDOMCited in: Prognosis and Prognostic Factors
  805. [805]

    Jones RH, Pinato DJ, Forster MD et al.. “Dendrimer-nanoparticle (DEP) delivery of cabazitaxel (DEP-cabazitaxel): A first-in-human phase 1/2 trial in patients with advanced solid tumours.” European journal of cancer (Oxford, England : 1990) (2026). PMID: 42208277 ↗

    L4TRIAL_NONRANDOMCited in: Prognosis and Prognostic Factors
  806. [806]

    De Bari B, Arcangeli S, Ciardo D et al.. “Extreme hypofractionation for early prostate cancer: Biology meets technology.” Cancer treatment reviews (2016). PMID: 27631875 ↗

    L5REVIEW_NARRATIVECited in: Prognosis and Prognostic Factors
  807. [807]

    Stavridi F, Karapanagiotou EM, Syrigos KN. “Targeted therapeutic approaches for hormone-refractory prostate cancer.” Cancer treatment reviews (2010). PMID: 20106600 ↗

    L5REVIEW_NARRATIVECited in: Prognosis and Prognostic Factors
  808. [808]

    Wang Y, Hadigol M, Lincha VR et al.. “Exposure-safety analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial.” Journal of pharmacokinetics and pharmacodynamics (2026). PMID: 42243460 ↗

    L1RCTCited in: Prognosis and Prognostic Factors
  809. [809]

    . “Stratifying prostate patients for olaparib.” Cancer discovery (2015). PMID: 25904654 ↗

    L5OTHERCited in: Prognosis and Prognostic Factors
  810. [810]

    . “Prostate Cancer Recurrence: Genomic Clues.” Cancer discovery (2017). PMID: 28148485 ↗

    L5OTHERCited in: Prognosis and Prognostic Factors
  811. [811]

    . “Enzalutamide before chemotherapy prolongs survival.” Cancer discovery (2014). PMID: 25002634 ↗

    L5OTHERCited in: Prognosis and Prognostic Factors
  812. [812]

    . “Olaparib Targets Some Advanced Prostate Cancers.” Cancer discovery (2015). PMID: 26658963 ↗

    L5OTHERCited in: Prognosis and Prognostic Factors
  813. [813]

    . “Surrogate Endpoint ID'd for Prostate Cancer Trials.” Cancer discovery (2017). PMID: 28851688 ↗

    L5OTHERCited in: Prognosis and Prognostic Factors
  814. [814]

    . “Abiraterone-Olaparib Combo Aids Men with mCRPC.” Cancer discovery (2018). PMID: 29954730 ↗

    L5OTHERCited in: Prognosis and Prognostic Factors
  815. [815]

    Pearson HB, Li J, Meniel VS et al.. “Identification of Pik3ca Mutation as a Genetic Driver of Prostate Cancer That Cooperates with Pten Loss to Accelerate Progression and Castration-Resistant Growth.” Cancer discovery (2018). PMID: 29581176 ↗

    L5OTHERCited in: Prognosis and Prognostic Factors
  816. [816]

    Yao Y, Dong J, Wang Z et al.. “A Nomogram for Predicting 28-Day Mortality in Critically Ill Patients With Prostate Cancer: A Retrospective Cohort Study Based on the MIMIC-IV Database.” Archivos espanoles de urologia (2026). PMID: 42265963 ↗

    L3COHORTCited in: Prognosis and Prognostic Factors
  817. [817]

    Dal Pra A, Ghadjar P, Ryu HM et al.. “Predicting dose response to prostate cancer radiotherapy: validation of a radiation signature in the randomized phase III NRG/RTOG 0126 and SAKK 09/10 trials.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 39986927 ↗

    L1RCTCited in: Special Populations
  818. [818]

    Henry DH, Costa L, Goldwasser F et al.. “Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 21343556 ↗

    L1RCTCited in: Special Populations
  819. [819]

    Catton CN, Lukka H, Gu CS et al.. “Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 28296582 ↗

    L1RCTCited in: Special Populations
  820. [820]

    van Wilpe S, Kloots ISH, Slootbeek PHJ et al.. “Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 39293514 ↗

    L4TRIAL_NONRANDOMCited in: Special Populations
  821. [821]

    Ávila M, Patel L, López S et al.. “Patient-reported outcomes after treatment for clinically localized prostate cancer: A systematic review and meta-analysis.” Cancer treatment reviews (2018). PMID: 29673922 ↗

    L1SR_OBSCited in: Special Populations
  822. [822]

    Puts MT, Tapscott B, Fitch M et al.. “A systematic review of factors influencing older adults' decision to accept or decline cancer treatment.” Cancer treatment reviews (2014). PMID: 25579752 ↗

    L2SR_OBSCited in: Special Populations
  823. [823]

    Riaz IB, Naqvi SAA, He H et al.. “First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer: A Living Systematic Review and Network Meta-analysis.” JAMA oncology (2023). PMID: 36862387 ↗

    L1SR_OBSCited in: Special Populations
  824. [824]

    Yap TA, Choudhury AD, Hamilton E et al.. “PF-06952229, a selective TGF-β-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors.” ESMO open (2024). PMID: 39214047 ↗

    L4TRIAL_NONRANDOMCited in: Special Populations
  825. [825]

    Goyal G, Enogela EM, Burkholder GA et al.. “Burden of Chronic Health Conditions Among People With HIV and Common Non-AIDS-Defining Cancers.” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 40490015 ↗

    L3OTHERCited in: Special Populations
  826. [826]

    Meissner VH, Imhof K, Jahnen M et al.. “Frailty in Long-Term Prostate Cancer Survivors and Its Association With Quality of Life and Emotional Health.” Journal of the National Comprehensive Cancer Network : JNCCN (2024). PMID: 39662044 ↗

    L4OTHERCited in: Special Populations
  827. [827]

    Chopra I, Dwibedi N, Mattes MD et al.. “Nonadherence to Statins and Antihypertensives and Hospitalizations Among Elderly Medicare Beneficiaries With Incident Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2017). PMID: 29118227 ↗

    L2OTHERCited in: Special Populations
  828. [828]

    Dragomir A, Touma N, Hu J et al.. “Androgen Deprivation Therapy and Risk of Cardiovascular Disease in Patients With Prostate Cancer Based on Existence of Cardiovascular Risk.” Journal of the National Comprehensive Cancer Network : JNCCN (2023). PMID: 36791755 ↗

    L2OTHERCited in: Special Populations
  829. [829]

    Climent MÁ, Torregrosa MD, Vázquez S et al.. “Aged patients with metastatic castration resistant prostate cancer: Should we treat with chemotherapy?” Cancer treatment reviews (2017). PMID: 28411479 ↗

    L5REVIEW_NARRATIVECited in: Special Populations
  830. [830]

    Body JJ, Terpos E, Tombal B et al.. “Bone health in the elderly cancer patient: A SIOG position paper.” Cancer treatment reviews (2016). PMID: 27863287 ↗

    L5REVIEW_NARRATIVECited in: Special Populations
  831. [831]

    Hadji P, Aapro M, Costa L et al.. “Antiresorptive treatment options and bone health in cancer patients-safety profiles and clinical considerations.” Cancer treatment reviews (2012). PMID: 22482938 ↗

    L5REVIEW_NARRATIVECited in: Special Populations
  832. [832]

    Mukherji D, Pezaro CJ, Shamseddine A et al.. “New treatment developments applied to elderly patients with advanced prostate cancer.” Cancer treatment reviews (2013). PMID: 23290885 ↗

    L5REVIEW_NARRATIVECited in: Special Populations
  833. [833]

    Dubois C, Vanden Abeele F, Lehen'kyi V et al.. “Remodeling of channel-forming ORAI proteins determines an oncogenic switch in prostate cancer.” Cancer cell (2014). PMID: 24954132 ↗

    L5OTHERCited in: Special Populations
  834. [834]

    Weischenfeldt J, Simon R, Feuerbach L et al.. “Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer.” Cancer cell (2013). PMID: 23410972 ↗

    L5OTHERCited in: Special Populations

Revision History

All updates applied to this page

Loading revisions…